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Abstract 
Pik1 is a yeast phosphatidylinositol-4 kinase that is critical for vesicular traffic to the 
plasma membrane and endosomes from the trans-Golgi (1, 2).  Pik1 is a soluble enzyme, 
and the small myristoylated, Ca2+ binding, EF hand protein, Frequenin (Frq1) facilitates 
its membrane localization (3).  It has been suggested that Pik1 finds its substrate, 
phosphatidylinositol (PI), within phospholipid bilayers with assistance from the PI/PC 
transfer protein Sec14 (4).  It is proposed that Sec14 stimulates the activity of Pik1 by 
partially removing PI from the bilayer and presenting it to the kinase as a more suitable 
substrate (4).  In order to test this hypothesis, the Bellbrook Labs Transcreener ADP2 FI 
Assay kit, a fluorescence-based enzyme assay kit that reports the production of ADP, was 
adapted to create a time-resolved, vesicle-based assay.  The assay was developed and 
validated with the catalytic subunit of Protein Kinase A (PKA) and the commercial 
human PI kinase PIK3C3.  An expression system for Pik1 was created in yeast.  To 
preserve the stability of the 125 kDa enzyme it was co-expressed with both Frq1 and the 
heat shock protein, Cdc37, producing the Pik1-Frq1 complex with a removable 
10xhistidine tag on Pik1.  The growth of the yeast transformants was investigated using 
different culture conditions, media, and methods of inducing protein expression.  The 
expression of the Pik1-Frq1 complex was confirmed on a Western blot that showed a 
band corresponding to the molecular weight of the complex.  Next steps will involve 
optimizing the purification of the Pik1-Frq1 complex on a metal affinity resin, with the 
ultimate goal being to test the Sec14 presentation mechanism by measuring the kinase 
activity of Pik1 from purified fractions in the presence and absence of Sec14.     
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1 
1 Introduction  
1.1 Phosphatidylinositol (PI) and Phosphoinositides (PIPs)  
1.1.1 PI 
 Phosphatidylinositol (PI) is a membrane phospholipid that is ubiquitous in 
eukaryotic cells (5), and constitutes approximately 5-7% of the total cellular 
phospholipids in mammalian cells (6).  PI is a glycerophospholipid with two fatty acyl 
chains esterified to positions sn-1 and sn-2, and an inositol ring linked to position sn-3 by 
a phosphate group (5) (Figure 1).  The fatty acid tail in the sn-1 position is typically 
saturated, and that in the sn-2 position is usually unsaturated (7).  The most common fatty 
acids at position sn-1 of PI are stearic acid (18:0) in humans and palmitic acid (16:0) in 
yeast.  Arachidonic acid (20:4) (in humans) and oleic (18:1) or palmitoleic acid (16:1) (in 
yeast) are the most common fatty acids in PI in the sn-2 position (5).   
 
Figure 1: The structure of PI with stearic acid (18:0) and arachidonic acid (20:4) in 
positions sn-1 and sn-2 respectively.  
  
PI is present in different proportions in living systems according to the type of 
membrane; in yeast, PI is present in two distinct compartments, the plasma membrane 
(PM) and the Golgi (5).  De novo synthesis of PI occurs mainly at the endoplasmic 
reticulum (ER) from phosphatidic acid (PA) (6).  In the final step of PI synthesis, cytidine 
diphosphate-diacylglycerol (CDP-DG) and myo-inositol are combined by PI synthase 
(Pis1 in yeast) mainly on the cytoplasmic face of the ER, but also on Golgi, 
mitochondria, and microsomes (5, 6).  PI is then transported to the correct membrane via 
vesicular transport or phosphatidylinositol transfer proteins (PITPs) (6, 8).  Loss-of-
function mutants of the PI synthase gene are lethal in both Drosophila melanogaster and 
Saccharomyces cerevisiae, emphasizing the central role of PI signaling in eukaryotic cell 
biology (6, 9).  PI participates in signaling mainly via phosphorylated derivatives called 
phosphatidylinositol phosphates (PIPs) (6).  
O
O
HO
O OP
O
O
HO
OH OH
OH
OH
OH 1 2 3
4
5
6
 
 
2 
1.1.2 PIPs 
Phosphatidylinositol phosphates (PIPs) are a minor constituent of cellular 
membranes making up approximately 1% of total cellular phospholipids, with PI 
representing approximately 5-7% (5, 6).  The inositol headgroup of PI can be 
phosphorylated at positions 3-, 4-, and/or 5- in different combinations to produce 7 
different PIPs: PI(3)P, PI(4)P, PI(5)P, PI(3,4)P2, PI(3,5)P2, PI(4,5)P2, PI(3,4,5)P3 (5) 
(Figure 2).  All 7 PIPs are essentially interconvertible; however, the organism must have 
the enzymes essential for the conversions (5).  Mammals synthesize all seven; yet yeast 
synthesize all but PI(3,4)P2 and PI(3,4,5)P3 (10).  PI(4)P and the enzyme that generates 
this species at the Golgi in yeast, Pik1, are two of the key players focused on in this 
thesis.        
 
Figure 2: PI and the metabolic reactions that result in the seven PIP species. Dotted 
arrows indicate transitions that have been shown in vitro, but their biological relevance is 
still ambiguous.  Figure used with permission from (8).  
PIPs show continuous turnover (11), are low in abundance, and their local 
concentration can be extremely variable (5).  PIPs are vital in regulating membrane-
cytosol interfaces by mediating signal transduction, assisting in defining organelle 
identity, and regulating the cytoskeleton, membrane traffic, permeability, and transport 
(8).  The seven different PIPs have distinct and essential regulatory functions that are 
executed via the recruitment and/or activation of effector proteins, and the creation of 
second messengers such as diacylglycerol (DAG) or inositol 1,4,5-trisphosphate (IP3) 
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(Figure 2) (5, 6, 11).  PIPs have properties that make them optimal mediators of signaling 
events; these include their differential intracellular distribution and their high turnover 
(8).  PIP signaling is covered in greater detail in Section 1.1.5.   
   PIP signaling is highly related to the spatial distribution of PIPs among cellular 
compartments.  The 7 different PIPs are not equally abundant; PI(4)P and PI(4,5)P2 are 
the most abundant and PI(3)P, PI(3,4)P2, and PI(3,4,5)P3 have a much lower abundance 
(6). In addition, the 7 PIPs are present in most cell types in different levels and each 
intracellular compartment has a signature PIP composition; for example, the predominant 
PIP at the plasma membrane, the Golgi, and endosomes are PI(4,5)P2, PI(4)P, and PI(3)P 
respectively (8) (Figure 3).  Moreover, the PIP composition of a given intracellular 
membrane may not be homogeneous (8).  The differential distribution assists in defining 
the membrane identity for different organelles and contributes to a powerful coincidence 
detection code for the regulation of membrane cytosol interactions (8) (covered in more 
detail in Section 1.1.3).  The presence and abundance of a particular PIP on a certain 
membrane is determined by the interplay between lipid kinases and phosphatases on that 
membrane in response to stimuli, thus resulting in the spatial and temporal regulation of 
PIPs (5, 6).  An overview of PI kinases is provided in Section 1.2.  The correct activity of 
PIP metabolizing enzymes is essential for proper PIP signaling and homeostasis, and this 
is relevant to medicine as imbalances in PIP metabolism have been linked to a variety of 
human pathologies (5, 8).    
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Figure 3: Fluorescence micrographs of Chinese hamster ovary cells showing the 
signature PIP compositions of the PM (PI(4,5)P2), Golgi (PI(4)P), and endosomes 
(PI(3)P).  The pleckstrin homology (PH) domains of PLC𝛿1 and FAPP1, and the tandem 
FYVE domain of hepatocyte growth factor-regulated tyrosine kinase substrate (Hrs) were 
fused to green fluorescent protein (GFP) to visualize PI(4,5)P2, PI(4)P, and PI(3)P 
respectively.  Image used with permission from (8).   
 
 
1.1.3 PIP Signaling  
The phospholipase C (PLC) signaling pathway is one of the well-studied PIP 
signaling pathways (7).  In this pathway PI(4,5)P2 is cleaved by PLC to give inositol 
1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) (7).  These products act as second 
messengers in signal transduction cascades that control important processes such as 
growth factor signaling and neurotransmitter release (7). (Figure 4) 
  
Figure 4: The PLC pathway up to the production of IP3 and DAG.  PI is sequentially 
phosphorylated to generate PI(4,5)P2, which is then cleaved by PLC to yield inositol 
1,4,5-trisphosphate (IP3) and diacylglycerol (DAG).  Image used with permission from 
(12).    
 There are multiple examples of PIPs acting as precursors to second messengers; 
however, PIPs have also been shown to act directly as signaling molecules.  PIPs exert 
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their signaling effects via the binding of the effector protein to the PIP head group 
thereby recruiting the effector proteins to the phospholipid membrane or by mediating the 
functions of the effector proteins (8).  Cytosolic proteins or the cytosolic domains of 
membrane proteins can bind the PIP head group via well-defined modular domains (11), 
such as the PH domain (13).  These binding interactions are generally of low affinity, but 
when PIPs cooperate with other membrane components to bind multiple sites on the 
effector protein, higher affinity interactions occur (8) (Figure 5).  Such multivalent 
interactions are the basis of the coincidence detection code.  In essence, the specificity 
and strength of membrane binding of an effector protein is a combination of affinities for 
lipids and co-resident proteins that assure proper signal integration (8).  For example, if it 
were a “two key mechanism” the two components (a GTPase and a PIP for example) can 
be independently regulated and the effector protein will only bind with high affinity and 
transduce a signal when both are correct.  This helps to distinguish where and when the 
effector protein should bind (8).  The specific intracellular distribution of PIPs and their 
co-receptors gives rise to the selective recruitment of effector proteins to particular 
compartments (11). The coincidence detection code allows for the fine control of PIP 
signaling in both space and time.   
 
  
Figure 5: Coincidence detection between PIPs and effector proteins.  High specificity 
and affinity are achieved when PIPs work in cooperation with co-receptors to bind 
effector proteins.  This plays a key contribution in the spatial and temporal regulation of 
PIP signaling.  A. A generic visualization of how coincidence detection is used to define 
organelle identity. B. A generic visualization of how binding affinity increases when an 
effector cooperatively binds two ligands.  In this example the two ligands are a PIP2 and a 
GTPase.  Figures used with permission from (8)  
 
 
B A 
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1.1.4 PI(4)P, Signaling, and Membrane Traffic 
PI(4)P accounts for approximately 30% and 45% of total PIPs in yeast and 
humans respectively (5).  PI(4)P is enriched at the Golgi and is also found at the PM (5).  
PI(4)P is an intermediate in the production of PI(4,5)P2 and PI(3,4,5)P3, which are 
essential in receptor-activated phospholipase C (PLC) (Figure 4) and phosphoinositide 3-
kinase signaling respectively (14).  However, PI(4)P itself has also been established as 
essential for cell function independent of these two signaling pathways, although it was 
initially considered solely as an intermediate in the production of other PIP species (11).   
 
PI(4)P is largely produced by the phosphorylation of PI by PI-4 kinases; however, 
it is also produced by the dephosphorylation of PI(4,5)P2 and PI(3,4)P2 (5).  In yeast there 
are two type III PI-4 kinases and each carries out this function at their respective 
organelle membrane; Pik1 acts at the Golgi and Stt4 at the PM (5).  Deletion of either 
STT4 or PIK1 is lethal and increased expression of either cannot compensate for the loss 
of the other, despite having the same biochemical activity; this is evidence that each 
enzyme produces functionally distinct pools of PI(4)P (15).  Temperature-conditional 
mutants led to the discovery that Stt4 activity is necessary for proper vacuole 
morphology, cell wall integrity, and actin cytoskeleton organization, and that Pik1 
activity is essential for normal secretion, Golgi and vacuole membrane dynamics, and 
endocytosis (2, 15).   
 
Direct evidence linking PI(4)P and Golgi trafficking in yeast was initially 
observed when secretory defects were seen in PI-4 kinase mutants (1, 2).  Since then 
multiple PI(4)P effectors have been identified through which PI(4)P spatially and 
temporally regulates a variety of functions on Golgi membranes.  One such function is 
the regulation of vesicle budding.  PIP composition is an important factor in vesicle 
budding and fusion and in the recruitment of the proteins required for these processes 
(Figure 6A).  The following are mammalian examples of some of these proteins.  PI(4)P 
cooperates with the small GTPase ADP-ribosylation factor 1 in its GTP bound state 
(ARF1-GTP) to recruit proteins that initiate vesicle formation, such as clathrin adaptor 
protein complex 1 (AP-1) (10, 16).  Four-phosphate-adaptor protein 1 and 2 (FAPP1 and 
FAPP2) control membrane traffic between the Golgi and the cell surface.  It is proposed 
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that FAPP1 and 2 do this by coordinating the budding and fission reactions that generate 
mature and properly tagged vesicles that are competent for fusion with the PM (17).  
FAPP1 and FAPP2 bind PI(4)P and ARF1 via their PH domain; these interactions recruit 
FAPP1 and FAPP2 to TGN exit sites (17, 18) (Figure 6B).  PI(4)P and ARF1 provide an 
example of recruitment by PIP coincidence detection code and it highlights another way 
PI(4)P is required in the secretory pathway from Golgi to the PM.  In addition, local 
concentrations of PI(4)P pools at different stages in vesicle maturity can lead to the 
activation of different effectors (19).  Some PI(4)P effectors have been shown to transport 
lipids in association with PI(4)P (5, 8), and PI(4)P also functions in the maintenance of 
Golgi structure (18).   
 
 
Figure 6: PIPs and membrane traffic. A. The PIP compositions of a vesicle, an 
acceptor membrane, and a budding membrane must be correct to recruit the correct 
factors required for fusion and budding.  This ensures vectoral membrane traffic.  Image 
used with permission from (8). B. The coincidence detection of PI(4)P, ARF1, and other 
membrane factors by OSBP, FAPP2, FAPP1, and goodpasture antigen-binding protein 
(GPBP) to coordinate budding and fission reactions to generate vesicles that are 
competent for fusion with the PM.  Image used with permission from (17).  
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1.2 The Story of PI Kinases  
 PI(4)P and PI(4,5)P2 were isolated in the 1940s by Folch (20).  This began a 
search for the enzymes that phosphorylate the inositol head group.  A PI kinase is an 
enzyme that uses PI or a PIP and ATP as its substrates, and which catalyzes the transfer 
of the gamma phosphate to position 3, 4, or 5 of the inositol ring.  By 1969 it was 
suspected that more than one PI kinase existed based on the differential activation of PI 
kinases in liver plasma membranes and endoplasmic reticulum by a nonionic detergent 
(21).  By 1984 different researchers had measured PI kinase activity in many different 
tissues and a connection had been made between the turnover of PI lipids and signal 
transduction (22).  As PI kinases were isolated prior to 1988, they were distinguished 
from each other by their sensitivity to adenosine and to nonionic detergents, and their 
apparent molecular weight and intracellular location (21).  Type I PI kinases were 
inhibited by detergent and were not inhibited by adenosine (21).  Type II PI kinases were 
activated by detergent and inhibited by adenosine (21).  Type III PI kinases were 
relatively resistant to inhibition by adenosine and were activated by detergents; they also 
had different apparent molecular weights, and were resistant to inhibition by a 
monoclonal antibody that caused greater than 90% inhibition of the Type II PI kinases 
(21).  However, prior to 1988 it was thought that the PIP pathway was simple and only 
consisted of the sequential phosphorylation of PI at positions 4 then 5 to form PI(4,5)P2, 
and the phospholipase C (PLC) signaling pathway (Figure 4) (21).  Up until this point the 
enzymes and products of this restricted original view of the PIP pathway had been found 
in virtually every organism and tissue studied, and no other phosphorylated PI derivatives 
had been detected.  Prior to 1988, the products of PI kinases were characterized using one 
and two dimensional thin layer chromatography (TLC), and since PI(3)P and PI(4)P 
appeared to co-migrate in these systems, all PI kinase enzymes were thought to be 
phosphatidylinositol-4 kinases (23).  However, in 1988, it was discovered that Type I PI 
kinases actually phosphorylate position D3 on the inositol ring to produce PI(3)P (23).  
The perceived complexity of PIP metabolism greatly increased between 1988 and 1990 
due to the discovery of PI-3 kinases and PI(3)P, the subsequent discovery of PI(3,4)P2, 
PI(3,5)P2, and PI(3,4,5)P3, and the detection of PI-3 kinase activity and PI(3)P in 
Saccharomyces cerevisiae (21, 23, 24).      
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1.2.1 Notes About PI Kinase Nomenclature and Classification  
PI kinase nomenclature and classification are valuable in denoting the 
characteristics of a PI kinase and how it is related to other PI kinases.  Regrettably, a 
concern is that the nomenclature and classification has not always been consistent and 
there are multiple factors that complicate the process of trying to understand PI kinase 
nomenclature and classification. Figure 7 and Table 1 are helpful tools to understand the 
nomenclature and classification of PI kinases.   
 
A PI kinase is denoted as a PI3K (phosphatidylinositol 3-kinase), PI4K 
(phosphatidylinositol 4-kinase), or PIPK (phosphatidylinositol phosphate kinase).  The 
number in this short form (e.g., PI3K) indicates the position onto which the enzyme adds 
a phosphate group.  This is not an indication of substrate specificity; for example, a PI3K 
always adds the phosphate to position 3, but different PI3K enzymes use PI, PI(4)P, 
and/or PI(4,5)P2 as substrates to produce PI(3)P, PI(3,4)P2, and PI(3,4,5)P3.  However, 
the next step in classification, the type or class of the enzyme, is meant to categorize the 
structure, the substrate, how the enzyme is related to other PI kinases, and gives an 
indication of other properties that characterize that class.  The PI3Ks are split into Classes 
IA, IB, II, and III, while the PI4Ks are split into Types II and III, and the PIPKs are split 
into Types I, II, and III (Figure 7).  See Sections 1.2.2-1.2.4 for information on how each 
subgroup is characterized.    
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This brings us to the first challenge, the fact that the two types of the PI4Ks are 
called Type II and Type III and that there is, in fact, no Type I.  This challenge was 
unfortunately initiated when PI3 kinases were incorrectly first identified as Type I PI4Ks.  
When this mistake was rectified, the Type I enzymes were classified as PI3Ks instead, 
but the PI4Ks were, and still are, classified as Type II and III, and the designation of 
Type I PI4Ks has been dropped.  It was not possible to devise a comprehensive and 
accurate classification system without more information about the enzymes.  As such, the 
classification has been expanded and adapted over time as a greater understanding of PI 
kinase sequence, structure, homology, etc. was achieved.  Another complicating factor 
was that the initial classifications were based on characteristics of the enzymes 
(phosphorylation position, inhibitors, molecular weight (MW), etc.) and were not based 
on sequence or phylogeny.  Once more information about sequence homology and 
phylogeny was known, Brown & Auger classified Type III PI4Ks as Type IV PI3Ks, 
because even though Type III PI4Ks phosphorylate position 4, they are more closely 
related to the PI3Ks than the Type II PI4Ks (25) (Figure 7B).  Nevertheless, this did not 
become standard, and they are still classified as Type III PI4Ks (Figure 7A).  This is an 
example of how sequence homology and phylogeny complicated the classification, but it 
also allowed types or classes to be characterized by sequence homology and by the 
presence or absence of particular domains, which makes the classes/types reflect 
information about structure, and relatedness, at least for the PI3Ks and the PIPKs.  It also 
makes the classification more robust; without phylogeny if a person just looked at 
substrate for example, one could look at Type IA PI3Ks, which mainly phosphorylate 
PI(4,5)P2 to form PI(3,4,5)P3, and think that these enzymes belong with the PIPKs.  
However, looking at the domains of the PI3Ks and the PIPKs, Type IA PI3Ks belong 
with the other PI3Ks.  An overview of the classification of PI kinases can be found in 
Figure 7 and Table 1.      
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Table 1: Mammalian and yeast PI Kinase classification and nomenclature. Modified 
from Sasaki et al. (26) 
Class/Type  Protein  Reaction  Gene  
(HUGO) 
(25, 26) 
Alternative 
Names  
Yeast 
Homolog  
Phosphoinositide 3-
kinases (PI3K) 
Class 
IA 
PI3K 
p110a PI(4,5)P2 à PI(3,4,5)P3 
     PI à PI(3)P 
     PI(4)P à PI(3,4)P2 
PIK3CA PI3Ka 
PIK3CA 
 
p110b PI(4,5)P2 à PI(3,4,5)P3 
     PI à PI(3)P 
     PI(4)P à PI(3,4)P2 
PIK3CB PI3Kb 
PIK3CB 
 
p110d PI(4,5)P2 à PI(3,4,5)P3 
     PI à PI(3)P 
     PI(4)P à PI(3,4)P2 
PIK3CD PI3Kd 
PIK3CD 
 
Class 
IB 
PI3K 
p110g PI(4,5)P2 à PI(3,4,5)P3 
     PI à PI(3)P 
     PI(4)P à PI(3,4)P2 
PIK3CG PI3Kg 
PIK3CG 
 
Class 
II 
PI3K  
PI3K-
C2a 
PI à PI(3)P 
     PI(4)P à PI(3,4)P2 
PIK3C2A PIK3C2a 
Cpk-m 
 
PI3K-
C2b 
PI à PI(3)P 
     PI(4)P à PI(3,4)P2 
PIK3C2B PIK3C2b  
PI3K-
C2g 
PI à PI(3)P 
     PI(4)P à PI(3,4)P2 
PIK3C2G PIK3C2g  
Class 
III 
Vps34 PI à PI(3)P PIK3C3 PIK3C3 
PI3KC3 
Vps34 
(25) 
Phosphatidylinositol 
4-kinases (PI4K) 
Type 
II 
PI4K  
PI4K 
IIa 
PI à PI(4)P PI4K2A PI4K2A Lsb6 (27) 
PI4K 
IIb 
PI à PI(4)P PI4K2B PI4K2B 
Type 
III 
PI4K 
PI4K 
IIIa 
PI à PI(4)P PIK4CA PIK4CA 
PI4KA 
Stt4 (27) 
PI4K 
IIIb 
PI à PI(4)P PIK4CB PIK4CB 
PI4KB 
Pik1 (27) 
Phosphatidylinositol 
phosphate kinases 
(PIPK)  
Type I 
PIPK 
PIPK Ia PI(4)P à PI(4,5)P2 PIP5K1A PIP5KIa 
PIP5K1A 
Mouse:  
  PIPKIb 
  PIP5K1B 
Both Type 
I and 
Type II 
PIPks are 
homologs 
to yeast 
Mss4 (25) 
PIPK Ib PI(4)P à PI(4,5)P2 PIP5K1B PIP5KIb 
PIP5K1B 
Mouse:  
  PIPKIa 
  PIP5K1A 
PIPK Ig PI(4)P à PI(4,5)P2 PIP5K1C PIP5KIg 
PIP5K1C 
Type 
II 
PIPK 
PIPK 
IIa 
PI(5)P à PI(4,5)P2 PIP4K2A PIP4K2A 
PIP5K2A 
PIP5IIa 
PIPK 
IIb 
PI(5)P à PI(4,5)P2 PIP4K2B PIP4K2B 
PIP5K2B 
PIP5KIIb 
PIPK IIg PI(5)P à PI(4,5)P2 PIP4K2C PIP4K2C 
PIP5K2C 
PIP5KIIg 
Type 
III 
PIPK  
PIPK III PI(3)P à PI(3,5)P2 
     PI à PI(5)P  
PIP5K3 PIKFYVE 
p235 
PIP5K3 
Fab1 (25) 
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Another complicating factor is that the complexity of PI metabolism was not 
known at the outset, and so a naming system was not initially devised, and discovery was 
subject to chance timing.  Some proteins were named based on how they were found by 
their cellular function (e.g., Vsp34, and sorting vacuole proteins) before their 
molecular/enzymatic function (phosphorylation of PI to PI(3)P) was elucidated.  In the 
late 1990s Gehrmann, Heilmeyer and colleagues tried a different approach to the 
nomenclature that used the PI3K or PI4K designation followed by the enzyme molecular 
weight.  For example, they called the S. cerevisiae protein Pik1 PI4K120 (28). Some 
papers were published with this nomenclature (29–31) but mostly just from this group of 
researchers.  The naming system that has survived includes the position the enzyme 
phosphorylates, the Class or Type, and the isoform (refer to Table 1).  It is also common 
to use the Human Genome Organisation (HUGO) gene name, which follows this format 
(position, type, isoform); if italicized it refers to the gene and if it is not italicized, it 
refers to the protein.  Despite this more standard naming system, it is still not perfectly 
consistent.  For example, the Type II PI4Ks have the 4 before the K but the Type IIIs are 
written PIK4CB and the only indication that PIK4CB is a Type III PI4K is that it does 
not have a 2 in the name like the Type II enzymes do (eg. PI4K2B).  However, Table 1 is 
very helpful in understanding the nomenclature of mammalian and yeast PI kinases.   
 
Figure 7A is a visual organization of the classification of PI kinases.  It is 
important to note again that the original classification is based on which position the PI 
kinases phosphorylate, what their substrate is, the effect of different inhibitors and other 
characteristics; therefore, Figure 7A is not based on or representative of relatedness or 
evolutionary relationships, or else the Type III PI4Ks would be classified with the PI3Ks 
next to the Type III PI3Ks (Figure 7B).  For a more in depth look at the phylogenomics 
of PI kinases see the paper by Brown and Auger (25).  The two PI kinases that were used 
and studied in this thesis are human PIK3C3 (a PI3K III) and yeast Pik1 (a PI4K III), 
therefore these and their respective yeast and human homologs (Vps34 and PI4KIIIb) are 
the only PI kinases that will be discussed in detail in this document.  See Table 2 (p.28) 
for a summary of the characteristics of these PI kinases.   
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1.2.2 Classification, Nomenclature, and Structure of PI3Ks  
 The Type I “PI4Ks” (aka PI3Ks) phosphorylate position D3, have molecular 
weights of approximately 100-200kDa, and are typically inhibited by non-ionic 
detergents but not by adenosine (21, 32).  Wortmannin is a potent, specific, covalent 
inhibitor of PI3Ks (33).  Wortmannin also has many other practical advantages such as 
being cell permeable, being commercially available, and having very little effect on other 
signaling molecules (33).  Wortmannin was therefore used extensively to study PI3Ks 
and to explore the role(s) of PI3Ks in cell surface receptor-mediated signaling pathways, 
and growth factor and oncogenic signaling (32, 33).  Research on PI3K contributed to the 
PI field in two significant ways: one was through its close association with cancer, and 
the second was evidence that the product PIP functions as a signaling entity in the 
membrane and not just as a precursor to other signaling molecules.  Furthermore, later 
work found that proteins must exist that respond to these changes in lipid composition 
(32).  Interest in the association between growth factor and oncogenic signaling and PI3K 
activity drove research on this class of enzymes and this effort resulted in the discovery 
of various subclasses of PI3Ks as well as the characterization of the primary structures of 
these enzymes and their adaptor proteins (32).       
 
Type I “PI4Ks”, also known as PI3Ks, began to be classified separately from the 
PI4Ks; however, they were still sometimes referred to as Type I enzymes and this type of 
PI kinases was further classified into different classes (Class IA, IB, II, and III).  Note 
that some older publications refer to PI3Ks as Type I, Class IA, IB, II, and III; however, 
some newer publications use Type IA, IB, II, and III.  The classes are characterized by 
enzyme structure, amino acid homology and regulatory domains (25), activation cascades 
(25), and by the preferred PI or PIP substrate.   
 
Class I PI3Ks are heterodimeric (a catalytic subunit and a regulatory subunit), and 
preferentially phosphorylate PI(4,5)P2 to generate PI(3,4,5)P3.  This class is further 
subdivided into Class IA and IB based on their associated regulatory proteins.  Each 
catalytic subunit contains a regulatory protein binding domain, Ras-binding domain, a C2 
domain, a helical domain (also known as the Lipid Kinase Unique (LKU) domain), and a 
lipid kinase domain (Figure 8).  The Ras-binding domain is where GTP-bound Ras binds 
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to activate the catalytic subunit.  The C2 domain is thought to participate in membrane 
interaction, and the LKU domain is important in interdomain packing (26).  
 
Class II PI3Ks are monomeric and they typically phosphorylate PI to generate 
PI(3)P.  Class II PI3Ks have structural similarity to Class I enzymes as seen by their 
common domains: the Ras-binding domain, the C2 domain, the LKU domain, and the 
lipid kinase domain.  Class II enzymes also have a phox (PX) domain, and an additional 
C2 domain at their C-termini, as well as at least two proline rich (PR) regions (Figure 8). 
The phox homology domain is known to bind PI(3)P and other PIP species (26, 34).  
 
Class III PI3Ks have a limited substrate specificity and only phosphorylate PI to 
form PI(3)P.  These proteins have a C2 domain, a helical domain, and a lipid kinase 
domain, however, they lack the other domains common to Class I and Class II enzymes 
(Figure 8).  Class III is further distinguished from Class I by their metal ion requirement; 
Class III enzymes have been demonstrated to have higher activity in the presence of Mn2+ 
than Mg2+.  The only PI3K found in S. cerevisiae is an enzyme called Vps34 (vacuolar 
protein sorting 34) and it is a Class III PI3K.  This enzyme has been conserved from yeast 
to humans and, of the known members of the mammalian PI3K family, the mammalian 
homolog of Vps34 is the only one that is classified as a Class III PI3K.  Vps34 and its 
homologs occur in all major taxonomic groups and it is the only PI3K in plant and fungus 
genomes (25).  (As of 2011, PIK3C3 was the only class III known, and even in 2019 
publications, PIK3C3 is the only one mentioned as a class III PI3K (35)).  Sometimes this 
mammalian protein is referred to as Vps34 and sometimes it is referred to as PIK3C3 as 
its HUGO gene name is PIK3C3.  To prevent this protein from getting confused with S. 
cerevisiae Vps34, PIK3C3 will be used in this document to denote the human Class III 
PI3K protein and Vps34 will be used to denote the S. cerevisiae homolog  (26).  
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Figure 8: The vertebrate family of PI3Ks and the yeast homolog Vps34.  The Class I 
PI3Ks are often called p110.  Vps34 is the only PI3K in yeast.  All PI3Ks have a 
conserved C-terminal catalytic domain (red) preceded by a lipid kinase unique (LKU) 
domain (yellow), and a C2 domain (bright green).  Other domains include a p85 binding 
region (p85BR) where the regulatory subunits bind (grey), Ras binding domains (Ras-
BD) (forest green), an N-terminal adaptor binding region (AdBR) (grey), a proline rich 
(PR) sequence (light blue), and a phox-homology (PX) domain (grey).  Modified with 
permission from (32).    
 
 
1.2.3 Classification, Nomenclature, and Structure of PI4Ks  
All PI4Ks use PI as their substrate and phosphorylate position D4 of the inositol 
ring to produce PI(4)P (26).  Type II PI4Ks are typically activated by detergent and 
inhibited by adenosine (21).  Type III PI4Ks are also activated by detergents but are 
relatively resistant to inhibition by adenosine.  They also are resistant to inhibition by a 
monoclonal antibody that caused greater than 90% inhibition of the Type II PI kinases 
(21).  There are no Type I PI4Ks.  
   
Type II PI4Ks are the most abundant subgroup of PI kinases in most animal cells 
and tissues.  As a result of this, they were among the first PI kinases to be detected and 
characterized biochemically and were originally thought to be the only source of PI(4)P 
(27).  Type II PI4Ks have an apparent MW of 45-55kDa, are stimulated by Triton X-100, 
and have a relatively low sensitivity to wortmannin (27).  Type II PI4Ks are also 
inhibited by Ca2+, a monoclonal antibody called mAb 4C5G, and by low concentrations 
of adenosine (27).  Type II PI4K enzymes do not share sequence homology with any of 
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the PI3Ks or the Type III PI4Ks (25).  The catalytic lipid kinase domain is split in two 
with a long insert between them (26, 27) (Figure 9).  In mammalian isoforms the N-
terminal half contains a cysteine-rich domain that is palmitoylated, which likely 
facilitates membrane targeting (26).  It is possible that the yeast isoform may also require 
S-palmitoylation (27).  There are two mammalian Type II PI4K isoforms, namely 
PI4KIIa and PI4KIIb, and one yeast isoform Lsb6 (Table 1, Figure 9).  However, these 
enzymes will not be covered in further detail in this thesis.   
 
Type III PI4Ks generally have much greater apparent MWs than Type II PI4Ks 
(26, 27).  Type III PI4Ks are stimulated by Triton X-100 and, like PI3Ks, are sensitive to 
inhibition by wortmannin (28, 36).  Ca2+ has no direct effect on Type III PI4K activity, 
they are not inhibited by the monoclonal antibody mAb 4C5G, and they display little or 
no inhibition by adenosine (27, 36).  Type III PI4Ks are structural relatives of PI3Ks and 
contain a C-terminal lipid kinase domain similar to the PI3K kinase domain, which 
explains the inhibition of Type III PI4Ks by wortmannin (25, 26, 36).  The structure of 
the human PI4KIIIb was close enough to the structure of the human PI3KIII (PIK3C3) 
that the structure could be solved by molecular replacement using the structure of 
PIK3C3 (37).  Mammalian Type III PI4Ks also contain a proline rich N-terminal region, 
and a lipid kinase unique (LKU) domain that is predicted to be helical and homologous to 
the helical domain in the PI3Ks (26, 36).  Type III PI4Ks are further classified into a and 
b isozymes based on their domains (26).  The a-isozymes have a pleckstrin homology 
(PH) domain between the LKU and the catalytic domain that may be involved in the 
association with membranes.  Mammalian a-isozymes also have a bipartite nuclear 
localization sequence (NLS) (26, 36).  The b-isozymes can share three regions of varying 
degrees of homology between the LKU and the catalytic domain.  In Pik1, the yeast PI4K 
IIIb, immediately following the C-terminus of the LKU domain is the Frq-binding site 
and there is some level of conservation in this region in the vertebrate PI4KIIIb.  
Following the Frq-binding site there is a serine rich region that contains multiple 
phosphorylation sites (not shown in Figure 9).  Adjacent to this region is a third region of 
homology that was shown to be a Rab binding domain in the mammalian b-isozymes 
(36).  Rab binding may regulate membrane transport from the Golgi to the PM (26).  
 
 
19 
There are two Type III PI4Ks in S. cerevisiae Stt4 (a PI4K IIIa isozyme) and Pik1 (a 
PI4K IIIb isozyme) and these are homologous to the two Type III PI4Ks in mammals, 
PI4KIIIa (aka PIK4CA, a PI4K IIIa isozyme) and PI4KIIIb (aka PIK4CB, a PI4K IIIb 
isozyme) (26, 36).  Pik1 and PI4KIIIb are the only Type III PI4Ks that will continue to be 
discussed in this document.  (Figure 9) 
 
 
Figure 9: The vertebrate family of PI4K enzymes and the yeast homologs.  The yeast 
proteins, Stt4, Pik1, and Lsb6, are depicted below their vertebrate homologs.  The type III 
PI4K enzymes are comprised of two proteins PI4KIII𝛼 (Stt4 in yeast) and PI4KIII𝛽 (Pik1 
in yeast).  They are related to the PI3Ks and they have some domains in common with the 
PI3Ks, including a highly conserved C-terminal catalytic domain (red) and a lipid kinase 
unique (LKU) domain (mustard yellow).  Other domains include proline-rich (PR) 
sequences (light blue), the binding site for the viral protein NS5A (grey), a nuclear 
localization signal (NLS, grey), pleckstrin homology (PH) domains (bright green), 
frequenin-binding (Fq) domains (royal blue), and Rab binding domains (forest green).  
There are two forms of type II PI4Ks in vertebrates, PI4KII𝛼 and PI4KII𝛽, and one form 
in S. cerevisiae (Lsb6).  There is a non-conserved insert between two halves of the lipid 
kinase domain and the vertebrate PI4Ks also have cysteine-rich (CR) sequences (yellow) 
that get palmitoylated.  Figure modified with permission from (32).    
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1.2.4 Classification, Nomenclature, and Structure of PIPKs  
 The third group of PI kinases are called phosphatidylinositol phosphate kinases 
(PIPKs).  These enzymes do not share significant sequence homology with any other 
known lipid or protein kinases, but all PIPKs share a central kinase core domain (PIPKc) 
that shows approximately 80% amino acid identity with other PIPK proteins (Figure 10).  
There are three types of PIPKs: Type I enzymes phosphorylate position D5 of PI(4)P, 
Type II enzymes phosphorylate position D4 of PI(5)P, and Type III enzymes 
phosphorylate PI and PI(3)P at position D5 to produce PI(5)P and PI(3,5)P (26).   
 
Figure 10: The vertebrate family of PIPK enzymes and the yeast homologs.  
Vertebrate Type I and Type II PIPKs generate PI(4,5)P2 from either PI(4)P (Type I) or 
PI(5)P (Type II) and there are six Type I and Type II PIPKs total.  There is only one yeast 
enzyme that generates PI(4,5)P2; it is called Mss4 and it uses PI(4)P as its substrate.  
Type III PIPKs generate PI(3,5)P2 from PI(3)P and Fab1 is the yeast Type III PIPK. 
PIPKs do not share significant sequence homology with PI3Ks or PI4Ks, but all PIPKs 
share a central kinase core domain (red).   Other domains include the PI(3)P binding 
domain FYVE (green), a dishevelled, Egl-10 and Pleckstrin domain (DEP) domain (navy 
blue), a Cpn60/TCP-1 chaperonin family domain (TCP-1) (light blue), and a cysteine-rich 
(CR) sequence (yellow).  Figure modified with permission from (32).   
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1.2.5 Type III PI-3 Kinases: PIK3C3 and Vps34  
 PIK3C3 and Vps34 are homologous proteins from humans and S. cerevisiae, 
respectively, and they show a high degree of homology over their entire length: 37% 
identity and 58% similarity at the amino acid level (38).  PIK3C3 and Vps34 are both 
Type III PI3Ks which specifically phosphorylate the D-3 position of PI to form PI(3)P 
(38–40).  They both also require Mn2+ for their activity, but can be weakly active in the 
presence of Mg2+ (38, 40).  PIK3C3 has a calculated MW of 101,549 Da (UniProtKb- 
Q8NEB9) (41), a specific activity between 78-216 nmol/min/mg (42), and it does not 
exhibit autophosphorylation (38).  Vps34 has a calculated MW of 100,921 Da 
(UniProtKB- P22543) (43), and it does undergo autophosphorylation in vivo and in vitro 
(39, 40).  See Table 2 (p.28) for an overview of the characteristics of the PI kinases 
focused on in this thesis.   
 
 The inhibitory or stimulatory effects of different entities on PI kinase activity 
have been explored to characterize their function.  PI3Ks are typically inhibited by non-
ionic detergents; this is consistent with PIK3C3 and Vps34, as both are inhibited by the 
non-ionic detergent NP40 with IC50 values of 0.01% and 1% for PIK3C3 and Vps34, 
respectively (38).  However, low concentrations of NP40 (around 0.05%) stimulated the 
of activity of Vps34, but no stimulation of activity was observed for PIK3C3 at the tested 
concentrations (i.e., NP40 was inhibitory at all concentrations tested for PIK3C3) (38).  
Adenosine sensitivity is another way of characterizing PI kinases; both PIK3C3 and 
Vps34 are insensitive to inhibition by adenosine up to 1mM (38).  PIK3C3 and Vps34 
differ in their sensitivity to wortmannin.  PIK3C3 is inhibited by wortmannin at low 
nanomolar concentrations and has an IC50 value of 2.5nM (38).  Vps34, however, is 
resistant to inhibition by wortmannin and has an IC50 value of 3µM (39, 40).   
 
These proteins are the only Type III PI-3 kinases in both S. cerevisiae and 
mammals (25, 26).  Yeast cells containing a null mutant form of Vps34 lack the PI3K 
activity that is seen in wild-type strains, thus indicating that Vps34 is the sole source of 
PI(3)P in S. cerevisiae (27).  PIK3C3 is likely the primary but not the only kinase that 
produces PI(3)P in mammals.  A reduction in PI(3)P levels in the quadriceps muscles of 
skeletal muscle specific PIK3C3 knockout verses wildtype mice supports this claim.  It is 
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hypothesized that the other enzyme producing PI(3)P is the type II PI3K Pik3c2b based 
on gene expression data.  However, the reduction of and not abolition of PI(3)P 
production may be caused by residual PIK3C3 expression in myofibers or PIK3C3 
expression in non-muscle cell types that are present in total muscle extracts (44).  Whole-
animal gene knockout of PIK3C3 results in early embryonic lethality (44).  S. cerevisiae 
with a Vps34 null allele are viable, but are compromised with respect to growth at 30°C 
and are inviable at 37°C (27). 
 
 
1.2.5.1 Adaptor Proteins and Recruitment to the Membrane  
 Vps34 was identified during genetic studies focused on finding cellular 
components required for vacuolar protein localization (45).  Many yeast mutants that 
were defective in vacuolar protein sorting (vps mutants) were identified, vps34 and vps15 
being two of them.  These two mutants were of particular interest because the phenotypes 
implied that they are specifically required for the sorting of soluble vacuolar proteins and 
that they act at the same step of the vacuolar protein sorting pathway (45, 46).  Vps15 
was found to be a 160kDa serine/threonine kinase that is myristoylated and is located on 
the cytoplasmic face of a late Golgi compartment or an intermediate membrane in the 
transport between the Golgi complex and the vacuole (38, 45).  Vps15 and Vps34 
physically and functionally interact; Vps15 is responsible for the membrane localization 
of Vps34 and Vps15 protein kinase activity is required for the stimulation of Vps34 PI 
kinase activity (27, 45, 46).  Vps15 and Vps34 act in two different multi-subunit 
complexes to regulate two different pathways (27).  Complex I comprises the proteins 
Vps15, Vps34, Vps30, and Atg14, and it regulates the autophagy/cytosol-to-vacuole 
transport pathway (27).  Complex II is composed of Vps15, Vps34, Vps30, and Vps38 
and it controls the Vps pathway (27). 
 
 In 1995 Volinia and coworkers identified and characterized a human 
phosphatidylinositol 3-kinase complex related to the yeast Vps34-Vps15 complex (38).  
The proteins of interest in this complex were later referred to as PIK3C3 and p150 (aka 
PIK3R4).  After PIK3C3 was found, cloned, and characterized using degenerate primers 
based on amino acid sequences that are conserved among yeast Vps34 and bovine p110a, 
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immunoprecipitation of PIK3C3 from human Jurkat 6 cell lysates revealed three proteins 
that associated with PIK3C3 (38).  The 150 kDa protein (p150), co-immunoprecipitated 
in an approximately equimolar ratio with PIK3C3 and further investigation revealed that 
p150 is homologous to Vps15 (38).  The amino acid sequences of these proteins are 
29.6% identical and 53% similar (47).  A region with 100% identity between Vps15 and 
p150 is a typical signature of protein kinases (38).  Details about the other proteins in this 
complex and the role of the complex in autophagy can be found in (48).   
 
1.2.6 Type III PI-4 Kinases: PI4K IIIb and Pik1  
PI4K III𝛽 and Pik1 are homologous proteins from human and S. cerevisiae, 
respectively, and they show a high degree of sequence homology, especially in particular 
domains.  PI4K III𝛽 and PIK1 have 42% sequence identity in the catalytic domain and 
17% in the lipid kinase unique domain (49).  The Pik1 protein also shares sequence 
similarity with p110 (a Class I PI3K) and S. cerevisiae Vps34 in these two regions (9).  
The C-terminal region of homology is the catalytic domain and Pik1 shares 30% identity 
with Vps34 and 29% identity with p110 in this region (9).  If conservative amino acid 
replacements are taken into account, the similarity of all three proteins exceeds 50% in 
this domain (9).  The second main region of homology is near the N-terminus and Pik1 
has 24% and 25% identity with Vps34 and p110 in this region (9).  However, Vps34 has 
a large insert in this region, while p110 does not (9).  This region is referred to as the 
LKU domain and this region is homologous to the helical domain (aka the LKU domain) 
in PI3Ks (26, 27, 32) (Figures 8 & 9).  See Table 2 for an overview of the characteristics 
of the PI kinases focused on in this thesis.   
 
PI4K III𝛽 and Pik1 are both Type III PI4Ks and specifically phosphorylate the D-
4 position of PI to form PI(4)P (49, 50).  Both are typically assayed in the presence of 
Mg2+ (50–52).  PI4K III𝛽 has a calculated MW of 91,379 Da (UniProtKb- Q9UBF8) 
(53), and the specific activity of apo PI4K III𝛽 was determined to be 0.8 (SD ± 0.11) or 
1.71 (SD ± 0.05) nmol ADP/min/mg depending on the vesicle substrate using the 
Transcreener ADP2 FI Assay (Bellbrook Labs) (see Section 1.4 for a description of the 
assay) (52).  PI4K III𝛽 is activated by the phosphorylation of Ser294 by protein kinase D; 
this phosphorylation mediates the recruitment of proteins that stabilize the lipid kinase 
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activity of PI4K III𝛽 (54).  Pik1 has a calculated MW of 119,923 Da (UniProtKB- 
P39104) (55), and the specific activity of a purified fraction of Pik1 was determined to be 
4.3 µmol/min/mg protein on detergent lipid micelles using a PI kinase assay based on [𝛾-
32P]ATP (50).    
 
The inhibitory or stimulatory effect of different entities on PI kinase activity also 
contributes to the characterization of PI4Ks.  PI4K III𝛽 is stimulated by non-ionic 
detergent, but not as much as Type II PI4Ks are (49).  The activity of Pik1 is stimulated 
by the non-ionic detergent Triton X-100; when Triton X-100 was removed from the assay ≤50% of the activity of the standard conditions was observed (50).  In general, Type III 
PI4Ks are inhibited by wortmannin but are not sensitive to adenosine (37).  However, 
PI4K III𝛽 and Pik1 differ in their sensitivity to wortmannin and to adenosine.  PI4K III𝛽 
is strongly inhibited by wortmannin (IC50 = 120nM -140nM) and experiences modest 
inhibition by 500µM adenosine (49).  Pik1 is unaffected by wortmannin and is insensitive 
to adenosine (27, 50).  No inhibition of Pik1 is observed up to 1mM adenosine and only 
modest inhibition (≤30%) is seen at very high concentrations of adenosine (10mM) (50).    
       
There are four mammalian PI4K isozymes: PI4KII𝛼, PI4KII𝛽, PI4KIII𝛼, and 
PI4KIII𝛽; each localizes to a specific cellular compartment, indicating that each produces 
a pool of PI(4)P required for a different function (26).  PI4KIII𝛽 was found to be 
ubiquitously expressed in rat tissues and it localized to either early Golgi compartments 
or the nucleus depending on the phosphorylation state of the PI4KIII𝛽 protein. 
Phosphorylation on Ser294 targeted the enzyme exclusively to the Golgi, whereas 
phosphorylation on Ser496 or Thr504 results in its detection in the nucleus (26).  In yeast, 
there are also two Type III PI4K isozymes: Type III𝛼 Stt4, and Type III𝛽 Pik1 (27).  
Both are essential for yeast cell viability and the overexpression of one cannot make up 
for the knockout of the other (27).  This is evidence that Pik1 and Stt4 generate discrete 
pools of PI(4)P that regulate different essential physiological processes (27).  Pik1 
generates PI(4)P at the Golgi and Stt4 generates PI(4)P at the plasma membrane (5).     
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1.2.6.1 Adaptor Proteins and Recruitment to the Membrane  
Frequenin (Frq1) is the 22kDa adaptor protein for Pik1.  Pik1 is the only essential 
target of Frq1, which is required for the optimal activity of Pik1 (3).  Frq1 is essential for 
the growth of budding yeast and it belongs to the recoverin/frequenin branch of the EF-
hand superfamily (56).  Proteins in this superfamily detect changes in intracellular Ca2+ 
levels and transduce the signal via conformational changes upon Ca2+-binding to control 
many important physiological processes (56).  N-Myristoylation and the Ca2+-binding 
contribute to the ability of Frq1 to associate with membranes in vivo (56).  However, the 
N-myristoylation is important but not essential for the recruitment and stimulation of the 
catalytic activity, and there is evidence that Frq1 does not contain a functional Ca2+ -
myristoyl switch (3, 57).  After Pik1 was initially characterized, further investigation lead 
to the discovery that the purified Pik1 was actually a tightly bound complex of Pik1 and 
Frq1, with the two proteins being present in a 1:1 ratio (3).  The binding energetics for the 
complex were determined by isothermal titration calorimetry and the dissociation 
constant and binding enthalpy were determined to be ~100nM and +7kcal/mol (57, 58).  
The NMR structure of Ca2+-bound Frq1 complexed to an N-terminal Pik1 fragment 
(residues 121-174) was determined (PDB code 2JU0) (57).  Frq1 forms a groove with 
two hydrophobic pockets, while the Pik1 fragment forms two helices connected by a 20-
residue loop such that each helix contacts a pocket in the groove of Frq1 (57).  This can 
be seen in Figure 11.  
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Figure 11: Solved NMR-derived structures of a fragment of Pik1 (residues 121-174) 
with Frq1 (PDB code 2JU0). A. Ribbon diagram of the average main chain structure of 
20 NMR-derived structures of the complex, viewed from the binding surface and rotated 
180°. Ca2+ ions are shown in orange and Pik1 residues are in magenta. B. Space-filling 
model of the average main chain of 20 NMR-derived structures of the complex.  The two 
hydrophobic patches in the groove of Frq1 are shown in yellow and the Pik1 residues are 
in magenta. This figure was reproduced with permission from Strahl et al. (57).   
 
Frq1 has been shown to facilitate the membrane targeting of Pik1 and to stimulate 
its activity (3, 56, 57).  Measuring the catalytic activity of Pik1 mutants showed that 
activation of Pik1 by Frq1 does not involve relief of an autoinhibitory constraint; instead 
the Pik1 catalytic domain by itself is inactive and requires interaction and stabilization by 
an auxiliary domain at the N-terminus (57).  The necessary auxiliary domain was 
determined to be the LKU domain (57).  The binding of Ca2+-bound Frq1 to Pik1 
imposes a U-turn in the Pik1 chain that may modulate the interaction between the LKU 
and catalytic domains (57).  This is the proposed model of the activation of Pik1 by Frq1 
and this model is depicted in Figure 12.  
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Figure 12: Cartoon diagram of how Frq1 is proposed to stimulate Pik1 activity. 
Figure reproduced with permission from Strahl et al. (57).  
 
The human orthologue of frequenin is neuronal calcium sensor-1 (NCS-1); 
however, the roles of NCS-1 and of Frq1 are likely to be different.  A helix that is 
involved in the binding of Frq1 with Pik1 is not conserved in PI4KIII𝛽 and although 
NCS-1 binds PI4KIII𝛽 and enhances its activity, it does not localize PI4KIII𝛽 to the 
Golgi (54).  However, three different proteins, the GTPase ADP-ribosylation factor 1 
(Arf1), the small GTPase Rab11, and the Acyl-CoA-binding domain containing protein 3 
(ACBD3), have been shown to recruit PI4KIII𝛽 to the Golgi.  The interaction between 
PI4KIII𝛽 and each of these proteins have been shown to be important in PI(4)P 
production at the Golgi and ultimately for efficient transport from the Golgi to the plasma 
membrane (26, 54).  PI4KIII𝛽 is also localized to the nucleus and localization is 
associated with phosphorylation at different protein sites.  For example, PI4KIII𝛽 
phosphorylated on Ser-294 is only found at the Golgi, while PI4KIII𝛽 phosphorylated on 
Ser-496 and Thr-504 is found in nuclear speckles (59).  Phosphorylation at Ser-294 
increases the lipid kinase activity (59).         
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Table 2: Summary of the characteristics of the PI kinases PIK3C3, Vps34, 
PI4KIIIb, and Pik1.  
Enzyme  PIK3C3 Vps34 PI4K IIIb Pik1 
Type  PI 3-kinase: 
Type III 
PI 3-kinase: 
Type III 
PI 4-kinase: Type 
III 
PI 4-kinase: 
Type III 
Organism  Human   Yeast  Human  Yeast  
MW 101,549 Da 
(UniProtKb- 
Q8NEB9)  
100,921 Da 
(UniProtKB- 
P22543)  
91,379 Da 
(UniProtKB- 
Q9UBF8)  
 119,923 Da 
(UniProtKB- 
P39104)  
Adaptor  
Molecule 
p150 (38) 
(aka PIK3R4) 
Vps15 (38, 39) 
 
ACBD3, Rab11, 
Arf1 (26, 51, 52, 
54, 60, 61) 
Frq1 (3) 
Substrate  
Specificity 
PI (38) PI (39, 40) 
 
PI (49) PI (50) 
Phosphorylates 
position:  
D3 (38) D3 (39, 40) D4 (49) D4 (50) 
Product PI(3)P (38) 
 
PI(3)P (39, 40) PI(4)P (49) PI(4)P (50) 
Null allele/ 
knockout lethal  
Yes (44) Yes at 37°C but 
viable 30°C (27) 
No (62) Yes (15) 
Cation  
Dependence  
  
Mn2+ dependent, 
weakly active 
with Mg2+ (38) 
Mn2+ dependent, 
weakly active 
with Mg2+ (40) 
Activity assayed 
with Mg2+ (51, 
52) 
Activity assayed 
with Mg2+ (50) 
Effect of low 
[non-ionic 
detergent 
NP40] / effect 
of Triton  
Inhibition (IC50 = 
0.01% ) at low 
[NP40]  
(38) 
Inhibition (IC50 
= 1%), but 
stimulation at 
very low [NP40] 
(38) 
Modestly affected 
by non-ionic 
detergent (49)  
Stimulated by 
Triton X-100. 
(50) 
IC50 for  
Wortmannin  
IC50 = 2.5nM  
Inhibited at low 
nanomolar range 
(38) 
IC50 = 3µM (39) 
Highly resistant 
to wortmannin 
(40)  
IC50 = 120nM - 
140nM  
Strongly inhibited 
by wortmannin 
(49) 
Unaffected by 
wortmannin (27) 
 
Adenosine 
Sensitivity  
Insensitive 
No inhibition up 
to 1mM (38) 
Insensitive  
No inhibition up 
to 1mM (38) 
Modest inhibition 
by 500µM (49) 
Insensitive (50) 
No inhibition up 
to 1mM (50) 
Sequence 
Homology  
Extensive 
sequence 
homology to 
yeast Vps34, 
37% identity, 
58% similarity at 
amino acid level 
(38) 
Extensive 
sequence 
homology to 
PIK3C3, 37% 
identity, 58% 
similarity at 
amino acid level 
(38) 
Shares sequence 
homology with 
yeast PIK1, 42% 
identity in the 
catalytic domain 
and 17% in the 
LKU domain at 
the gene level 
(49) 
Shares sequence 
homology with 
yeast Vps34, 
30% identity in 
the catalytic 
domain, and 
24% identity in 
the LKU domain 
at the amino acid 
level (9) 
 
 
 
29 
1.3 Lipid Transfer Proteins, Sec14, and the Regulation of Pik1  
1.3.1 The Structure of Sec14 and the Sec14 Superfamily  
Sec14 is the archetypal member of the Sec14 superfamily.  This family is 
composed of phosphatidylinositol (PI)/phosphatidylcholine (PC) transfer proteins 
(PITPs), which are ancient, eukaryotic, non-enzymatic proteins that bind PI and mediate 
the transfer of PI between membrane bilayers in vitro in an energy independent manner.  
PITPs exhibit similar in vitro biochemical activities; however, they are categorized into 
two groups based on their structure and their primary sequence homology.  The two 
groups are not structurally related and do not share primary sequence similarity.  These 
two groups are the Sec14-like PITPs and the START-like PITPs (steroidogenic acute 
response related transfer domain).  Only Sec14-like PITPs will be covered further within 
this thesis (4).  
 
The Sec14 fold is composed of 12 𝛼-helices, 6 𝛽-strands, and 8 310 helices 
(Figure 13) (4).  The 6 𝛽-strands and 3 of the 𝛼-helices form a hydrophobic pocket that is 
gated by a A10/T4 helix gating module; the phospholipid binds in this hydrophobic 
pocket.  The A10/T4 helix gating module is mobile and is in different conformations based 
on the presence or absence of bound hydrophobic ligand, or if the protein is bound to a 
membrane or not (shown in red in Figure 13).  Sec14 likely associates with a membrane 
and inserts the gating module into the hydrophobic core as it transitions to the open state 
(63).  The A1-A4 𝛼-helices at the N-terminus form a tripod like motif and this structural 
segment is responsible for the targeting of Sec14 to Golgi membranes.  The crystal 
structure of apo-Sec14 (1AUA – open, crystalized with bound detergent) and of holo-
Sfh1 (3B7N - closed and containing PI in the hydrophobic pocket) are shown in Figure 
13.  The detergent 𝛽-octylglucoside was required for the crystallization of Sec14, 
therefore the crystal structure represents the open conformation with the detergent in the 
lipid binding site.  However, the crystal structure of the closest Sec14 homolog, Sfh1 
(62.3% identity with Sec14), was achieved without detergent and with physiologically 
relevant phospholipid ligands.  Therefore the structure of Sfh1 could be used to infer how 
Sec14 binds its physiological ligands (4, 64).   
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Figure 13: Ribbon diagram of (A) Apo-Sec14 (1AUA) and (B) Holo-Sfh1bound to PI 
(3B7N).  𝛼-Helices are in blue, 𝛽-strands are in yellow, and the A10/T4 helix gating 
module is in red. Image reproduced with permission from (65).  
 
The classical functional description of Sec14 involves its action as a lipid ligand 
transfer agent between membranes (63).  In this model, Sec14 in its closed, ligand-bound 
state associates with a membrane and inserts the A10/T4 helix gating module into the 
bilayer as it transitions to the open state (63).  In the open state, the bound phospholipid is 
released into the membrane and a different phospholipid can bind in the hydrophobic 
pocket (63).  Multiple exchange cycles may occur but ultimately the helix gating module 
closes and Sec14 dissociates from the membrane (63).  Sec14 then shuttles its 
phospholipid ligand to a different membrane and the processes repeats. This is visualized 
in Figure 14 (63).  However, genetic studies and the analysis of the structure of wild type 
Sec14 suggest that the function of Sec14 is more complicated than membrane-to-
membrane phospholipid exchange (66).  Sec14 has been shown to act as a signal 
integrator between lipid metabolism and PIP signaling (4) and it stimulates the kinase 
activity of Pik1 in vivo (1, 64, 67–70).  This led to a presentation model of Sec14 
mediated Pik1 activation. 
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Figure 14: Classical lipid transfer model of Sec14 activity.  Helix gating module 
shown as a cylinder, PI shown in blue, and PC shown in yellow.  Image used with 
permission from (63).  
 
1.3.2 Presentation Model of Sec14-Mediated Pik1 Stimulation  
Bankaitis and colleagues proposed a lipid presentation model to describe the 
stimulation of Pik1 by Sec14 (Figure 15).  In this model, Sec14 is proposed to mediate 
heterotypic exchange, binding both PI and PC, and during this exchange PI is presented 
to Pik1 making it a better substrate for phosphorylation.  In this model, the in vitro PITP 
ligand transfer activity of Sec14 does not describe the in vivo activity; the essential 
activity of Sec14 is not to transport a phospholipid between lipid layers, rather it is to 
undergo heterotypic exchange at the membrane.  Any cytosolic Sec14 bound to PI or PC 
would therefore be non-functional artefacts instead of active components or intermediate 
stages of the essential activity.  There are two hypotheses for how the presentation of PI 
occurs during the heterotypic exchange; however, these hypotheses are not mutually 
exclusive (64).  The exchange may occur through different portals so that as PC is 
entering the Sec14 ligand binding site via one portal, PI is ejected from the hydrophobic 
binding pocket through an exit portal.  As PI is ejected, it transiently exists as an exposed 
intermediate and the inositol head group is susceptible to phosphorylation by Pik1.  
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Under the second hypothesis, the exchange occurs via overlapping entry and exit portals.  
The headgroup of PC is bound deep within the hydrophobic binding pocket (Figure 16) 
and PC will therefore slowly egress from the binding pocket.  The headgroup of PI, 
however, is bound with a higher affinity than PC by a network of residues nearby but 
below the surface of the protein.  Sec14 has a ~16-fold preference for PI over PC.  
Therefore, PI will ultimately displace bound PC from Sec14 but during the process there 
may be multiple unsuccessful attempts of PI to bind.  During these attempts, PI would 
exist as an exposed intermediate susceptible to Pik1. See Figure 15 for a diagram of this 
presentation model (10, 64).  
 
 
Figure 15: Proposed PI presentation model for the function of Sec14 in PIP 
homeostasis. A. Sec14 presentation of PI to Pik1 via heterotypic exchange of PI (pink) 
for PC (blue) through distinct entry and exit portals.  B. Sec14 presentation of PI via 
heterotypic exchange through overlapping portals.  Images modified with permission 
from (64, 65). 
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Figure 16: Ribbon diagram Sfh1 bound to PC (A) or PI (B).  𝛼-Helices shown in 
green, 310 helices are shown in orange, and 𝛽 strands are shown in yellow.   Images 
modified with permission from (64).  
   
1.3.3 Genetic and Structural Evidence of Mechanism  
 In 1989 the SEC14 gene was observed to be essential for yeast vegetative growth 
and the SEC14 gene product was identified as a cytosolic factor that was required for the 
transport of secretory proteins from the yeast Golgi complex (71).  The SEC14 gene was 
later determined to be identical to the independently characterized PIT1 gene, which was 
known to encode a PI/PC transfer protein in yeast (72).  This established an in vivo 
function (the stimulation of compartment-specific secretion) for a phospholipid transfer 
protein for the first time (72).  To determine if the in vivo activity of Sec14 was 
represented by its in vitro PITP activity, rat PITP, which has very similar catalytic 
properties as Sec14 but no detectable primary sequence homology, was expressed in 
Sec14 mutants (73).  Rat PITP mediated complementation of Sec14 defects but could not 
fully substitute for Sec14 function (73).  There are two main possible explanations for 
this observation.  First, the rat PITP and Sec14 act via different in vivo mechanisms, such 
that one may genuinely act as a PITP in vivo and the other’s in vitro PITP activity reflects 
a different phospholipid binding activity in vivo (73).  Second, the two proteins operate in 
a mechanistically similar way, but the rat PITP is missing an additional capability, such 
as the targeted binding of Golgi membranes, that is required for the in vivo activity of 
Sec14 (73).  It was observed that Sec14 levels impact the apparent rate of PC 
biosynthesis via the CDP-choline pathway in vivo and this led to the hypothesis that 
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Sec14 senses the phospholipid composition of Golgi membranes and functions in the 
maintenance of proper composition of these membranes.  This hypothesis also supposes 
that this is how Sec14 mediates secretion in yeast, because phospholipid composition is 
proposed as a critical determinant of Golgi secretory competence (73, 74).   
 
 The specific role that Sec14 has in secretion from the Golgi was investigated by 
generating suppressor mutations that are able to rescue temperature sensitive sec14 
mutants.  SAC1 encodes a phosphatase that hydrolyzes PI4P and some other PIPs.  sac1-
22 is a full length but non-functional mutant of SAC1 (75).   sac1-22 led to the 
accumulation of PI4P and was a suppressor mutation that rescued cells containing 
mutated non-functional sec14 when inositol was provided in the media (75).  This 
indicated that PI4P may be limited in cells having mutant sec14 causing the observed 
secretory defects.  This hypothesis was tested by measuring PI4P levels in the sec14-3 
mutant and by measuring the growth of mutant sec14 cells carrying a plasmid for 
different PI kinases at normally non-permissive temperatures.  This mutant is sometimes 
referred to as CTY1-1A and the genotype is MATa ura3-52 𝛥his3-200 lys2-801(Am) 
sec14-1(Ts) (76).  The sec14-1ts mutation is a missense mutation that disrupts the T5 helix 
(77).  sec14-3 mutants had decreased levels of PI4P and cells overexpressing PIK1, but 
not STT4 (the other yeast PI4K gene) or VPS34 (the yeast PI3K gene), could grow at an 
otherwise non-permissive temperature.  Furthermore, two pik1ts mutants both experienced 
an ~60% drop in PI4P level within 1h of growth at the restrictive temperature.  A drop in 
the secretion of invertase was also observed; however, no change was seen in the 
maturation of the vacuolar enzyme carboxypeptidase Y.  Overall, three conclusions were 
made from all these experiments.  The first was that PI4P is limited in cells with mutant 
sec14 and that this is a major factor in the secretory defect.  The second was that in vivo 
function of Sec14 is coupled to the activity of Pik1.  The final conclusion was that PI4P 
plays an important role in secretion between the Golgi and the plasma membrane (1).   
       
PI(4)P and the other PIPs are involved in distinct outcomes in a cell, even 
sometimes when the PIP is produced by the same PI kinase (64).  This suggests that 
additional layers of functional specification exist in PIP signaling (64).  There is 
mounting evidence that PITPs are involved in PI kinase pathways and that they contribute 
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to the functional specification in PIP signaling (64).  For example, both Sec14 and Sfh3 
have been shown to influence the production of PI(4)P by Pik1.  Sec14 regulates the 
activity of Pik1 in a pathway controlling the TGN and endosomal trafficking (1).  Sfh3 
stimulates PI(4)P production by Pik1 in modulation of the consumption of lipid droplets 
(78).  Sfh2 and Sfh5 activate phospholipase D (PLD) by stimulating PI(4,5)P2 synthesis 
in a way that is coupled to Stt4 (79).  Sfh5 also works with Mss4 to facilitate Cdc42 
activation and regulate both actin and protein trafficking (80).  Overall, the genetic and 
biochemical data do not indicate that Sfh proteins stimulate PIP production directly, 
rather the evidence supports that they regulate the delivery of PI to the kinase (77) and 
that their involvement contributes to the signaling outcome of the PIP produced.  PITPs 
are likely key players in PIP homeostasis.   
 
The crystal structure of Sacharomyces cerevisiae Sec14 (1AUA) was published in 
1998 (81).  High resolution crystal structures of the yeast Sec14 homolog Sfh1 with 
phosphatidylethanolamine, phosphatidylcholine, or phosphatidylinositol were determined 
in 2008 (3B74, 3B7N, 3B7Q, 3B7Z) (64).  From these structures, and from various 
genetic experiments, Bankaitis and colleagues made 5 conclusions (64).  First, 
Sfh1/Sec14 bind PC and PI differently.  Sfh1 binds PC or PI one phospholipid at a time 
in its hydrophobic cavity; however, the headgroup of PC is sequestered deep in the 
binding cavity, while the headgroup of PI is coordinated near but beneath the protein 
surface (Figure 16) (64).  Second, the capacity of Sec14 to bind PC and PI is required for 
Sec14 to fulfill its essential in vivo roles.  Three types of sec14 mutants were made: pinch 
mutants (obstructed the acyl-chain space in the hydrophobic cavity), non-PI-binding 
mutants (exhibit steric or electrostatic incompatibility with PI phosphate binding), and 
non-PC-binding mutants (exhibited inability to coordinate PC headgroup).  These 
mutants were studied using a variety of functional assays that investigated the 
complementation of sec14-1ts or employed plasmid shuffle assays.  Pinch mutants were 
defective in all functional assays, non-PC-binding mutants were also defective, and the 
non-PI-binding mutants showed that PI binding is an essential event in Sec14 activity.  
Further experiments with mixed in vivo populations of non-PI-binding and non-PC-
binding mutants provide evidence that the PI and PC binding activities must be in cis (on 
the same Sec14) (64).  This led to the third conclusion, that Sec14 must have both PI and 
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PC binding activities on the same Sec14 molecule for biological activity (64).  The fourth 
conclusion was that PI and PC binding are both required for Sec14-mediated regulation 
of PIP homeostasis.  Non-PI-binding and non-PC-binding sec14 mutants were expressed 
individually in a yeast strain that has only basal PIP levels; neither type of mutant was 
capable of restoring wild-type PIP profiles in vivo (64).   The fifth conclusion was that the 
Kes1 oxysterol-binding protein (also known as Osh4) that antagonizes Pik1 kinase action 
is countered by Sec14-mediated regulation of PIP synthesis (64).  Pik1 generates the PI4P 
in the Golgi that is required for efficient secretory trafficking from the Golgi to the 
plasma membrane, and Sec14 increases this kinase activity in vivo.  Kes1 deficiencies 
create “bypass Sec14” and partial rescue of pik1ts alleles, providing evidence that Kes1 
antagonizes the Sec14 pathway.   Kes1 retrieves and removes PI(4)P as it delivers sterols 
to the Golgi, therefore Kes1 deficiencies would cause high PI(4)P levels in the Golgi 
therefore compensating for the sec14 and pik1 mutants and antagonizing the Sec14 
pathway (82, 83).  
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1.4 Lipid Kinase Assays  
A variety of methods have been developed to assay the activity of lipid kinases.  
These include radioactivity (84), bioluminescent (85–87), and electrochemical (88) based 
assays.  Due to the sensitive and reliable nature of radioactive assays, they are commonly 
used to measure lipid kinase activity (2, 84, 89–92).  However, the use of radioactive 
compounds is undesirable and labour intensive.  In addition, these methods are not time 
resolved, and as a result kinetic data on kinase activity cannot easily be obtained.  The 
standard approach of these existing assays is to measure the signal under standardized 
conditions at a single arbitrary time point.  This is sufficient to measure the effect of 
inhibitors on the activity but does not reveal information on how the signal evolved to the 
point where it was measured.  Therefore, a change in the conditions (a change in the 
phospholipid composition, the presence of an inhibitor, or the presence of a protein that 
may cooperate or impede kinase activity) may change the rate at which the kinase 
phosphorylates and therefore the rate at which the signal evolves, but this change could 
be invisible to the single time point assay methods (as seen in Figure 17).  Therefore, a 
time resolved assay for the activity of a lipid kinase is more valuable for probing the 
activity and the mechanism of the kinase and its accessory and regulatory proteins.     
 
Figure 17: Arbitrary single time-point vs. time-resolved assays. Current available 
assays, including the Bellbrook Transcreener® ADP2 FI Assay, are designed for end-point 
read-out, which is insufficient for measuring initial rates.    
 
Many of the previously used lipid kinase assays use lipid substrates that are 
solubilized by detergents (2, 9, 50, 92).  Therefore, the lipid substrates are soluble, likely 
in mixed micelles, and readily available to the kinase, but do not reside in a more 
appropriate model of biological membranes, such as vesicles.  The goal of this project 
was to develop a lipid kinase assay to probe the presentation mechanism by which Sec14 
is proposed to stimulate the activity of Pik1.  If this presentation mechanism is correct 
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(i.e., if Pik1 is not able to efficiently phosphorylate PI while PI is in the phospholipid 
bilayer, and therefore it needs Sec14 to present PI as a more suitable substrate) than using 
detergent micelles/detergent solubilized lipids as the substrate would abolish the need for 
Sec14 and it would be impossible to probe this mechanism.  Therefore, it was imperative 
to design an assay that used phospholipid vesicles as the lipid substrates.   
 
Sensitivity and ease of use are important factors in assay development.  The assay 
that was developed in this project was a modification of Bellbrook Labs Transcreener® 
ADP2 FI Assay.  This kit can provide a high throughput screening assay platform with a 
simple fluorescence intensity (FI) readout.  It is a simple, one-step homogenous detection 
assay that measures the production of ADP (Figure 18).  The detection method employs 
an ADP2 monoclonal antibody that is conjugated to an IRDye® QC-1 quencher and an 
ADP Alexa Fluor® 594 Tracer as the fluorophore.  When the antibody-quencher 
conjugate is bound to the ADP Alexa Fluor® 594 Tracer the fluorescence is quenched.  
Then, as the enzyme produces ADP, the ADP displaces the ADP Alexa Fluor® 594 
Tracer from the antibody-quencher conjugate.  When the ADP Alexa Fluor® 594 Tracer 
is released, the fluorescence quenching is diminished and an increase in fluorescence 
intensity is measured.  The increase in fluorescence is therefore proportional to the 
production of ADP.  This commercial kit is designed for end-point reading and it was 
used to develop a time-resolved assay (93).     
   
Figure 18: Schematic of the Transcreener® ADP2 FI Assay.  A commercial one-step 
homogenous detection assay designed to measure the production of ADP by any ADP-
producing enzyme.  FI: fluorescence intensity. Quenched ADP Alexa Fluor® 594 Tracer 
(red circle). IRDye QC-1: quencher (orange circle). ADP2 Antibody-IRDye®QC-1: ADP 
antibody conjugated to quencher (orange antibody-dye conjugate). Free ADP Alexa 
Fluor® 594 Tracer (red star).  
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1.5 Purpose of the Project   
There is genetic evidence and structural evidence for the presentation model that was 
outlined in Section 1.3.2, but there is no direct kinetic evidence.  In this presentation 
model, Sec14 is proposed to mediate heterotypic exchange, binding both PI and PC, and 
during this exchange PI is presented to Pik1 making it a better substrate for 
phosphorylation.  This thesis initiates work to test this proposed action of Sec14 on 
stimulating the production of PI(4)P by Pik1.  This will require the lipid kinase activity of 
Pik1 to be measured in the presence and absence of Sec14, and with different substrates 
and conditions, etc. to probe this mechanism.  The purpose of this project was to adapt 
the Bellbrook Labs Transcreener® ADP2 FI Assay into a time-resolved and vesicle-based 
assay to measure the lipid kinase activity of Pik1.   
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2 Materials 
2.1 Chemicals and Stock Solutions  
2.2 DNA and Vectors  
The cDNA for CDC37 (YDR168W), FRQ1 (YDR373W), and PIK1 (YNL267W) were 
purchased in BG1805 from GE Dharmacon (94); BG1805 was developed by Eric 
Phizicky (University of Rochester) and Mike Snyder (Yale University).  
CDC37 and FRQ1 were cloned into the high copy number plasmid pESC-Trp (Agilent 
#217453 (95)) by Candace Panagabko (Brock University). pESC-Trp was received as a 
gift curtesy of Vince Qu (Brock University).  
The low copy number plasmids pINIT_cat (Addgene plasmid #46858) and pYEXC3H 
(Addgene plasmid #49026) were purchased from Addgene, courtesy of Eric Geertsma 
(Goethe University) and Raimund Dutzler (University of Zurich), for the cloning and 
expression of PIK1.  The cloning was done by Candace Panagabko.   
 
2.3 Yeast and Bacterial Strains  
Yeast: BJ2168 Saccharomyces cerevisiae was cultured for protein expression  
 MATa, ura3-52, trp1-289, leu2-3, 112, prb1-1122, prc1-407, pep4-3 
 
B8NA: transformed BJ2168 with clone 8 (pYEXC3H+PIK1) and clone N (pESC- 
Trp+FRQ1+CDC37) at the same time, colony A 
B8ND: transformed BJ2168 with clone 8 (pYEXC3H+PIK1) and clone N (pESC- 
Trp+FRQ1+CDC37) at the same time, colony D 
10NE: transformed BJ2168 with clone 10 (pYEXC3H+PIK1) and clone N  
(pESC-Trp+FRQ1+CDC37) sequentially, colony E 
B10NC: transformed BJ2168 with clone 10 (pYEXC3H+PIK1) and clone N 
(pESC-Trp+FRQ1+CDC37) at the same time, colony C 
 pVEX: BJ2168 transformed with empty pYEXC3H and pESC-Trp vectors 
 
Naming Explanation:  
B: transformed BJ2168 with both vectors (pYEXC3H+PIK1 and pESC-Trp+FRQ1+ 
CDC37) at the same time, no B means sequentially transformed    
8 and 10: aka SC8 and SC10, SC= sub cloning and 8 and 10 refer to successful clone of 
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PIK1   
*SC8 and SC10 were the bacterial colonies from which the DNA was sent for sequencing 
for carrying pYEXC3H with PIK1  
N: successful clone of pESC-Trp with FRQ1 and CDC37   
A or C: colony "#"   
NEB stable cells were the bacteria that were used for cloning and propagation.  The 
propagation was done by plate.  It was noted that the Pik1 expression plasmid was toxic 
to the bacteria. 
 
2.4 Buffers, Solutions, and Media  
2.4.1 Yeast Media  
All yeast media was made with reverse osmosis (RO) H2O and autoclaved (Panasonic 
MLS-3751L) using the liquid sterilization program (1-1: 121°C, 30min) 
YPAD Plates (Yeast extract, Peptone, Adenine, Dextrose): 2.5g yeast extract, 5g 
peptone, 10mg adenine sulfate, 5g dextrose, 5g agar, 1 pellet NaOH (~50mg), dissolved 
in 250mL RO H2O, autoclaved, poured plates  
YPAD (Yeast extract, Peptone, Adenine, Dextrose): 2.5g yeast extract, 5g peptone, 10mg 
adenine sulfate, 5g dextrose, dissolved in 250mL RO H2O, autoclaved  
SCAT (Selective Complete, Adenine, Tryptophan): 1.74g/L yeast nitrogen base, 20g/L 
dextrose, 0.080g/L adenine sulfate, 0.040g/L tryptophan, 5g/L ammonium sulfate, 2g/L 
tryptophan dropout powder 
SCUTA (Selective Complete, Ura-Trp- dropout, Adenine): 1.74g/L yeast nitrogen base, 
5g/L ammonium sulfate, *sugar, 0.72g/L Trp- Ura- dropout powder, 0.08g/L adenine 
sulfate  
 *sugar:  
 SCUTA: no sugar  
 SCUTAD: 2% Dextrose – autoclaved as SCUTAD, or the components to make 
100mL of SCUTA were weighed, dissolved in 95mL RO H2O, and autoclaved, 
then 5mL of 20x dextrose stock was added to the 95mL of SCUTA to dilute to 
100mL before use  
 SCUTAR: 2% Raffinose – autoclaved as SCUTA that was not completely 
diluted, then the appropriate volume of sterile raffinose stock was added after it 
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was autoclaved to produce the full volume and correct concentration of all 
components.  The solution was autoclaved as SCUTA that was diluted to 95mL 
instead of all the way to 100mL and 6.9mL of 29% raffinose stock was added to 
95mL of not fully diluted SCUTA before used (~100mL SCUTAR flasks). The 
solution was autoclaved as 93mL/100mL SCUTA and 7mL of 29% Raffinose was 
added before used (100mL SCUTAR flasks).  The solution was autoclaved as 
460mL SCUTA and 40mL of 25% Raffinose was added before used (500mL 
SCUTAR flasks).    
 
SCUTAD Plates (Selective Complete, Ura-Trp- dropout, Adenine, Dextrose): 1.74g/L 
yeast nitrogen base, 5g/L ammonium sulfate, 20g/L dextrose (2%), 0.72g/L Trp- Ura- 
dropout powder, 0.08g/L adenine sulfate, 20g/L agar (2%), pinch NaOH  
SCUTAGE Plates (Selective Complete, Ura- Trp- dropout, Adenine, Glycerol, Ethanol): 
1.74g/L yeast nitrogen base, 5g/L ammonium sulfate, 0.720g/L Ura- Trp- dropout 
powder, 0.08g/L adenine sulfate, 26g/L glycerol (~20.8mL), 22g/L agar, 27.5mL 95% 
ethanol  
All ingredients except 95% ethanol were dissolved in RO H2O, and the pH was 
adjusted to 5.5.  The solution was diluted to 970mL and autoclaved, then 27.5mL 
95% ethanol was added, the solution was mixed, and immediately poured into 
plates.     
3xYEPG (Yeast Extract, Peptone, Galactose): 6% peptone, 3% yeast extract, 6% 
galactose.  For 200mL 3x YEPG: 12g peptone, 6g yeast extract, 12g galactose dissolved 
in 200mL of RO H2O.  
 
2.4.2 Yeast Protein Extraction for SDS-PAGE  
Lysis Buffer: 0.1M NaOH, 0.05M ethylenediaminetetraacetic acid (EDTA), 2% SDS, 
2% b-mercaptoethanol (200mg NaOH, 730.6mg EDTA, 1000mg SDS, 895µL b-
mercaptoethanol in 50mL RO H2O) 
Loading Buffer: 0.25M Tris-HCl pH 6.8, 50% Glycerol, 0.05% Bromophenol blue  
 
Resolving Gel (10%): 3.8mL RO H2O, 2mL 1.5M Tris-HCl pH 8.8, 2mL Acrylamide/ 
Bis-Acrylamide (37.5:1) 40% solution, 80µL 10% SDS, were all mixed then 80µL of 
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10% ammonium persulfate (APS) and 8µL of TEMED were added immediately before 
casting. This recipe makes two gels.   
Stacking Gel (6%): 2.9mL RO H2O, 1.25mL 0.5M Tris-HCl pH 6.8, 0.75mL 
Acrylamide/Bis-Acrylamide (37.5:1) 40% solution, 50µL 10% SDS, were all mixed then 
50µL of 10% APS and 5µL of TEMED were added immediately before casting. This 
recipe makes two gels.   
 
10x SDS-PAGE Running Buffer: 250mM Tris-HCl (pH 8.3), 1.92M Glycine, 1% SDS.  
1L of 10x SDS-PAGE running buffer was made and stored at room temperature.  The 
10x solution was diluted to 1x (100mL 10x solution diluted to 1000mL) before it was 
used. The 1x SDS-PAGE running buffer was also stored at room temperature.   
 
2.4.3 Glass Bead Lysis  
Extraction Buffer (pH 8): 25mM Tris-HCl, 10mM MgCl2, 10% glycerol, 150mM NaCl, 
2mM b-mercaptoethanol, 0.5% Triton X-100. 
One protease inhibitor tablet (cOmplete ULTRA Tablets, Mini, EDTA-free, 
EASYpack)/20mL of extraction buffer was added immediately before it was used in the 
extraction protocol.  After the cells were resuspended in extraction buffer, 3µL of DNase 
(1000 units) and 50µL of 10mg/mL RNase were added to the extraction mixture.    
 
2.4.4 IMAC Co2+ Affinity Chromatography  
IMAC Resin Wash Solution: 50mM sodium acetate, 0.3M NaCl, pH 4.0  
Co2+ IMAC Charging Solution: 0.2M CoCl2 
Buffer A (no imidazole): 25mM Tris-HCl, 300mM NaCl, pH 8   
Buffer B (max imidazole): 25mM Tris-HCl, 300mM NaCl, 300mM or 500mM 
imidazole, pH 8  
Co2+ Stripping Buffer: 1.5g sodium phosphate dibasic, 3.5g NaCl, 30g EDTA, pH 7.5, 
diluted to 200mL (All components did not dissolve until the solution was pH > 7)  
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2.5 Bellbrook Labs Transcreener® ADP2 FI Assay  
2.5.1 Materials Provided  
ADP2 Antibody-IRDye® QC-1: 1.4mg/mL solution in 100mM KH2PO4 (pH 8.5)  
ADP Alexa Fluor® 594 Tracer: 800nM solution in 2mM HEPES (pH 7.5) containing 
0.01% Brij-35  
Stop and Detect Buffer B, 10x: 200mM HEPES (pH 7.5), 400mM EDTA, and 0.2% 
Brij-35  
ATP: 5mM ATP, ADP: 5mM ADP 
 
2.5.2 Assay Buffers and Solutions  
Note: all solutions for the assay should be made with autoclaved mQH2O  
PKA Reconstitution Solution: 6mg/mL dithiothreitol (DTT), 10mM MgCl2•6H2O  
PKA Assay and Detect Buffer, 10x: 1000mM HEPES (pH 7.5), 0.2% Brij-35  
Lipid Dilution Buffer, 2.5x: 62.5mM HEPES (pH 7.5), 1.25mM ethylene glycol-bis(β-
aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA), sterile filtered then stored at -20°C 
PIK3C3 Assay Buffer, 10x: 250mM HEPES (pH 7.5), 500mM NaCl, 30mM MgCl2, 
0.25mg/mL BSA, 50mM MnCl2* 
* MnCl2 was eventually omitted because it was causing precipitation problems 
with the KH2PO4 buffer which the antibody is dissolved in the Bellbrook kit 
 
2.5.3 Enzymes and Substrates   
Protein Kinase A catalytic subunit from bovine heart: purchased from Sigma-Aldrich 
(catalog number: P2645)  
Casein from bovine milk: purchased from Sigma-Aldrich (catalog number C5890) 
PIK3C3 (Vps34): purchased from Sigma-Aldrich as the active, GST, human 
PRECISIO® Kinase, recombinant (product number: SRP5306, lot number: Y1019-2). It 
was supplied in 50mM Tris-HCl (pH 7.5), 150mM NaCl, 10mM glutathione, 0.1mM 
EDTA, 0.25mM DTT, 0.1mM PMSF, and 25% glycerol.    
L-𝜶-Phosphatidylinositol (PI): Liver PI purchased from Avanti Polar Lipids   
L-𝜶-Phosphatidylserine (PS): Brain PS purchased from Avanti Polar Lipids   
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC): DOPC purchased from Avanti 
Polar Lipids  
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3 Methods 
3.1 Creation of Pik1 Expression System  
This procedure was written and performed by Candace Panagabko (Brock 
University).  Unless otherwise stated, all materials were from New England Biolabs.  
This Pik1 expression system comprises 3 proteins: Pik1, Cdc37, and Frq1.  Cdc37 is a 
molecular chaperone that assists in the correct folding of Pik1 (personal communication 
from Jeremy Thorner - University of California Berkeley) and Frq1 is the adaptor protein 
for Pik1 (3).    
 
Yeast FRQ1 and yeast CDC37 genes were amplified from the cDNA clones from 
GE Dharmacon for insertion into the bidirectional yeast E. coli shuttle vector pESC-Trp 
vector.   In E. coli, the vector confers ampicillin resistance whereas the vector enables 
growth of yeast in tryptophan deficient media.  FRQ1 was inserted under the control of 
the GAL10 promoter using EcoRI and NotI restriction sites to create a C-terminal FLAG-
tag.  CDC37 was placed under the direction of the GAL1 promoter using BamHI and SalI 
creating a C-terminal c-myc fusion.   
 
The yeast PIK1 was cloned via the FX cloning system.  Similar to the Gateway 
System (Invitrogen), the gene was cloned into an initial vector pINITIAL (pINIT) which 
can be a transition point for different expression hosts.  The pINITIAL vector carried the 
chloramphenicol acetyltransferase (CAT) gene for selection on chloramphenicol media in 
E. coli.  Primers for amplification were selected by the FX cloning website 
(http://www.fxcloning.org/) which appends SapI restriction sites to the gene without its 
start or stop codons.  The pINIT-CAT vector also contains the ccdB gene that encodes 
transcriptional repressor of the ccdAB operon.  Expression of the gene promotes cell 
survival of plasmid containing cells.  The ccdB gene binds to DNA gyrase resulting in 
destruction of plasmid DNA.  Thus, the pINIT-CAT vector was supplied in a DNA 
gyrase mutant E. coli strain DB3.1.  Cloning of a gene into the pINIT-CAT vector 
disrupts the ccdB gene.  Therefore, only cells containing recombinant plasmids should 
survive when the ligation mix is transformed into a ccdB susceptible E. coli strain. 
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   For yeast expression, PIK1 was subcloned from the pINIT-CAT–PIK1 clone into 
pYEXC3H for creation of a C-terminal 10xHis-tag cleavable by PreScission protease 
(Human Rhinovirus 3C protease). The pYEXC3H vector carried both the CAT gene and 
the 𝛽-lactamase gene for ampicillin and chloramphenicol resistance in addition to the B. 
subtilis sacB gene.  The sacB gene metabolizes sucrose to levan, leading to accumulation 
of levan within the periplasmic space and death of the cell.  Sub-cloning of PIK1 
interrupted the sacB gene allowing selection of transformants by plating on ampicillin 
and 7% sucrose containing media.  The pYEXC3H vector also carries the URA3 gene for 
selection in uracil deficient media.  
 
All genes for cloning were amplified by Pfu or Q5 polymerases.  Plasmids were 
transformed into NEB Stable chemically competent cells following the manufacturer’s 
instructions.  Colony PCR using One Taq DNA polymerase enabled transformant 
selection for all three genes.  DNA from successful transformants was recovered easily 
for pINIT-CAT-PIK1 and pESC-Trp-FRQ1-CDC37.  Despite pYEXC3H being a yeast 
expression vector, the PIK1-pYEXC3H clones appeared toxic to E. coli suggesting 
recognition by the bacterial transcriptional machinery.  As such, upon identification of 
the clones, the cells were propagated solely on solid media (plates) at room temperature 
as transfer to liquid media or higher temperature led to loss of the PIK1 gene.  Clones 
from pESC-Trp-FRQ1-CDC37 (clone N), pINIT-CAT-PIK1 (clone 8) and pYEXC3H-
PIK1 (clones 8 and 10) were verified by sequencing. 
 
Yeast cells (BJ2168) were transformed with the clones (FRQ1-CDC37 (clone N) 
and PIK1 clones (8 and 10)) either successively (N-series - e.g., 10NE) or concurrently 
(B-N series - e.g., B8NA) using lithium acetate for plating on selective complete media 
lacking both uracil and tryptophan.  The presence of both plasmids in the yeast colonies 
was verified by colony PCR.  
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3.2 Growth Curves  
3.2.1 Inoculation and Protein Expression  
B8NA (transformed BJ2168 with clone 8 (pYEXC3H+PIK1) and clone N (pESC-
Trp+FRQ1+CDC37) at the same time, colony A), and/or 10NE (transformed BJ2168 
with clone 10 (pYEXC3H+PIK1) and clone N (pESC-Trp+FRQ1+CDC37) sequentially, 
colony E) were re-plated onto a fresh SCUTAD plate then placed in a static incubator 
(Thermo Electron Corporation REVCO or VWR Gravity Convection General Incubator) 
at 26°C for approximately 3 days.  The cells did not grow as quickly from older plates; 
therefore, it was decided to always inoculate liquid cultures from plates that were less 
than 1 week old.  SCUTAD pre-culture tubes (5 or 10mL) were inoculated from the plate 
with an inoculation loop in the presence of a flame.  The pre-culture tubes were grown for 
at least 24h in a shaking incubator (New Brunswick Scientific I 26 Incubator Shaker 
Series or New Brunswick Scientific Series 25 Incubator Shaker) at 26°C and 300 RPM 
(Note: 30°C, and 220 RPM, 250 RPM, 260 RPM, and 310 RPM were also tried).  The 
pre-culture tubes were poured into SCUTAR culture flasks (one 5mL pre-culture 
tube/100mL culture or two 10mL pre-culture tubes/500mL culture), which were 
subsequently placed in a shaking incubator for at least 24h at 26°C and 300 RPM.  
Optical density (OD) measurements were recorded at various time points to monitor cell 
growth.  Galactose (2g of galactose/500mL culture) was used to induce expression and it 
was added at an OD between 1 and 3.  Galactose was measured onto a piece of 
autoclaved tin foil using an autoclaved scoopula (however, sterile technique could not be 
used because of the balance).  The solid galactose was added to the culture flask and was 
dissolved by swirling.  A second induction method was also tested: 50mL of 3x YEPG 
were added to 100mL of culture at an OD of ~2.  YEPG is a non-selective media that 
contains yeast extract, peptone, and galactose.  The culture flasks were grown at 26°C 
and 300 RPM for at least 24h following the addition of galactose as a solid or in YEPG.  
OD measurements were taken at various time points to monitor growth.  One of the times 
that this inoculation method was tested, a sample was taken approximately 24h post-
induction and was used to inoculate a plate of SCUTAD, a selective medium.  The plate 
was grown at 26°C for approximately 32h.  This procedure was performed to check for 
plasmid loss or retention.  Visually there appeared to be the same amount of growth, (i.e., 
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the plasmid appeared stable).  This small test was carried out by Candace Panagabko 
(Brock University).       
 
3.2.2 Sample Harvesting  
 Optical density measurements, and in certain cases cell counts, were measured at 
different time points before and after induction to monitor the growth of the yeast.  The 
time that the sample was taken from the flask was recorded along with each cell count 
and/or OD.  The OD measurements and the cell counts could not be performed using 
sterile conditions; however, the sample was removed from the culture tube or flask in the 
presence of a flame, thus preventing contamination of the culture tube or flask.  After the 
measurement was taken, the contents of the cuvette were transferred to an Eppendorf 
tube, placed in a microcentrifuge (ThermoIEC Micromax), and centrifuged at 14,000 
RPM for 7 min.  The media was decanted with a pipette into a waste beaker to be 
bleached and the Eppendorf tube with the cell pellet was stored at -20°C.    
 
3.2.3 Optical Density Measurements  
Optical density (OD) measurements were taken to monitor growth.  All of the OD 
measurements were measured at 600nm and the instrument (Thermo Scientific 
GENESYS 10S UV-Vis) was blanked using uninoculated media that matched the media 
of the sample being measured.  The culture tube or flask was mixed to agitate any settled 
cells before the sample volume was taken.  A 1mL sample was taken to measure the OD, 
unless the OD was (or was suspected to be) 1 or greater; in this case, a smaller sample 
was taken and diluted with media to 1mL.  A 1:5 dilution was the most common, in 
which 200µL of culture was taken and diluted with 800µL of the appropriate media.  The 
cuvettes were covered with parafilm, inverted multiple times, and the sides wiped with a 
Kimwipe prior to insertion into the instrument.  The OD was measured and multiplied by 
the appropriate factor (5 for a 1:5 dilution) to obtain the OD of the culture tube or flask.       
 
3.2.4 Correlating OD to an Approximate Cell Count  
 To correlate OD to an approximate cell count, both measurements were made at 
each time point during the first 7h of the first growth curve that was completed.  
Untransformed BJ2168 was grown in YPAD at 26°C and 260RPM.  A 1mL sample of 
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culture was taken every 1-2 h for approximately 11 h on the first day and samples and 
OD measurements were carried out at various time points during the subsequent 3 days.  
During the first 7 h of the first day, both OD measurements and cell counts were carried 
out.  After the OD was measured, 10µL of the sample was taken from the cuvette, 
pipetted onto a hemocytometer, and a cover slip was added.  The cells were counted 
using a microscope (Zeiss ID 03) under 10x magnification.  The number of cells/mL was 
determined by taking the average of the cell count total from each set of 16 corner 
squares (one set of 16 corner squares is boxed in blue in Figure 19) and multiplying it by 
104.  This growth curve was conducted before it was known that the sample should be 
diluted if the OD was greater than 1, therefore no dilutions were made except the last two 
measurements.  The approximate number of cells was determined using the OD prior to 
centrifugation and the average number of cells per mL per OD unit was determined to be 
9.02 x 107 cells/mL/OD unit.    
 
Figure 19: Hemocytometer gridlines.  The blue box designates one of four sets of 16 
corner squares that were used for counting.  Figure reproduced from (96).  
 
3.2.5 Specific Conditions of the Growth Curve Experiments  
The specific conditions for each of the growth curve experiments can be seen in 
Table 3. The experiments are organized based on purpose and conditions.  The purpose of 
the first set was to establish baseline/normal growth in rich and selective media.  The 
purpose of the second set of experiments was to establish how temperature and agitation 
influence growth.  The purpose of the third set was to investigate the effect on growth 
upon inducing with solid galactose at different ODs. The fourth, fifth, and sixth sets 
include experiments that used SCUTAD* (0.2% dextrose) instead of SCUTAD (2% 
dextrose) as the pre-culture medium.  The fourth set studied the impact of the carbon 
 
 
50 
source on growth and compared growth in dextrose verses raffinose containing media.  
The fifth and sixth sets investigated growth related to induction by solid galactose and 
YEPG respectively.   
 
Table 3: The details for the growth experiments with different transformants, 
media, carbon sources, and induction methods.  BJ2168: untransformed yeast strain, 
pVEX: BJ2168 transformed with both empty vectors, B8NA: a transformant of BJ2168 
in which the cells were transformed with both vectors at the same time (transformed 
BJ2168 with clone 8 (pYEXC3H+PIK1) and clone N (pESC-Trp+FRQ1+CDC37) at the 
same time, colony A). 10NE: a transformant of BJ2168 in which the cells were 
sequentially transformed with each vector (transformed BJ2168 with clone 10 
(pYEXC3H+PIK1) and clone N (pESC-Trp+FRQ1+CDC37) sequentially, colony E).   
Growth 
Curve  
Cell  Media, Temperature, RPM, Culture Volume  
Plate  Pre-Culture Culture Tube or Flask   
     
BJ2168 in 
SCAT  
BJ2168  YPAD 
26°C 
  
SCAT 
26°C  
310 RPM 
5mL 
 
SCAT  
26°C  
310 RPM 
5mL pre-culture into 50mL in 
250mL flask  
pVEX in 
SCUTAD 
pVEX SCUTAD 
26°C   
SCUTAD 
26°C 
310 RPM  
5mL  
 
SCUTAD 
26°C 
310 RPM  
5mL pre-culture into 50mL in 
250mL flask 
     
Growth 
Condition 
Test: 26°C, 
250 RPM  
BJ2168  YPAD 
26°C  
 
SCAT 
26°C  
250 RPM 
Overnight  
5mL  
 
SCAT 
26°C 
250 RPM 
24 hours  
500µL used to inoculate 
culture tube (5mL)  
Growth 
Condition 
Test: 30°C, 
250 RPM 
BJ2168 YPAD 
26°C  
 
Used pre-culture 
from above   
SCAT 
30°C 
250 RPM 
24 hours  
500µL used to inoculate 
culture tube (5mL) 
Growth 
Condition 
Test: 26°C, 
220 RPM 
BJ2168 YPAD 
26°C  
 
Used pre-culture 
from above  
SCAT 
26°C 
220 RPM 
500µL used to inoculate 
culture tube (5mL) 
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Table 3: continued  
Growth 
Curve  
Cell  Media, Temperature, RPM, Culture Volume  
Plate  Pre-Culture Culture Tube or Flask   
     
B8NA  
Non-
Induced  
B8NA  SCUTAD 
26°C  
  
SCUTAD  
26°C  
300 RPM  
Overnight 
(~24h) 
5mL  
SCUTAR  
26°C  
300 RPM  
Whole 5mL pre-culture used 
to inoculate 100mL culture 
in 500mL flask 
B8NA  
Induced 
OD ~2 with 
solid Gal  
B8NA  SCUTAD 
26°C  
  
SCUTAD  
26°C  
300 RPM  
Overnight 
(~24h) 
5mL  
SCUTAR  
26°C  
300 RPM  
Whole 5mL pre-culture used 
to inoculate 100mL culture 
in 500mL flask 
B8NA  
Induced 
OD ~3 with 
solid Gal  
B8NA  SCUTAD 
26°C  
SCUTAD  
26°C  
300 RPM  
Overnight 
(~24h) 
5mL  
SCUTAR  
26°C  
300 RPM  
Whole 5mL pre-culture used 
to inoculate 100mL culture 
in 500mL flask 
B8NA 
Induced 
OD~2 with 
solid Gal 
B8NA  SCUTAD  
26°C  
SCUTAD 
26°C 
300 RPM  
Overnight 
(~24h)  
5mL  
SCUTAR 
26°C 
300 RPM  
Whole 5mL pre-culture used 
to inoculate 100mL culture 
in 500mL flask 
     
pVEX in 
SCUTAR  
 
(SCUTAD* 
pre-culture)   
pVEX SCUTAD 
26°C 
 
SCUTAD* 
26°C 
300 RPM  
Overnight  
5mL  
 
SCUTAR 
26°C 
300 RPM  
Whole 5mL pre-culture used 
to inoculate ~100mL culture 
in 500mL flask  
B8NA in 
SCUTAD 
 
(SCUTAD* 
pre-culture)  
B8NA SCUTAD 
26°C 
 
SCUTAD* 
26°C 
300 RPM  
Overnight  
5mL 
 
SCUTAD 
26°C 
300 RPM 
Whole 5mL pre-culture used 
to inoculate ~100mL culture 
in 500mL flask 
B8NA in 
SCUTAR  
 
(SCUTAD* 
pre-culture)   
 
B8NA  SCUTAD 
26°C 
 
SCUTAD* 
26°C 
300 RPM  
Overnight  
5mL 
 
SCUTAR 
26°C 
300 RPM 
Whole 5mL pre-culture used 
to inoculate ~100mL culture 
in 500mL flask 
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Table 3: continued  
Growth 
Curve  
Cell  Media, Temperature, RPM, Culture Volume  
Plate  Pre-Culture Culture Tube or Flask   
10NE in 
SCUTAD 
 
 
10NE SCUTAD 
26°C 
 
SCUTAD 
26°C 
300 RPM  
Overnight  
5mL 
 
SCUTAD 
26°C 
300 RPM 
1mL of pre-culture used to 
inoculate ~100mL culture in 
500mL flask 
10NE in 
SCUTAR  
 
  
 
10NE SCUTAD 
26°C 
 
SCUTAD 
26°C 
300 RPM  
Overnight  
5mL 
 
SCUTAR 
26°C 
300 RPM 
1mL of pre-culture used to 
inoculate ~100mL culture in 
500mL flask 
     
B8NA 
Induced 
OD ~1.5 
with solid 
Gal  
B8NA  
  
SCUTAD 
26°C 
 
SCUTAD* 
26°C 
300 RPM  
Overnight 
5mL  
 
SCUTAR 
26°C 
300 RPM  
Whole 5mL pre-culture used 
to inoculate 100mL culture 
in 500mL flask 
B8NA 
Induced 
OD ~2  
with solid 
Gal  
B8NA  
 
Same plate 
as above  
SCUTAD* 
26°C 
300 RPM  
Overnight  
5mL 
 
SCUTAR 
26°C 
300 RPM  
Whole 5mL pre-culture used 
to inoculate 100mL culture 
in 500mL flask 
     
B8NA 
Induced  
OD ~2  
with YEPG 
B8NA 
 
Same plate 
at 6a 
SCUTAD* 
26°C 
300 RPM  
Overnight  
5mL  
 
SCUTAR 
26°C 
300 RPM  
Whole 5mL pre-culture used 
to inoculate 100mL culture 
in 500mL flask 
10NE 
Induced 
OD ~2  
with YEPG 
10NE  
 
SCUTAD 
26°C 
 
SCUTAD* 
26°C 
300 RPM  
Overnight  
5mL  
 
SCUTAR 
26°C 
300 RPM  
Whole 5mL pre-culture used 
to inoculate 100mL culture 
in 500mL flask 
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3.3 Yeast Protein Extraction for SDS-PAGE 
3.3.1 SDS-PAGE Sample Preparation  
This method was based on the one outlined by von der Haar (97).  A pellet of 
~108 yeast cells was resuspended in 200µL of lysis buffer and the mixture was vortexed 
then placed in a 90°C water bath for 10min.  Acetic acid (5µL, 4M) was added, the 
mixture was vortexed for ~30s, and then placed in a 90°C water bath for an additional 
10min.  In an attempt to increase the extraction of high molecular weight proteins, the 
two 10min incubations were lengthened to two 18min incubations for some samples.  
Loading buffer (50µL) was added, and the mixture was vortexed.  The volumes of each 
step were scaled up accordingly for pellets with a greater number of cells.  The 
approximate number of cells was determined using the OD prior to centrifugation and 
average number of cells per mL per OD unit determined to be 9.02 x 107 cells/mL/OD 
unit.  The prepared samples were stored at -20°C.  After thawing, the samples were 
centrifuged at 5000rpm for 5min to clear the lysate prior to loading into the gel.  (Note: 
This method of cell lysis was insufficient to extract proteins with molecular weights 
higher than approximately 95kDa, even when boiled for 18min.  Some samples were also 
taken at various points in the process of the glass bead lysis protocol; this method was 
more effective at extracting protein especially proteins of higher molecular weights.)     
Sample calculation for scale up:  
Sample: B8NA OD1 Uninduced 
Lysis Buffer:  𝑂𝐷 = 1.495 1.495	 ∙ 9.0223 ∙ 106𝑐𝑒𝑙𝑙𝑠𝑚𝐿𝑂𝐷	𝑢𝑛𝑖𝑡	 ∙ 1𝑚𝐿 ∙ 200µ𝐿1 ∙ 10A𝑐𝑒𝑙𝑙𝑠 = 269.8µ𝐿	 ≈ 270µ𝐿	 
 Therefore, the pellet was resuspended in 270µL of lysis buffer.  
 
Acetic Acid:  270µ𝐿	 ∙ 5µ𝐿200µ𝐿 = 6.75µ𝐿	 
 Therefore, 6.75µL of 4M acetic acid was used.  
 
Loading Dye:  270µ𝐿 ∙ 50µ𝐿200µ𝐿 = 67.5µ𝐿 
 Therefore, 67.5µL of loading dye was used. 
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3.3.2 Casting SDS-PAGE Gels (6% Stacking, 10% Resolving)  
The resolving and the stacking buffers were prepared, and the pH was adjusted in 
50mL Falcon® tubes.  Two sets of plates were cleaned, wrapped in Parafilm®, assembled 
into the casting stand, and RO H2O was added to check for leaks; the RO H2O was then 
poured out, and the plates were patted dry with a Kimwipe®. The 10% resolving gel was 
prepared, the 10% APS and the TEMED were added right before casting, and two sets of 
plates were filled ¾ of the height of the plate with resolving gel.  Isopropanol (200µL) 
was pipetted on top of the resolving gel to eliminate air bubbles, then the gel was left to 
polymerize on the counter for 30-40min.  The isopropanol was poured out and the plates 
were patted dry with a Kimwipe®, then residual isopropanol was rinsed out with 3 rinses 
of RO H2O, and the plates were patted dry with a Kimwipe®.  The 6% stacking gel was 
prepared, the 10% APS and the TEMED were added right before casting, and the top 
portion of both sets of plates were filled with stacking gel.  A comb was inserted such 
that there were no bubbles below the teeth and the gel was left to polymerize on the 
counter for 30-40min.  The gels were wrapped in a damp paper towel, placed in a sealed 
plastic bag, and stored at 4°C until they were used.   
 
3.3.3 SDS-PAGE  
The SDS-PAGE gel was run at 120V for approximately 1h using a Bio-Rad Mini-
PROTEAN® Tetra System.  The gel was stained overnight with a mixture of 45mL of 
Protoblue Safe Colloidal stain and 10mL of absolute ethanol.  The gel was de-stained 
with RO H2O and imaged with a Bio-Rad Gel Doc® EZ Imager (white tray).  
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3.4 Glass Bead Lysis 
3.4.1 Pellet Formation  
Centrifuge bottles (250mL) were labelled, filled with cell culture, weighed, and 
balanced, and then centrifuged (Beckman Coulter Allegra X-30R Centrifuge) for 20min 
at 4700 RPM and 4°C using a SX 4400 rotor.  Most of the media was removed and 
pooled in a beaker for bleaching; a small amount of media was left in the tubes to 
resuspend and combine the pellets.  The combined pellet(s) were centrifuged (Beckman 
Coulter Allegra X-30R Centrifuge or Thermo Scientific Sorvall RC6+ Centrifuge) again 
for 20min at 4700 RPM and 4°C using the SX 4400 rotor or the F12-6x500 LEX rotor, 
depending on the sample size and the centrifuge used.  The media supernatant was 
carefully poured off and the pellet was stored at -80°C.   
 
3.4.2 Glass Bead Acid Wash  
The glass beads were washed by soaking them for 1h in concentrated nitric acid.  
The beads were then rinsed thoroughly with water, autoclaved, and then dried in an oven 
at 100°C.  The beads were cooled to room temperature, then stored at 4°C.   
 
3.4.3 Yeast Cell Lysis  
 The yeast cell lysis was completed while the IMAC (Immobilized Metal Affinity 
Chromatography) resin was equilibrating with 0.2M CoCl2 (see Preparation of the IMAC 
Resin).  The TissueLyser (Qiagen TissueLyser II) Eppendorf tube holders were placed in 
the -80°C freezer to pre-cool.  The protease inhibitor tablet was added to the extraction 
buffer (1 tablet/20mL of extraction buffer).  The cell pellet was resuspended in just 
enough extraction buffer to get the consistency of an iced cappuccino (~1-2mL for a 15g 
pellet).  DNase (3µL, 1000 units) and 50µL of 10mg/mL RNase were added to the 
suspension, which was then mixed, and aliquoted into Eppendorf tubes (1mL into each 
2mL tube).  Approximately 1mL of glass beads was added to each tube and the tubes 
were placed in the pre-cooled TissueLyser holders.  The tubes were agitated for 6min at a 
frequency of 30.0 oscillations/s, then the holders containing the tubes were placed in the -
80°C freezer to cool for 6min.  The cycle of agitation and cooling was repeated 5 
additional times.  To ensure adequate lysis, two tubes were centrifuged at 13 800 RPM 
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for 3min at 4°C; additional rounds of beating and cooling would be needed if the 
supernatant was clear.  The preparation of the IMAC resin was completed during the 
TissueLyser and the extraction buffer washing wait times.    
       
 The Eppendorf tubes were placed on ice, and the supernatants from each tube 
were decanted and pooled into a 50mL centrifuge tube.  Extraction buffer (500µL) was 
added to each Eppendorf tube, the tube was vortexed, then the extraction buffer was 
decanted into the same thin centrifuge tube after the beads settled.  The pooled lysate was 
centrifuged (Thermo Scientific Sorvall RC6+ Centrifuge) for 25min, at 17,500 RPM and 
4°C, using rotor 521-8x-50y.  The supernatant was carefully poured onto the prepared 
IMAC resin, and the Falcon® tube was placed on a rocker in the 4°C fridge overnight.   
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3.5 IMAC Co2+ Affinity Chromatography  
3.5.1 Preparation of IMAC Resin  
 The resin was disrupted to form a slurry with the 20% EtOH that it was stored in 
and a graduated cylinder was used to measure 4mL of settled resin (settled volume of 
resin = column volume).  The 20% EtOH was decanted, one column volume of IMAC 
Resin Wash Solution was added and used to make a slurry; the slurry was transferred to a 
50mL Falcon® tube.  This step was repeated until 5 column volumes had been used and 
all of the resin had been transferred to the 50mL Falcon® tube.  The Falcon® tube was 
inverted ~10 times, then the IMAC Resin Wash Solution was decanted off.  Four column 
volumes of 0.2M CoCl2 was added to the Falcon tube and the tube was placed on a rocker 
in a 4°C fridge to equilibrate for at least 2 h.  During this equilibration the yeast cells 
were lysed.   
 The Falcon® tube containing IMAC resin was retrieved from the 4°C fridge and 
was placed upright on the counter to allow the resin to settle. The 0.2M CoCl2 solution 
was decanted off and was stored in a glass bottle at room temperature for reuse.  The 
resin was washed twice each with 2.5 column volumes (5 column volumes total) of 
IMAC Resin Wash Solution (washed = added solution, inverted multiple times, settled, 
decanted).  The resin was then washed twice each with 5 column volumes (10 column 
volumes total) with RO H2O.  The resin was then washed with at least 5 column volumes 
of extraction buffer or buffer A.  After buffer A was decanted the resin was ready for the 
supernatant of the glass bead lysate.   
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3.5.2 Setting Up the FPLC Column   
 
A.                                                      B.  
Figure 20: Diagram of the FPLC (Fast Protein Liquid Chromatography) set up.  
A. Column assembly. B. Column attachment. Images adapted from Bio-Rad user 
manuals.  
 
 The distribution screen, the frit, and the lower bed support were placed in the 
bottom of the glass column and the glass column was clamped to a retort stand with a 
beaker under it.  The Co2+ loaded resin incubated with cell lysate from the previous day 
was poured into the glass column.  Some lysate was allowed to flow through and drip 
into the beaker, but the level of liquid was kept above the resin.  The flow through 
collected by the beaker was used to rinse all of the resin out of the Falcon® tube into the 
glass column.  A pipette bulb was used to apply pressure to encourage the lysate to drip 
out until there was approximately 0.5cm of lysate left above the resin; this was to ensure 
the resin did not dry since the lysate continues to drip as the column was being 
assembled.  The upper bed support was placed in the top of the glass column.  Next the 
plastic protective shield was screwed into the lower end cap.  Then the lock nut was 
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screwed into the upper end cap and this was placed on the top of the glass column such 
that the notch of the upper bed support matched the groove on the upper end cap.  The 
glass column and the upper end cap were then assembled and screwed together with the 
protective shield and lower end cap until tight.  If the lysate did not drip out of the bottom 
of the apparatus, this was an indication of an internal leak, and the apparatus was adjusted 
and tightened until the lysate properly dripped out of the bottom.  The upper end fitting 
and the lower end fitting were screwed into the upper and lower end caps respectively.  
The lysate was allowed to drip out of the lower end fitting until the lysate level was only 
a few millimeters above the resin.  The whole apparatus was then attached to the FPLC as 
seen in Figure 20. 
 
3.5.3 Using the FPLC  
 The FPLC and the fraction collector were turned on, then the Bio-Logic Duo 
Flow program was opened on the computer.  The system was washed with 70% EtOH, 
mQH2O, and buffer A (no imidazole): Flow rate = 5mL/min, Inlet A= 50%, Inlet B=50%, 
Time = 3min, Pressure: high limit = 130psi, low limit = 1psi.  Both lines A and B were in 
the same jar for all 3 washes and the lines were purged of air bubbles when switching 
between the jars of wash solutions.  Lines A and B were set up and purged with buffer A 
(no imidazole) and buffer B (max imidazole) respectively.  The column was attached to 
the system as seen in Figure 20.  The desired FPLC protocol was run.  The column was 
removed from the system and the 70% EtOH and mQH2O wash steps were repeated.  The 
program was closed then the FPLC and the fraction collector were turned off.   
   
3.5.4 The FPLC Protocol  
The first FPLC protocol that was attempted for the purification of the Pik1-Frq1 
complex was a protocol that is standard in the Atkinson lab group for isolating a His-
tagged version of the wtOSBP (wild type Oxysterol-binding protein 1) protein designed 
and standardized by Parthajit Mukherjee (Brock University).  Solution A was the running 
buffer (25mM Tris-HCl, 300mM NaCl, pH = 8) and Solution B was the elution buffer 
(25mM Tris-HCl, 300mM NaCl, 300mM imidazole, pH = 8).  This protocol can be seen 
in Table 4.  However, no sample was detected by the UV-Vis detector that was 
monitoring the eluate during the elution step.  Therefore, the column was subjected to a 
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second elution protocol that consisted of an elution gradient that went up to 100% of a 
500mM imidazole Solution B (Table 5), however, no peaks were observed.  Another 
attempt at expression and purification was carried out, and another gradient elution was 
attempted with a 500mM imidazole Solution B (Table 6).   
 
Table 4: The FPLC protocol for the first attempt to purify the Pik1-Frq1 complex 
from Co2+-loaded IMAC resin.  Solution B contained 300mM imidazole.  The 
concentration of imidazole for the wash step was 24mM and elution was attempted at 
240mM imidazole.  Protocol designed and standardized by Parthajit Mukherjee.   
 Volume (mL)  Description  Parameters 
1 0 Collection fractions 
within 1 time 
window(s) ending at 
120.0mL  
 
2 0.00 Lamp (UV detector)  ON  
3 0.00 Isocratic flow  A: 100%     B: 0% 
V= 40.00mL 
Flow = 3.0mL/min  
4 40.00 Isocratic flow  A: 92%       B: 8% 
V = 40.00mL  
Flow = 3.0mL  
5 80.00 Isocratic flow  A: 20%       B: 80% 
V = 40.00mL  
Flow = 3.0mL/min   
 120.00 End of Protocol   
 
 
Table 5: The second FPLC elution protocol for the first attempt to purify the Pik1-
Frq1 complex from Co2+-loaded IMAC resin.  Solution B contained 500mM 
imidazole.  A gradient elution from 300mM imidazole to 500mM imidazole was used. 
 Volume (mL)  Description  Parameters  
1 0.00 Collection fractions 
within 1 time 
window(s) ending at 
240.00mL  
 
2 0.00 Lamp (UV detector)  Turn ON  
3 0.00 Isocratic flow  A: 100%      B: 0% 
V = 40.00mL  
Flow = 3mL/min  
4 40.00 Linear Gradient  A: 40% à 0% 
B: 60% à 100%  
V = 200mL  
Flow = 3mL/min  
 240.00mL  End of Protocol   
 
 
 
61 
Table 6: The FPLC protocol for the second attempt to purify the Pik1-Frq1 complex 
from Co2+-loaded IMAC resin.  Solution B contained 500mM imidazole.  The wash 
step contained 40mM imidazole and it was followed by a gradient elution from 100mM 
to 500mM imidazole.   
 Volume (mL)  Description  Parameters  
1 0.00 Collection fractions 
within 1 time 
window(s) ending at 
240.00mL  
 
2 0.00 Lamp (UV detector)  Turn ON  
3 0.00 Isocratic flow  A: 100%      B: 0% 
V = 40.00mL  
Flow = 3mL/min  
4 40.00 Isocratic flow  A: 92%        B: 8% 
V = 40.00mL  
Flow = 3mL/min  
5 80.00 Linear Gradient  A: 80% à 0% 
B: 20% à 100%  
V = 200mL  
Flow = 3mL/min  
 280.00mL  End of Protocol   
 
 
3.5.5 Stripping Co2+ From the IMAC Resin  
The FPLC was used to strip the Co2+ from the IMAC resin (Table 7).  The IMAC 
resin was washed with Strip Co2+ buffer, 70% EtOH, then Buffer A for 20min each at 
2mL/min.  Then the column was washed with water at 2mL/min for 10min.  To do this, 
the Strip IMAC resin FPLC protocol was set up with Strip Co2+ buffer and 70% EtOH as 
A and B respectively and the protocol was run.  During the pause, A and B was switched 
to Buffer A and water respectively, then the protocol was resumed.  After the Co2+ was 
stripped, the resin can be stored in 20% EtOH for future use. 
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Table 7: The FPLC protocol for stripping the IMAC resin of the Co2+ ions  
 Volume (mL)  Description  Parameters  
1 0.00 Collection fractions 
within 1 time 
window(s) ending at 
20.0 min. 
 
2 0.00 Lamp (UV detector)  Turn ON  
3 0.00 Isocratic flow  A: 100%    B: 0% 
Time: 20.00min 
Flow = 2mL/min  
4 20.00 Isocratic flow  A: 0%        B: 100% 
Time: 20.00min 
Flow = 2mL/min 
5 40.00 Pause No timeout  
6 40.0 Isocratic flow A: 100%    B: 0% 
Time: 20.00min 
Flow = 2mL/min 
7 60.0 Isocratic flow A: 0%        B: 100% 
Time: 10.00min 
Flow = 2mL/min 
 280.00mL  End of Protocol   
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3.6 The Assays  
3.6.1 Defining the FI Assay Window  
The Bellbrook Labs Transcreener® ADP2 FI Assay kit requires that minimum and 
maximum fluorescence values be assessed so that the breath of the detection window is 
known.  The Fluorescence Intensity (FI) Assay Window was determined by measuring 
the lowest and highest possible signals at the conditions and concentrations used for the 
assay (low = tracer with antibody + quencher, high = tracer but no antibody + quencher).  
The compositions of the low and high RFU mixtures are found in Table 8 and 9 for the 
PKA assay and Table 10 and 11 for the PIK3C3 assay respectively.  The components of 
each were measured into 1.5mL Eppendorf tubes that were labelled either High or Low.  
The tubes were then rotated at room temperature for at least 15min, then the mixtures 
were aliquoted into the assay microplate with 50µL/well.  The fluorescence was 
measured with either the Endpoint FI Assay Window protocol, the PKA Kinetic Assay 
protocol, or the PIK3C3 Kinetic Assay protocol. 
 
Table 8: Low Relative Fluorescence Units (RFUs) Mixture PKA Assay Conditions 
(to make 200µL)  
Component [Stock] [Final]  Volume  
ADP2 Antibody-
IRDye® QC-1 
1.4mg/mL  5µg/mL  0.71µL 
10x PKA Assay 
and Detect Buffer 
10x 0.5x 10µL  
ADP Alexa Fluor® 
594 Tracer 
800nM  4nM  1µL  
mQH2O *   188.29µL  
Total  200µL  
*mQH2O was used but autoclaved mQH2O should have been used   
Table 9: High RFU Mixture PKA Assay Conditions (to make 200µL)  
Component [Stock] [Final]  Volume  
10x PKA Assay 
and Detect Buffer 
10x 0.5x 10µL  
ADP Alexa Fluor® 
594 Tracer 
800nM  4nM  1µL  
mQH2O *   189µL  
Total  200µL 
*mQH2O was used but autoclaved mQH2O should have been used   
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Table 10: Low Relative Fluorescence Units (RFUs) Mixture PIK3C3 Assay 
Conditions (to make 200µL)  
Component [Stock] [Final]  Volume  
ADP2 Antibody-
IRDye® QC-1 
1.4mg/mL  28.25µg/mL  4.04µL 
10x PIK3C3 Assay 
Buffer 
10x 1x 20µL  
ADP Alexa Fluor® 
594 Tracer 
800nM  4nM  1µL  
mQH2O *   174.96µL  
Total  200µL  
*mQH2O was used but autoclaved mQH2O should have been used   
Table 11: High RFU Mixture PIK3C3 Assay Conditions (to make 200µL)  
Component [Stock] [Final]  Volume  
10x PIK3C3 Assay 
Buffer 
10x 1x 20µL  
ADP Alexa Fluor® 
594 Tracer 
800nM  4nM  1µL  
mQH2O *   179µL  
Total  200µL 
*mQH2O was used but autoclaved mQH2O should have been used   
 
 
3.6.2 Preparation of the Kinase Substrates 
3.6.2.1 Dephosphorylation of Casein  
Casein was dephosphorylated based on the method used by Mayer et al. (98).  
Casein (5.02g) was measured, poured into a 250mL graduated cylinder and 40mL of RO 
H2O were added.  The pH was adjusted to 9.5 very slowly.  Water was heated in a 1L 
beaker using a hot plate; the top of the beaker was covered in aluminum foil.  When the 
temperature of the water was approximately 95°C the graduated cylinder was placed in 
the water and the graduated cylinder and the top of the beaker were wrapped in aluminum 
foil to assist the hot plate in maintaining a temperature around 95°C.  The pH of the 
casein solution was monitored with a pH meter and 1M NaOH was added as needed to 
maintain the pH of the solution at 9.5, while the solution was in the water bath for 10min.  
The aluminum foil was removed, and the graduated cylinder was taken out of the water 
bath and was placed on a stir plate.  The casein solution in the graduated cylinder was 
stirred until it reached room temperature (~1h), then it was diluted to 60mL with RO 
H2O.  During cooling the pH rose to 10.74.  Next the pH of the solution was adjusted 
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very slowly while stirring vigorously to 5.75 with 1N HCl.  The solution was poured in 
centrifuge tubes, which were then balanced and placed at -20°C overnight.   
 
The centrifuge tubes were placed on the counter to thaw, then were centrifuged 
(Thermo Scientific Sorvall RC6+ Centrifuge) using rotor 521-8x-50y for 20min at 20 000 
RPM.  The infranatant was carefully removed using a pipette while avoiding floating 
particulates and pooled into a 250mL flask.  The pH was adjusted to 5.9 and the 
centrifugation step was repeated.  A Bradford Assay was conducted to determine the 
concentration of casein in each tube (121.92mg/mL in tube 1).   A working stock of 60 
mg/mL of dephosphorylated casein was made from the solution in tube 1.   
 
3.6.2.2 Preparation of 50nm PI:3PS Vesicles  
To prepare 1.5mL of PI:3PS, 18.75µL of 10mg/mL liver PI and 56.25µL of 
10mg/mL brain PS were measured into a glass vial.  The chloroform was evaporated 
using a stream of nitrogen, then the vial was placed under high vacuum for at least 1h.  
The lipid mixture was resuspended in 1.5mL of 2.5x Lipid Dilution Buffer and was 
stored at 4°C.  The same protocol was followed for the PC:3PS control, except 7.5µL of 
25mg/mL DOPC and 56.25µL of 10mg/mL brain PS was used.   
 
The sonicator (Qsonica sonicators, Model CL-334) was set to a 35% duty cycle 
(amp), 5 min, pulse 1s on 1s off, and enter was pressed to set (on these settings the 
sample is subjected to sonication for 5 min over 10min, 1s on 1s off). The sonication 
probe was carefully set up with the vial to ensure that the tip of the probe was in the lipid 
solution but did not touch the bottom of the glass vial.  The vial of lipids was sonicated 
on ice with the above parameters; following the 10min, the ice was replaced, and the 
sonication was repeated (total of 20min).  The content of the vial was transferred to an 
Eppendorf® tube and centrifuged (ThermoIEC Micromax) at 15000 RPM for 5min to 
remove particulates from the tip of the sonicator probe.  The lipid mixture was then 
immediately transferred to a large glass vial to minimize contact with plastic and to allow 
the syringes to fit through the mouth of the vial.  The large glass vial was placed in a 
water bath at ~40°C for ~10min, during this time the Mini-Extruder apparatus (Avanti 
Polar Lipids) was set up.  A small amount of 2.5x Lipid Dilution Buffer was passed 
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through the Mini-Extruder apparatus to wet the apparatus with the buffer to be used and 
to check for leaks.  The lipid mixture was passed through the apparatus at least 5 times, 
then deposited into a new and labelled large glass vial.  The cap of the glass vial was 
wrapped in parafilm and the vial was stored at 4°C, and the lipids were used within 1 
week.   
 
3.6.3 Preparation of the Enzyme Mix  
3.6.3.1 Preparation of PKA and of the PKA Enzyme Mix  
PKA (400units) was purchased as a dried solid (9-11units/1µg PKA).  The PKA 
was reconstituted to 550units/mL (50µg/mL) by adding 272µL of PKA Reconstitution 
Solution to the commercial vial of dried PKA and the solution was mixed with a pipette.  
The PKA Reconstitution Solution was composed of 6mg/mL DTT and 10mM Mg2+ and 
the freshly reconstituted PKA was left on the benchtop at room temperature for 10min, as 
per the instructions on the PKA product information sheet.  The reconstituted PKA 
solution acted as the 550units/mL PKA stock, and a second 11units/mL PKA stock was 
made by diluting 2µL of 550units/mL PKA stock with 98µL of PKA Reconstitution 
Solution.   
 
The Enzyme Mix was composed of PKA stock and PKA Reconstitution Solution.  
The PKA Reconstitution Solution was used to dilute the PKA stock so that the 
concentration of DTT and Mg2+ was consistent between the assays independent of the 
enzyme concentration.  An enzyme titration was carried out in which different Enzyme 
Mixes were made with different concentrations of PKA.  Since the optimal concentration 
of PKA for this assay was unknown, the concentrations of PKA chosen for the titration 
were chosen to cover a wide range and based on ease of pipetting/calculating.  Enzyme 
concentration titrations were carried out using the values listed in Table 12 and the 
columns labelled Vol PKA Stock/Assay and Vol PKA Reconstitution Solution/Assay 
were multiplied by (the number of assays to be completed with that enzyme concentration 
+0.5 or 1). The +0.5 or +1 is to make a little bit of extra to account for small volumes that 
stick to the sides of the Eppendorf® tubes or small variations in pipette calibrations that 
cause problems with repeated pipetting (e.g., if a pipette actually pipettes 20.5µL when it 
is set to 20µL, repeated pipetting from the same stock will cause a person to run out if 
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only the exact theoretical amount was made).  Those respective volumes were then added 
to Eppendorf tubes such that there was one tube per concentration of PKA in the titration.  
The assays were carried out on PKA within two days after it was reconstituted.   
 
Table 12: PKA Enzyme Concentration Titration. The concentrations of PKA tested in 
the time-resolved version of the Bellbrook assay to determine the optimal concentration 
of PKA for these conditions.    
[PKA] Stock  Vol 
PKA 
Stock/ 
Assay  
Vol PKA 
Reconstitution 
Solution 
/Assay  
[PKA] in 20µL 
Enzyme Mix 
[PKA] in 50µL 
Assay  
µg/mL  Units/ 
mL 
µg/mL  Units/ 
mL 
µg/mL  Units/ 
mL 
50 550 20µL 0µL 50 550 20 220 
50 550 18.2µL  1.8µL  45.5 500 18.2 200 
50 550 13.6µL  6.4µL  34 375 13.6 150 
50 550 9.1µL  10.9µL  22.75 250 9.1 100 
50 550 4.5µL  15.5µL  11.25 125 4.5 50 
50 550 2µL  18µL 5 55 2 22 
1 11 10µL 10µL 0.5 5.5 0.2 2.2 
1 11 1µL 19µL  0.05 0.55 0.02 0.22 
- - - 20µL  0 0 0 0 
 
 
3.6.3.2  Preparation of PIK3C3 and of the PIK3C3 Enzyme Mix  
The PIK3C3 was purchased as a 100µg/mL solution of PIK3C3 in 50mM Tris-
HCl (pH 7.5), 150mM NaCl, 10mM glutathione, 0.1mM EDTA, 0.25mM DTT, 0.1mM 
PMSF, and 25% glycerol.  To make the working stock for the assay, 25µL of this 
solution was diluted with 475µL of mQH2O, then ~100µL was aliquoted into 4 
Eppendorf® tubes, and the tubes were stored at -80°C.  The smaller aliquots in separate 
tubes were used to prevent freeze-thaw cycles.  The PIK3C3 titration was carried out as 
seen in Table 13.  
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Table 13: The PIK3C3 Enzyme Concentration Titration.   The concentrations of 
PIK3C3 tested in the time-resolved version of the Bellbrook assay to determine the 
optimal concentration of PIK3C3 for these conditions.    
[PIK3C3] in 
Assay  
[PIK3C3] 
in Stock  
Vol of 
PIK3C3 
Stock/Assay  
Vol 
mQH2O* / 
Assay  
Vol PIK3C3 
Stock/4 
Assays  
Vol 
mQH2O* / 
4 Assays  
10µg/mL  100µg/mL  5µL  15µL  17.5µL** 52.5µL ** 
5µg/mL  100µg/mL  2.5µL 17.5µL  8.75µL ** 61.25µL ** 
2µg/mL  5µg/mL  20µL  0µL  80µL  0µL  
0.5µg/mL  5µg/mL 5µL  15µL  20µL  60µL  
0.2µg/mL  5µg/mL 2µL  18µL  8µL  72µL  
0.05µg/mL  5µg/mL 0.5µL  19.5µL  2µL  78µL  
0µg/mL   0µL  20µL  0µL  80µL  
*used autoclaved mQH2O 
**volumes were for 3.5 assays instead of 4 assays, this was because measuring for 4 
assays was wasteful  
 
3.6.4 Preparation of the Bellbrook Labs Transcreener® ADP2 FI Assay Mix  
The appropriate volume of autoclaved mQH2O, ADP Alexa Fluor® 594 Tracer, 
and ADP2 Antibody-IRDye® QC-1 were added into a 1.5mL Eppendorf tube according to 
Table 14 or Table 15.  In the case of the PKA assay, the dephosphorylated casein was 
also added at this time.  The tube was vortexed and rotated at room temperature for at 
least 15min.  The ATP, and the lipid substrate for PIK3C3 Assay Mix, were only added 
after everything was ready (See section 3.6.5 Running the Assay for more details) and 
immediately before the mixture was aliquoted into the assay wells.  This was to prevent 
contact between lipid substrate and the plastic tube.  Following the addition of ATP and 
lipid substrate, the mixture was vortexed, and if necessary, it was pulsed quickly in a 
microcentrifuge to collect the mixture from the walls of the Eppendorf® tube.   
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Table 14: PKA Assay Mix  
Component [Stock] Vol of Stock/ 
Assay  
Concentration 
in 30µL Assay 
Mix 
Concentration 
in 50µL Assay  
ATP 500µM  1µL  16.67µM  10µM  
Dephosphorylated  
Casein  
60mg/mL  4µL  8mg/mL  4.8mg/mL  
ADP2 Antibody-
IRDye® QC-1 
1400µg/mL  0.345µL  16.1µg/mL  9.66µg/mL  
ADP Alexa 
Fluor® 594 Tracer 
800nM  0.25µL  6.67nM  4nM  
10x PKA Assay 
and Detect Buffer  
10x:  
1000mM 
HEPES 
0.2% Brij-35 
2.5µL  0.83x:  
83.33mM 
HEPES 
0.017% Brij-
35 
0.5x:  
50mM HEPES 
0.01% Brij-35  
mQH2O *  21.905µL    
*mQH2O was used but autoclaved mQH2O should have been used   
 
Table 15: PIK3C3 Assay Mix   
Component [Stock] V of 
Stock/ 
Assay  
Concentration in 
30µL Assay Mix 
Concentration 
in 50µL Assay  
ATP 500µM  3µL  50µM  30µM  
Lipid Substrate 0.5mg/mL lipid 
in  
62.5mM HEPES 
1.25mM EGTA  
20µL  0.33mg/mL lipid  
in 
41.7mM HEPES 
0.83mM EGTA  
0.2mg/mL lipid 
in  
25mM HEPES 
0.5mM EGTA 
ADP2 
Antibody-
IRDye® QC-1 
1400µg/mL  1µL  46.67µg/mL  28.25µg/mL  
ADP Alexa 
Fluor® 594 
Tracer 
800nM  0.25µL  6.67nM  4nM  
10x PIK3C3 
Assay Buffer  
10x:  
250mM HEPES 
500mM NaCl 
30mM MgCl2 
0.25mg/mL BSA  
50mM MnCl2** 
5µL  1.67x:  
41.67mM HEPES 
83.33mM NaCl 
5mM MgCl2 
0.042mg/mL 
BSA 
8.33mM 
MnCl2** 
1x:  
25mM HEPES 
50mM NaCl  
3mM MgCl2 
0.025mg/mL 
BSA 
5mM MnCl2** 
mQH2O *  0.75µL    
*Used autoclaved mQH2O  
**MnCl2 was used in the initial stages of assay development, but was not present in the 
final working assay conditions  
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 Assay substrates were either ATP and dephosphorylated casein, or ATP and 50nm 
vesicles made from PI:3PS. A PKA assay concentration of 10µM ATP was chosen, as 
this was supposedly within the range of the kit (0.1µM ATP - 1000µM ATP) and seemed 
like a reasonable but not wasteful amount.  The ATP concentration (30µM) was chosen 
for the PIK3C3 assay because this was the concentration found in literature (99) and this 
is at or below the reported Km and ADP-Glo technical manual reports the apparent Km to 
be 40µM.  Casein (4.8mg/mL) was used as the substrate concentration because 4µL of 
the 60mg/mL dephosphorylated casein stock was a convenient volume, and calculations 
were done to ensure that there was excess casein, assuming the maximum specific 
activity of PKA (based on the product data sheet) and assuming only one phosphorylation 
site per casein subunit (even though there are multiple sites, because the number of sites 
available to be phosphorylated was unknown, and the goal was to make sure that casein 
was not limiting).  A concentration of 4.8mg/mL dephosphorylated casein is 
approximately 8×greater than the amount of casein that would be phosphorylated in 2h 
assuming maximum specific activity and if casein was only phosphorylated once.  The 
vesicle size, lipid composition and ratio, and the lipid dilution buffer for the lipid 
substrate for the PIK3C3 assay were taken from the description of the lipid substrates in 
the Promega ADP-Glo Lipid Kinase Systems technical manual (100).   
 
 The concentration of ADP2 Antibody-IR Dye® QC-1 that was used for each assay 
was calculated using a slight modification of the equation in the technical manual.   
 Equation from the technical manual: 𝑦 = 0.93𝑥 + 0.7 𝑦 = [ADP2 Antibody-IR Dye® QC-1 (µg/mL)] in the 25µL Detection mixture for 
the end-point format 
 𝑥 = [ATP (µM)] in the 25µL Enzyme Reaction for the end-point format   
The equation was designed to be used with the 25µL Enzyme Reaction + 25µL Detection 
Mixture end-point format.  To adjust to the 50µL assay volume (20µL Enzyme Mix + 
30µL Assay Mix) for the time-resolved assay format, the [ATP] for the assay was 
multiplied by two, substituted into the equation as x, solved for y, and y was divided by 2 
to get the antibody concentration in the 50µL assay.   
 [ATP] for time-resolved 50µL PKA assay = 10µM  
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 10µ𝑀 ∗ 2 = 20µ𝑀	 
 𝑦 = 0.93(20µ𝑀) + 0.7 
 𝑦 = 19.3µ𝑔/𝑚𝐿	antibody  
 PQ = 9.65µ𝑔/𝑚𝐿	antibody in time-resolved 50µL PKA assay  
The assay concentration of the ADP Alexa Fluor® 594 Tracer is always 4nM, 
independent of the other assay conditions as inferred from the technical manual (93).  
 
The PKA assay buffer recipe was based on information included in the Bellbrook 
Labs Transcreener® ADP2 FI Assay kit technical manual (93).  The PIK3C3 assay buffer 
was taken from the Promega ADP-Glo technical manual (100), then was adjusted based 
on the challenges that were faced in the development of the assay.  This process is 
outlined in the Results and Discussion Section 5.5.1 10x PIK3C3 Assay Buffer: 
Precipitation Problems.   
 
The length of the assay was determined in proportion to the [ATP], the [enzyme], 
and the specific activity reported on the material data sheets.  The equilibration time of 
the displacement of the ADP Alexa Fluor® 594 Tracer by the non-fluorescent ADP 
produced by the enzyme is greater than 15min (93).  Therefore, the kit cannot confidently 
be used with short-term enzyme reactions.  Thus, the length of time, the [ATP], and the 
[enzyme] were chosen to ensure that the enzyme was working slowly enough that ADP 
was being produced at a slower rate than the displacement.  This was to ensure that the 
rate measured by the assay was the rate of ADP production and not the rate of 
displacement.   
It was also important to ensure initial rate conditions as there would be less than 10% 
ATP conversion during the length of the assay.   
   
3.6.5 Running the Assay  
Prior to beginning the assay everything was prepared and set up – the enzyme 
solution, the assay mix, the pipettes, the autoclaved pipette tips, the plate reader, the 
plate, and the map of which samples go where in the assay plate was already planned out.  
Then the last components of assay mix were added (lipid substrate and ATP), the 
Eppendorf® tube was vortexed, and the contents of the tube were spun down in a 
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microcentrifuge if necessary.  The Assay Mix (30µL) was aliquoted into each well, then 
20µL of the Enzyme Mix was added into each well to start the reaction.  The plate was 
placed into plate reader, and the Read button was clicked immediately.  The “set first 
point to zero” box was unchecked to ensure that the raw data was displayed instead of 
data that was arbitrarily normalized.     
 
3.6.6 ATP/ADP Standard Curves  
Twelve autoclaved 1.5mL Eppendorf® tubes were labeled 0%-100% according to 
the first column of Table 16.  Autoclaved mQH2O was pipetted into each tube according 
to column 7 in Table 16, followed by the proper volume of the ATP and ADP stock 
solutions (columns 5 and 6, Table 16).  Next, the Assay Mix was made (Table 17).  The 
volumes of each component necessary for 52 microtiter wells were measured into a 2mL 
Eppendorf® tube, the tube was mixed and rotated at room temperature for at least 15 min.  
Then 108.38uL of Assay Mix was added to each % ATP conversion Eppendorf® tube, the 
tubes were vortexed and were rotated at room temperature for at least 15min.  50µL of 
each %ATP conversion was pipetted into 3 wells and the FI was measured using the 
Endpoint FI Assay Window protocol/settings.  The same procedure was followed for the 
PIK3C3 ATP/ADP standard curve with a few exceptions.  The volumes used are found in 
Tables 18 and 19.  When the Assay Mix was made the lipid substrate was not added until 
right before the Assay Mix was aliquoted into the % ATP conversion tubes, this was to 
reduce the contact of the lipid substrate with plastic.  The Assay Mix (105µL) was added 
to each % ATP conversion Eppendorf® tube.   
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Table 16: The volumes required to make the ATP/ADP solutions to make 200µL 
total of each % ATP conversion for the PKA ATP/ADP standard curve (91.62µL 
ATP/ADP solution + 108.38µL of Assay Mix = 200µL of the % ATP Conversion).     
% ATP 
Conversion 
[ATP] 
(µM) 
[ADP] 
(µM)  
Vol of 
100µM 
ATP 
Stock 
(µL) 
Vol of 
10µM 
ADP 
stock 
(µL)  
Vol of 
100µM 
ADP 
stock 
(µL) 
Vol of 
autoclaved 
mQH2O 
(µL)  
Total 
Volume 
(µL)   
0 10 0 20 0  71.62 91.62 
2 9.8 0.2 19.6 4.0  68.02 91.62 
4 9.6 0.4 19.2 8.0  64.42 91.62 
6 9.4 0.6 18.8 12.0  60.82 91.62 
8 9.2 0.8 18.4  1.6 71.62 91.62 
10 9.0 1.0 18.0  2.0 71.62 91.62 
15 8.5 1.5 17.0  3.0 71.62 91.62 
20 8.0 2.0 16.0  4.0 71.62 91.62 
30 7.0 3.0 14.0  6.0 71.62 91.62 
40 6.0 4.0 12.0  8.0 71.62 91.62 
60 4.0 6.0 8.0  12.0 71.62 91.62 
100 0 10 0  20.0 71.62 91.62 
 
Table 17: Assay Mix for the PKA ATP/ADP Standard Curve (Volumes to make 
200µL of each % Conversion, 108.38µL of Assay Mix per % Conversion)   
Component [Stock] Vol per well (µL)  Vol for 52 wells 
(µL)  
PKA Buffer  6mg/mL DTT 
10mM MgCl2 
20µL  1040µL  
Casein  60mg/mL  4µL  208µL  
ADP2 Antibody-IR 
Dye® QC-1 
1400ug/mL  0.345µL  17.94µL  
ADP Alexa Fluor® 
594 Tracer 
800nM  0.25µL 13µL  
10x PKA Assay + 
Detect Buffer  
10x 
1000mM HEPES 
0.2% Brij  
2.5µL  130µL  
Total    1408.94µL  
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Table 18: The volumes required to make the ATP/ADP solutions to make 175µL 
total of each % ATP conversion for the PIK3C3 ATP/ADP standard curve (70µL 
ATP/ADP solution + 105µL of Assay Mix = 175µL of the % ATP Conversion).     
% ATP 
Conversion 
[ATP] 
(µM) 
[ADP] 
(µM)  
Vol of 
100µM 
ATP 
Stock 
(µL) 
Vol of 
100µM 
ADP 
stock 
(µL)  
Vol of 
autoclaved 
mQH2O 
(µL)  
Total 
Volume 
(µL)   
0 30.0 0.0 52.5 0 17.5 70 
2 29.4 0.6 51.45 1.05 17.5 70 
4 28.8 1.2 50.4 2.1 17.5 70 
6 28.2 1.8 49.35 3.15 17.5 70 
8 27.6 2.4 48.3 4.2 17.5 70 
10 27.0 3.0 47.25 5.25 17.5 70 
15 25.5 4.5 44.62 7.88 17.5 70 
20 24.0 6.0 42.0 10.5 17.5 70 
30 21.0 9.0 36.75 15.75 17.5 70 
40 18.0 12.0 31.5 21.0 17.5 70 
60 12.0 18.0 21.0 31.5 17.5 70 
100 0.0 30.0 0 52.5 17.5 70 
 
Table 19: Assay Mix for the PIK3C3 ATP/ADP Standard Curve (Volumes to make 
175µL of each % Conversion, 105µL of Assay Mix per % Conversion)   
Component [Stock] Vol per well (µL)  Vol for 45.5 wells 
(µL)  
PI:3PS Lipid 
Substrate  
0.5mg/mL  20µL  910µL  
ADP2 Antibody-IR 
Dye® QC-1 
1400ug/mL  1µL  45.5µL  
ADP Alexa Fluor® 
594 Tracer 
800nM  0.25µL 11.38µL  
10x PIK3C3 Assay 
Buffer  
10x 5µL  227.5µL  
Autoclaved 
mQH2O 
 3.75µL  170.62µL  
Total   30µL  1365µL  
 
3.6.7 Assay Controls 
Control assays in which the enzyme, a substrate, or both were omitted, were 
conducted for the same time and with the same conditions as the respective assay, having 
all of the components.  The volume of the missing component was compensated for with 
autoclaved mQH2O for the Background (no antibody and no tracer), No Antibody, No 
Tracer, No ATP, No Casein, No PIK3C3, No Lipid, and the No Lipid and No PIK3C3 
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controls.  In the case of the PKA controls without PKA, the respective volume of PKA 
reconstitution solution was added.  In the case of the PC:3PS control, the volume and 
concentration of lipid substrate was the same as the assay conditions, the vesicles were 
just composed of PC:3PS instead of PI:3PS.  The PI:3PS + mQH2O control contained 
0.2mg/mL PI:3PS and autoclaved mQH2O.  The PI:3PS + Buffer control contained 
0.2mg/mL PI:3PS, 1x PIK3C3 Assay Buffer, and autoclaved mQH2O.  0% ATP 
conversion and 100% ATP conversion controls were completed as the first and last points 
of the ATP/ADP standard curves.   
 
3.6.8 Sneaking Mn2+ into the Assay 
The “sneak” Mn2+ assay was conducted in the same way as the PIK3C3 assay 
with two key changes.  The first change was that the 10x PIK3C3 assay buffer was made 
without MgCl2 and without MnCl2.  The second change was that MnCl2 was added to the 
enzyme mix such that the final assay concentration of Mn2+ was either 3mM or 3µM.   
 
3.6.9 Fluorescence Plate Reader 
Molecular Devices SpectraMax M2  
Software: SoftMax pro 7.03 
Assay Plates: Corning, Assay Plate, 96 Well Half Area, No Lid, Flat Bottom, Non-
Binding Surface, Black Polystyrene (REF 3686) 
 
Settings for Endpoint FI Assay Window:  
 Endpoint  
 Fluorescence 
  Excitation Wavelength: 575nm, Emission Wavelength: 620nm 
  Auto-cutoff: 610nm  
 PMT and Optics: Auto, 6 flashes/read  
 More Settings: shake once before 1st read, calibrate on, carriage speed normal, 
column priority  
Temperature: room temperature (~22°C)  
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Settings for PKA Kinetic Assay:  
 Kinetic, Time: 1h, Interval: 2min, Reads: 31  
 Fluorescence 
  Excitation Wavelength: 575nm, Emission Wavelength: 620nm 
  Auto-cutoff: 610nm  
 PMT and Optics: Medium, 6 flashes/read  
More Settings: shake on, calibrate on, carriage speed normal, column priority  
Temperature: room temperature (~22°C)  
 
Settings for PIK3C3 Kinetic Assay:  
 Kinetic, Time: 3h, Interval: 2min, Reads: 91  
 Fluorescence 
  Excitation Wavelength: 575nm, Emission Wavelength: 620nm 
  Auto-cutoff: 610nm  
 PMT and Optics: Medium, 6 flashes/read  
More Settings: shake on, calibrate on, carriage speed normal, column priority  
Temperature: room temperature (~22-24°C)  
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4 Results and Discussion: Protein Expression and Purification  
Notes for whole Results and Discussion section: the colour code  
BJ2168 = pink, pVEX = green, B8NA = blue, 10NE = purple  
     Not Induced         Induced with solid Galactose           Induced with YEPG 
Black fit line: 2% Dextrose SCUTAD pre-culture  
Coloured fit line + black outline around symbols: 0.2% Dextrose SCUTAD* pre-culture  
 
 
4.1 Growth Curve Experiments: pVEX in SCUTAD and BJ2168 in SCAT 
and YPAD 
BJ2168 was grown in SCAT (Figure 21).  The time to reach mid-log phase was 
approximately 700min.  The maximum OD (600nm) predicted by the fit was 5.353 and 
the data began to plateau around 1000min.  pVEX (BJ2168 transformed with empty 
pYEXC3H and pESC-Trp vectors) was grown in SCUTAD (Figure 21).  The time to 
reach the mid-log phase was approximately 1000min and a maximum OD around 3.6 was 
reached by 1900min.  The maximum OD predicted by the fit was 3.722.   
 
Figure 21: BJ2168 and pVEX were grown in either SCUTAD or SCAT.  pVEX: 
BJ2168 transformed with empty vectors pYEXC3H and pESC-Trp.  Growth was 
measured by following the optical density (OD) measured at 600nm.  The growth curves 
were fit using a Gompertz growth model.  
 
 
It took longer for pVEX in SCUTAD to reach its mid-log and its maximum OD 
than for BJ2168 in SCAT.  This makes sense because SCAT is not a selective medium, 
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while SCUTAD is a selective medium that works based on the principle that BJ2168 is a 
tryptophan (Trp) and uracil (Ura) auxotroph, meaning that BJ2168 is not capable of 
making either on its own.  SCAT has both of these nutrients while SCUTAD does not.  
The two vectors that pVEX is transformed with confer the ability to make Trp and Ura 
respectively, therefore, when pVEX is grown on media that does not contain Trp and Ura, 
only cells that contain both vectors can make these amino acids and survive.  Therefore, 
pVEX in SCUTAD are not expected to grow as efficiently as BJ2168 in SCAT because 
they have the additional work of producing Trp and Ura (resources have to go into that 
instead of into growth and division) and any cells that have lost a plasmid die, therefore 
also slowing the overall population growth.   pVEX in SCUTAD also have the additional 
work of replicating the plasmids.  BJ2168 (which does not contain the plasmids) in 
SCAT was expected to have the fastest growth as it is a non-selective medium.   
 
The first time that BJ2168 was grown in YPAD both OD and cell count 
measurements were made at each time point; this was to correlate OD with approximate 
cell counts.  This data can be seen in Figure 22.   The same samples were plotted two 
different ways, one with the OD measurements and one with the cell counts.  OD vs Time 
(min) and #cells/mL vs. Time (min) are both approximately linear and follow the same 
trend.  It was calculated that there were approximately 9.02 x 107 cells/mL per OD unit.   
 
  
Figure 22:  Correlation of optical density at 600nm and cell counts from BJ2168 
grown in YPAD.  The same samples were plotted two different ways, one with the OD 
measurements and one with the cell counts.  
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4.2 Growth Curve Experiments: Pre-Culture Tube Growth Condition Tests  
BJ2168 was grown in 5mL of SCAT in culture tubes for 24h at different 
conditions (Figure 23).  There was a slight decrease in growth at 220 RPM compared to 
250 RPM, which is likely due to a decrease in aeration.  Given that the maximum ODs 
did not change substantially with temperature or shaking speed, 26°C and 300 RPM were 
the conditions that were chosen based on practicality; 26°C was chosen over 30°C 
because  26°C is the recommended growth temperature for this strain (101).   
 
 
 
Figure 23: Pre-culture tube growth condition tests.  Growth as determined by OD 
(600nm) measurements for BJ2168 grown in 5mL of SCAT medium in culture tubes for 
24h at different conditions of temperature and agitation.   
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4.3 Growth Curve Experiments: B8NA in SCUTAR – Non-induced and 
Induced with Solid Galactose  
B8NA (transformed BJ2168 with clone 8 (pYEXC3H+PIK1) and clone N (pESC-
Trp+FRQ1+CDC37) at the same time, colony A) was grown in SCUTAR (Figure 24).  
The time to reach the mid-log phase was approximately 940min.  The maximum OD 
(600nm) predicted by the fit was 3.585 and it began to plateau around 2300min.   
 
 
Figure 24: B8NA grown in SCUTAR.  B8NA: transformed BJ2168 with clone 8 
(pYEXC3H+PIK1) and clone N (pESC-Trp+FRQ1+CDC37) at the same time, colony A.  
No induction.  Grown at 26°C and 300 RPM.  The growth curves were fit using a 
Gompertz growth model.    
 
B8NA was grown in SCUTAR and protein expression was induced by the 
addition of solid galactose at different ODs.  The time to reach mid-log phase was 
approximately 1050min for the majority of the curves (Figure 25).  The growth plateaued 
between about OD 3.8-4 by 3000min.  The maximum values predicted by the Gompertz 
growth model fits are 4.207 (baby blue), 4.005 (navy blue), and 3.857 (teal).  Non-
induced B8NA grown in SCUTAR (blue) is also shown in Figure 25 for comparison.  
There was not a drastic difference in growth if B8NA was not induced or if it was 
induced with solid galactose, and there was not a drastic difference between the growth of 
B8NA when it was induced with solid galactose at different ODs.  This indicated either 
that adding the sugar galactose (the inducer) added an additional carbon source that 
assisted the cells to grow despite the extra burden of protein expression or that following 
induction with solid galactose, B8NA was not producing a substantial amount of protein, 
so the energy drain on the growth and division was not large.  These experiments 
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monitored cell growth via measuring the OD at 600nm; therefore, the level of protein 
expression based on these different conditions is not known, and it will be the work of a 
future student to optimize protein expression.        
 
Figure 25: B8NA grown in SCUTAR, induced with solid galactose at different 
optical densities.  B8NA: transformed BJ2168 with clone 8 (pYEXC3H+PIK1) and 
clone N (pESC-Trp+FRQ1+CDC37) at the same time, colony A.  Grown at 26°C and 
300 RPM.  All plateau OD ~3-4. The growth curves were fit using a Gompertz growth 
model.    
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4.4 Growth Curves: SCUTAD vs SCUTAD*  
Other growth curve experiments were completed prior to the ones shown in 
Sections 4.1-4.3.  However, after their completion it was realized that the SCUTAD pre-
culture tubes used for these experiments contained 10-fold less dextrose than they were 
supposed to (0.2% dextrose instead of 2%).  This error is denoted by SCUTAD* in this 
document when this 0.2% dextrose media was used.   The cells in the SCUTAD* pre-
cultures grew less in 24h than those in SCUTAD, therefore the inoculum used to 
inoculate the SCUTAR flasks for these growth curve experiments was smaller than that 
of the SCUTAD pre-cultures used in the growth curve experiments discussed in the 
previous sections.  As a result, the growth curves took a longer time to evolve, as seen in 
Figure 26.  The difference in the time to reach mid-log phase for B8NA (transformed 
BJ2168 with clone 8 (pYEXC3H+PIK1) and clone N (pESC-Trp+FRQ1+CDC37) at the 
same time, colony A) in SCUTAR for SCUTAD* vs SCUTAD pre-cultures was 
1050min (~17h).  However, given the time, the cultures grown from SCUTAD* pre-
cultures still reached a plateau in OD between 3 and 4.  Overall these experiments are still 
meaningful, but the timing of the growth cannot be compared with the experiments that 
used SCUTAD pre-cultures.  The data presented in Section 4.4 (4.4.1 - 4.4.3) was 
gathered from cultures that were grown in SCUTAD* pre-cultures except where 
otherwise stated.  The 10NE (transformed BJ2168 with clone 10 (pYEXC3H+PIK1) and 
clone N (pESC-Trp+FRQ1+CDC37) sequentially, colony E) experiments were not grown 
in the SCUTAD* pre-cultures, the pre-culture used as the inoculum for this experiment 
was grown in SCUTAD.  However, only 1mL of pre-culture was used instead of 5mL to 
inoculate 100mL of SCUTAR for the growth curve.  This is why these cultures follow the 
same delayed growth as the ones grown in SCUTAD* pre-cultures as both of them began 
with fewer cells as the inoculum.       
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Figure 26: B8NA grown in SCUTAR from either SCUTAD (2% dextrose, black 
trendline) or SCUTAD* (0.2% dextrose, coloured trendline) pre-cultures.  B8NA: 
transformed BJ2168 with clone 8 (pYEXC3H+PIK1) and clone N (pESC-Trp+FRQ1+ 
CDC37) at the same time, colony A.  No induction.  Grown at 26°C and 300 RPM.  The 
growth curves were fit using a Gompertz growth model.   An additional data point around 
10000min exists for the SCUTAD* pre-culture data set; it was used to generate the fit, 
but it was truncated for consistency and clarity in the visual representation.    
 
 
 
4.4.1 Maximum Plateau  
It is easily observed from Figures 24-28 that all the growth curves of B8NA 
(transformed BJ2168 with clone 8 (pYEXC3H+PIK1) and clone N (pESC-
Trp+FRQ1+CDC37) at the same time, colony A) in SCUTAR or SCUTAD have a 
maximum OD value very close to or between 3 and 4.  This is observed independent of 
the various growth conditions- if the cultures were induced with solid galactose or not, if 
they were grown in dextrose or raffinose, or if pre-culture dextrose concentration was 
0.2% or 2%.  The two growth curves of 10NE (transformed BJ2168 with clone 10 
(pYEXC3H+PIK1) and clone N (pESC-Trp+FRQ1+CDC37) sequentially, colony E) also 
seem to follow this trend (Figure 27).   
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Figure 27: A comparison of growth in dextrose vs raffinose, pVEX, B8NA, and 
10NE grown in SCUTAD and SCUTAR.  pVEX: BJ2168 transformed with empty 
vectors pYEXC3H and pESC-Trp.  B8NA: transformed BJ2168 with clone 8 
(pYEXC3H+PIK1) and clone N (pESC-Trp+FRQ1+CDC37) at the same time, colony A.  
10NE: transformed BJ2168 with clone 10 (pYEXC3H+PIK1) and clone N (pESC-
Trp+FRQ1+CDC37) sequentially, colony E).  SCUTAD* pre-cultures.  No induction.  
Grown at 26°C and 300 RPM.  All plateau OD ~3-4.  The growth curves were fit using a 
Gompertz growth model.  Additional data points around 10000min exist; they were used 
to generate the fits but were truncated for consistency and clarity in the visual 
representation.    
 
 
 
 
Figure 28: B8NA grown in SCUTAR, induced with solid galactose at different 
optical densities.  B8NA: transformed BJ2168 with clone 8 (pYEXC3H+PIK1) and 
clone N (pESC-Trp+FRQ1+CDC37) at the same time, colony A.  SCUTAD* pre-
cultures.  Grown at 26°C and 300 RPM.  All plateau OD ~3-4. The growth curves were 
fit using a Gompertz growth model.   An additional data point around 10000min exists 
for the B8NA in SCUTAR data set; it was used to generate the fit, but it was truncated for 
consistency and clarity in the visual representation.    
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4.4.2 B8NA in Dextrose vs Raffinose  
A comparison between growth in dextrose vs raffinose containing media was 
carried out with pVEX (BJ2168 transformed with empty vectors pYEXC3H and pESC-
Trp), B8NA (transformed BJ2168 with clone 8 (pYEXC3H+PIK1) and clone N (pESC-
Trp+FRQ1+CDC37) at the same time, colony A), and 10NE (transformed BJ2168 with 
clone 10 (pYEXC3H+PIK1) and clone N (pESC-Trp+FRQ1+CDC37) sequentially, 
colony E) (Figure 27).  These experiments were not done in replicates; however, a trend 
can be seen between the cultures grown in SCUTAD vs the cultures grown in SCUTAR.  
B8NA and 10NE grown in SCUTAD reached the mid-log phase at least 9h faster than 
pVEX, B8NA, and 10NE grown in SCUTAR.  This trend indicated that growth was more 
efficient when the culture was grown in dextrose vs raffinose containing media.  This 
makes sense as glucose is the favoured carbon and energy source in yeast (102).  
However, raffinose did not negatively impact overall growth, as the growth curves in 
SCUTAR still plateaued between an OD of 3 and 4, and they reached their maximum OD 
around a similar time as the SCUTAD cultures.  This is advantageous for this expression 
system because it means that growth is not sacrificed when raffinose is used.  Raffinose is 
advantageous because it is a non-glucose and non-inducing sugar.  Glucose is the 
favoured carbon source in yeast and it suppresses the expression of galactose metabolism 
genes, along with other sugar metabolism genes (102, 103).  Galactose induction occurs 
when the concentration of glucose is low enough and the concentration of galactose is 
high enough to create the appropriate glucose:galactose ratio (103).  Growing the cells in 
a non-inducing, non-glucose sugar containing medium prior to induction with galactose 
eliminates the repression of galactose metabolizing genes, allowing them to be quickly 
activated upon the addition of galactose (102, 103).    
 
 
4.4.3 B8NA and 10NE Induced with YEPG  
 B8NA (transformed BJ2168 with clone 8 (pYEXC3H+PIK1) and clone N (pESC-
Trp+FRQ1+CDC37) at the same time, colony A) and 10NE (transformed BJ2168 with 
clone 10 (pYEXC3H+PIK1) and clone N (pESC-Trp+FRQ1+CDC37) sequentially, 
colony E) were grown in SCUTAR and induced at an OD of ~2 with YEPG (rich media 
containing galactose) (Figure 29).  There was a dip in OD between the time points taken 
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immediately before and after the addition of YEPG (between 2500min-2800min in Figure 
29).  YEPG (50mL, 3x) was added to 100mL of growing culture, this diluted the culture, 
thus causing the dip in the observed OD.  YEPG is a rich media that lifts the selection, 
therefore these cells received fresh nutrients, and they no longer had to make their own 
Ura and Trp to survive.  This relieved the cells of this work and allowed them to channel 
more energy and resources into growing and dividing.  This was probably why the OD of 
the final measurement was so high (OD = ~9).  The lack of selection may have also led to 
loss of the vectors, and this also may have caused the large amount of growth.  
Measurements were ceased due to time constraints and due to suspicions that the cells 
were losing the plasmids as a result of the lack of selection.  As a result, the plateau (max 
OD) for YEPG induced B8NA or 10NE is unknown.  A test of plasmid stability was 
subsequently conducted and 24h after induction with YEPG a sample was taken and 
plated on SCUTAD and SCUTA and grown for 32h.  Visually there appeared to be the 
same amount of growth regardless of selective or non-selective media, which indicated 
that the plasmids were stable.  Therefore, the growth was likely due to the fresh nutrients 
and the relief of the auxotrophic selection.      
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Figure 29: B8NA and 10NE grown in SCUTAR, induced with YEPG at different 
OD ~2.  B8NA: transformed BJ2168 with clone 8 (pYEXC3H+PIK1) and clone N 
(pESC-Trp+FRQ1+CDC37) at the same time, colony A.  10NE: transformed BJ2168 
with clone 10 (pYEXC3H+PIK1) and clone N (pESC-Trp+FRQ1+CDC37) sequentially, 
colony E. SCUTAD* pre-cultures.  Grown at 26°C and 300 RPM.  Huge amounts of 
subsequent growth were observed after addition of rich YEPG media and as a result the 
plateau/maximum OD was not reached.  An additional data point around 10000min exists 
for the B8NA in SCUTAR data set; it was used to generate the fit, but it was truncated for 
consistency and clarity in the visual representation.    
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4.5 Analyzing Growth Curve Experiments Using SDS-PAGE 
4.5.1 Method of Yeast Cell Lysis Matters  
 
   
Figure 30: A comparison of the methods of yeast cell lysis.  A. The samples were 
prepared by boiling for 10min at 90°C with lysis buffer (0.1M NaOH, 0.05M EDTA, 2% 
SDS, and 2% 𝛽-mercaptoethanol) and acetic acid.  The gel was a 6% stacking, 10% 
resolving SDS-PAGE gel and it was run at 120V for ~1.75h.  B. The samples were 
prepared the same as A. except they were boiled for 18min instead of 10min.  The gel 
was a 6% stacking, 10% resolving SDS-PAGE gel and it was run at 120V for ~2h.  C. 
The cells were lysed by vortexing (VWR Analog Vortex Mixer) five times with glass 
beads, at maximum speed (10) for 30s, with 1.5min in between to cool on ice.  The gel 
was a precast commercial 12% SDS-PAGE gel.   
 
 
 Three methods of yeast cell lysis were tried; the first two involved boiling the 
cells at 90°C with lysis buffer (0.1M NaOH, 0.05M EDTA, 2% SDS, and 2% 𝛽-
mercaptoethanol) and acetic acid for different amounts of time, while the third method 
involved the use of glass beads.  The first method of yeast cell lysis (boiling for 10min 
90°C with lysis buffer and acetic acid) did not effectively extract proteins that were larger 
than approximately 100kDa.  This is seen in the sample lanes shown in Figure 30A and it 
was also observed with all of the samples that were prepared using this method.  The 
second method was the same as the first except the cells were boiled for 18min.  
Extending the boiling time from 10min to 18min did not improve the protein extraction 
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problem with respect to the extraction of high MW proteins; no proteins larger than 
100kDa were observed in any of the lanes with any of the samples that were prepared in 
this manner.  The samples in Figure 30B are examples of this.  However, proteins larger 
than 100kDa could be seen on the SDS-PAGE gels when glass beads were used for the 
cell lysis.  This can be seen in Figure 30C.  
 
 The difference in the size of extracted proteins was caused by a difference in the 
degree to which the cell membrane and cell wall were disrupted by the lysis technique.  
Boiling the cells in lysis buffer (0.1M NaOH, 0.05M EDTA, 2% SDS, and 2% 𝛽-
mercaptoethanol) disrupted the cell membrane and the cell wall, making them more 
permeable, without completely breaking the cells open (97).  This explains the size cut-
off that was observed; the cells became permeable enough to let out proteins of smaller 
molecular weight, but proteins with molecular weights greater than ~100kDa were too 
big to be released.  However, glass beads collide with the cells and mechanically break 
the membranes by shear force (104).  Cell membranes can be completely disintegrated 
using glass beads, therefore this method is a very efficient method for lysing cells and the 
entire contents of the cell is released independent of molecular weight (104).    
 
 
4.5.2 Western Blot  
A western blot was performed on galactose-induced transformants (B8NA: 
transformed BJ2168 with clone 8 (pYEXC3H+PIK1) and clone N (pESC-
Trp+FRQ1+CDC37) at the same time, colony A, and 10NE: transformed BJ2168 with 
clone 10 (pYEXC3H+PIK1) and clone N (pESC-Trp+FRQ1+CDC37) sequentially, 
colony E) by Candace Panagabko (Brock University) (Figure 31).  Frq1 was tagged with 
FLAG and an anti-FLAG (Sigma) antibody was used for the western blot.  There was 
some cross reactivity, but the largest and darkest bands between 20-25kDa correspond to 
Frq1, a 22kDa protein.  Bands corresponding to the Pik1-Frq1 complex can be seen at 
~100kDa.  The non-induced pVEX and B8ND controls, and the induced pVEX control, 
did not have any bands (lanes 1-3 in Figure 31).  No distinct bands were observed in 
lanes 5 and 6.  The induced B8NA sample in lane 5 was an old sample that was lysed 
using the boiling protocol.  It is very likely that the sample was not completely 
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neutralized leading to the degradation of the protein in the sample.  This smearing was 
observed as the samples that were lysed with this method aged.  The induced B8NA 
sample in lane 6 was lysed with a different method and it is likely that this method was 
ineffective.  The western blot confirmed that the transformants were expressing Pik1 and 
Frq1 and that the two form a complex that is stable during lysis.   
 
 
Figure 31: A Western blot showing the expression of Frq1 and the Pik1-Frq1 
complex in B8NA and 10NE induced with galactose.  B8NA: transformed BJ2168 with 
clone 8 (pYEXC3H+PIK1) and clone N (pESC-Trp+FRQ1+CDC37) at the same time, 
colony A.  10NE: transformed BJ2168 with clone 10 (pYEXC3H+PIK1) and clone N 
(pESC-Trp+FRQ1+CDC37) sequentially, colony E. The Western blot was performed by 
Candace Panagabko (Brock University). The samples of yeast cells were lysed using the 
boiling protocol or glass beads prior to subjection to SDS-PAGE.  The proteins where 
blotted onto a PVDF membrane and an anti-FLAG primary antibody was used for 
detection.    
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4.6 Purification  
The complete expression and purification of the Pik1-Frq1 complex was 
attempted twice; however, both attempts were unsuccessful at yielding the complex.  The 
FPLC was set up with a UV-Vis detector to monitor the eluate from the IMAC column at 
280nm to detect protein.  No protein peak was detected during the imidazole elution steps 
for either attempt.  This is possibly due to low expression levels; however, protein 
expression was not measured in these experiments.  The expression of the Pik1-Frq1 
complex was confirmed by the Western blot, and therefore the expression and 
purification of the complex just needed to be fine-tuned and optimized.  It was deemed 
more critical to move on to the development of a time-resolved assay and therefore this 
work was set aside for future students to continue and focus was placed on assay 
development.   
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5 Results and Discussion: Development of the Assay  
Assay development requires answers to questions regarding buffer components 
and their concentrations, the concentrations of assay components, signal intensity, and the 
reliability and sensitivity of the instrument.  The following sections describe efforts to 
elucidate this information.   
5.1 Assay Plates and Instrument Settings and Sensitivity  
The first questions that were addressed were regarding the plate reader.  Which 
plate reader should be used? Is the plate reader sensitive enough to distinguish between 
the high and low FI signals?  If so, what settings are required so that the plate reader can 
do that?  Which excitation, emission, and cutoff wavelengths should be used?  Which 
microplates should be used for the assay?  
These questions were answered over the course of 3 months as 4 different plate 
readers were attempted in succession: Cary Eclipse (Agilent Technologies), POLARstar 
Optima (BMG LABTECH), SpectraMax i3 (Molecular Devices), and SpectraMax M2 
(Molecular Devices).  The FI assay window experiment was used to determine the 
sensitivity of the instrument and the settings required to achieve a FI window in which 
the high signals are at least 5 times greater than the low signals.  The narrow difference 
between the optimal excitation and emission wavelengths of the ADP Alexa Fluor® 594 
Tracer posed an issue (especially for the older machines, thus making the use of the 
newer machines essential).  It was determined that 575nm, 620nm, and 610nm should be 
used for the excitation, emission, and cutoff wavelengths respectively.  The use of ½ area 
plates instead of full area plates was also deemed essential.  The Cary Eclipse and 
POLARstar Optima were not sensitive enough to distinguish the difference between the 
high and low FI samples.  Both SpectraMax i3 and SpectraMax M2 were adequate for 
this assay but SpectraMax M2 was used because it was more readily available for use.  A 
default setting of the software of SpectraMax M2 when performing kinetic measurements 
is to “Set first data point to zero”.  When this data reduction setting was on, it normalized 
all the data to 0, making the high and low FI measurements the same, resulting in 
illogical and meaningless data.  This setting must therefore be turned off.  One benefit is 
that this setting effects the processing and presentation of the data, but not the acquisition 
of the data.  Therefore, file(s) that were recorded with this setting on were opened, this 
box unchecked, and the file saved with the raw/unnormalized data.    
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5.2 How the Commercial Bellbrook Transcreener ADP FI Assay Is 
Designed to Work and How the Protocol Was Modified to Make the 
Assay Time-Resolved   
 
The assay kit was designed as an endpoint assay in which the enzyme reaction 
occurs in 25µL for a particular amount of time, then the enzyme activity is stopped by 
adding 25µL of the 1x Detection Mixture which contains EDTA.  EDTA strips the metal 
cation from the active site of the enzyme effectively stopping the reaction from 
continuing.  During the 1-hour incubation period, the ADP that was produced during the 
enzyme reaction displaces the ADP Alexa Fluor® 594 Tracer from the ADP2 Antibody-IR 
Dye® QC-1.  After the 1-hour incubation, the fluorescence intensity is measured once.   
 
The key changes that needed to be made and/or accounted for to make this a time-
resolved assay, were a change in the enzyme reaction volume from 25µL to 50µL, the 
removal of EDTA, and an increase in the number of FI measurements.  The enzyme 
reaction and the detection components need to be added together and at the beginning of 
the assay, thus increasing the enzyme reaction volume to 50µL instead of 25µL.  The 
amounts of the assay components need to be increased to account for this increase in 
volume so that the concentrations were sufficient.  The buffer does not contain EDTA so 
that the enzyme remains functional throughout the duration of the measurements.  The 
last key change is a change in the data acquisition, such that the FI is measured at regular 
time intervals for the duration of the assay.      
 
 The two solutions defined in the endpoint protocol are the Enzyme Reaction Mix 
and the 1x ADP Detection Mixture.  How these two solutions are defined, what is in each 
of them and how they are used, were not conducive to a time-resolved assay (one for 
enzyme reaction, one to stop the reaction and detect the signal).  Therefore, two different 
solutions were defined: the Enzyme Mix and the Assay Mix (to be mixed with each other 
at the beginning to start the reaction) (Table 20).  The ATP and acceptor substrate were 
included in the Assay Mix instead of with the enzyme, and the concentrations in the 
Enzyme Mix and Assay Mix were such that when 20µL of Enzyme Mix was added to 
30µL of Assay Mix, each component had the desired concentration in the 50µL assay.  It 
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was decided to change the recipe from 25µL + 25µL = 50µL to 20µL + 30µL = 50µL 
because the solutions were getting mixed at the beginning of the reaction anyway, so the 
volume proportions did not matter with respect to the enzyme reaction volume.  It made it 
easier to pipette all the components into the assay mix and keep the volume below 
30µL/assay, and 20µL of “space” for the enzyme titration was helpful to get a wide range 
of enzyme concentrations.  For example, if the volume split was 40/10 instead, then the 
highest concentration of enzyme available would be 10µL/50µL of the 
reconstituted/commercial (highest concentration) enzyme stock, instead of 20µL of this 
stock, which would give a lower maximum enzyme concentration and a smaller enzyme 
concentration window to work in for the titration.         
 
Table 20: The components of the two solutions for the Endpoint and Time-Resolved 
assay formats.   
Endpoint  Time-Resolved  
Complete Enzyme Reaction Mix:  
Enzyme  
Autoclaved mQH2O  
ATP  
Acceptor Substrate 
Enzyme Mix:  
Enzyme  
Autoclaved mQH2O  
1x ADP Detection Mixture:  
ADP2 Antibody-IRDye® QC-1 
ADP Alexa Fluor® 594 Tracer 
Stop and Detect Buffer B 
Autoclaved mQH2O  
Complete Assay Mix:  
ADP2 Antibody-IRDye® QC-1 
ADP Alexa Fluor® 594 Tracer 
Assay Buffer  
Autoclaved mQH2O 
ATP  
Acceptor Substrate  
 
Figure 32 and 33 outline the procedures for the endpoint and time-resolved assays.  The 
colour coding in Table 20 matches the colour coding in Figures 32 and 33.    
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Figure 32: Endpoint Format. The commercial design for the Bellbrook Transcreener® 
ADP2 FI Assay.  
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Figure 33: Time-resolved Format.  The application of the Bellbrook Transcreener® 
ADP2 FI Assay that was developed and described in this thesis.  
 
 The end-point assay format measures the FI at a single arbitrary time-point.  The 
time-resolved assay format measures the FI at many time points throughout the 
progression of the reaction.  As a result, kinetic data on kinase activity can easily be 
obtained.  A diagram of the type of data generated by each format can be seen in Figure 
34.   
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Figure 34: A comparison between the data gathered from the end-point vs time-
resolved formats.  A. A representation of typical data gathered from the end-point 
format.  A FI signal is measured at a single arbitrary time point, which is insufficient for 
measuring initial rates.  This format is typically used to measure the effect of inhibitors 
on kinase activity.  B. A representation of typical data gathered from the time-resolved 
format.  The FI is measured at regular intervals during the course of the assay, and thus 
gives sufficient information for measuring initial rates.   
 
  
A. B. 
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5.3 The PKA Assay  
The purpose of the PKA assay was to learn how to use the plate reader, how to use 
the Bellbrook Transcreener® ADP2 FI Assay kit, and to figure out how to adapt this 
commercial kinase kit into a time-resolved assay.  This process was detailed above.  The 
following section presents the data that shows the successful development of a time-
resolved assay.   
  
 
5.3.1 The Maximum FI Window for the PKA Assay Conditions  
Before the assay could be carried out, it was essential to determine the FI window 
for the PKA assay conditions (Figure 35).  The mean FI for the minimum FI sample (Min 
FI) was 0.65 RFUs and that of the maximum FI sample (Max FI) was 8.29 RFUs.  Max 
FI was over 12-fold greater than Min FI, which was excellent because the ratio of Max 
FI:Min FI must be greater than 5 for the window to be wide enough for the assay.  The 
maximum FI window for the PKA assay conditions was 7.65 RFUs.   
 
 
Figure 35: The FI window for the PKA assay conditions. Min FI: 9.66µg/mL ADP2 
Antibody-IRDye® QC-1, 0.5x 10x PKA Assay and Detect Buffer, 4nM ADP Alexa 
Fluor® 594 Tracer.  Max FI: 0.5x 10x PKA Assay and Detect Buffer, 4nM ADP Alexa 
Fluor® 594 Tracer.   
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5.3.2 The ATP/ADP Standard Curve for the PKA Assay Conditions  
An ATP/ADP standard curve was obtained for the PKA assay conditions (Figure 
36).  This standard curve mimicked an enzyme reaction over 12 points in which ATP was 
decreasing and ADP was increasing proportionally.  The FI was plotted against the 
log[ADP] and a linear regression of the ATP/ADP standard curve was conducted to give 
the equation: 𝑦 = 1.361𝑥 + 4.424.  This curve correlates FI and the concentration of 
ADP produced; therefore, the equation could be used to calculate %ATP conversion 
based on FI and vice versa.  The [ATP] used in this assay was 10µM, therefore 10% ATP 
conversion corresponds to 1µM ADP.  Based on the equation, an FI equal to or lower 
than 4.42 RFUs corresponds with a % ATP conversion that is 10% or lower.  It is 
important to have this estimate for the assays because the aim is to choose enzyme and 
substrate concentrations and run the assay for the time corresponding to less than 10% 
ATP conversion to ensure that the assumption of initial rates of conversion hold true, 
where the change in [ATP] is small enough to not significantly decrease the rate of the 
enzyme (99, 100).   
 
Figure 36: ATP/ADP standard curve for the PKA assay conditions. Varied [ATP] 
and [ADP], 2.4mg/mL DTT, 4mM Mg2+, 4.8mg/mL casein, 9.66µg/mL ADP2 Antibody-
IRDye® QC-1, 4nM ADP Alexa Fluor® 594 Tracer, 50mM HEPES, 0.01% Brij    
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5.3.3 Assay Results  
The time-resolved assay of PKA was conducted at 8 different concentrations of 
PKA ranging between 0.22 units/mL and 220 units/mL (Figures 37 and 38).  An increase 
in signal over the time of the assay was observed for all concentrations of PKA except 
0.22 units/mL and 2.2 units/mL.  The evolution of a FI signal over time that was 
dependent on the kinase concentration and therefore dependent on the production ADP 
by a kinase was observed.  Therefore, this data showed that the goal of adapting the 
Bellbrook Transcreener® ADP2 FI Assay kit into a time-resolved assay was 
accomplished.   
 
 
Figure 37: Time-Resolved assay of PKA using the Bellbrook Transcreener® ADP2 
FI Assay.  The evolution of FI was measured over 120min for 4 different concentrations 
of PKA.  10µM ATP, 2.4mg/mL DTT, 4mM Mg2+, 4.8mg/mL casein, 9.66µg/mL ADP2 
Antibody-IRDye® QC-1, 4nM ADP Alexa Fluor® 594 Tracer, 50mM HEPES, 0.01% Brij    
 
 
The enzyme titration had two purposes, first to establish if the evolution of the 
signal was dependent the concentration of enzyme (as it would be expected to), and 
second to determine the optimal PKA concentration for these assay conditions (Figure 
38).  To ensure that kinase reactions are performed under initial rate conditions it is 
important to use a concentration of enzyme that results in less than 10% ATP conversion 
over the time of the assay.  Based on the ATP/ADP standard curve for the PKA assay 
conditions, an FI equal to or lower than 4.42 corresponds with a % ATP conversion that 
is 10% or lower.  It is also important that the enzyme concentration is chosen such that 
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the time of the assay is much longer than 20min.  This is because the equilibration time 
for the ADP Alexa Fluor® 594 Tracer and the ADP2 Antibody-IRDye® QC-1 is greater 
than ≥ 15min, making it difficult to quantify ADP production during short term enzyme 
reactions.  Based on the enzyme titration shown in Figure 38, the enzyme concentrations 
between 100-220 units/mL (inclusive) are too high; they all reach a FI around or above 4 
by 20min.  Therefore, past 20min the enzyme reactions are no longer in initial rate 
conditions and before 20min the reaction time is too short to reliably quantify the rate of 
production of ADP because of the equilibration time of the ADP Alexa Fluor® 594 Tracer 
and the ADP2 Antibody-IRDye® QC-1.  These traces all also overlap during the first 20 
min and there is no significant difference between them; thus, increasing the 
concentration of PKA past 100 units/mL does not result in a significant change in rate.  
This likely indicates that at or above ~100units/mL the speed of ADP production is 
quicker than the displacement of ADP Alexa Fluor® 594 Tracer from the ADP2 
Antibody-IRDye® QC-1.  Therefore, the rate of signal production measured in these 
assays was actually likely the rate of displacement rather than the rate of phosphorylation 
by PKA.  Based on Figures 37 and 38, 22units/mL is the most optimal assay 
concentration of PKA out of the ones that were tested.  This is because the signal 
increased off the baseline and the % ATP conversion did not exceed 10%.   
 
Figure 38: PKA titration for the time-Resolved assay of PKA using the Bellbrook 
Transcreener® ADP2 FI Assay.  The evolution of FI was measured over 60min for 6 
different concentrations of PKA.  10µM ATP, 2.4mg/mL DTT, 4mM Mg2+, 4.8mg/mL 
casein, 9.66µg/mL ADP2 Antibody-IRDye® QC-1, 4nM ADP Alexa Fluor® 594 Tracer, 
50mM HEPES, 0.01% Brij.  
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5.3.4 Controls  
The Background, the No Antibody, and the No Tracer controls all gave the 
expected results (Figure 39).  There was no ADP Alexa Fluor® 594 Tracer to give the FI 
signal in the Background and in the No-tracer controls, therefore the baseline FI 
measurements that were observed, was expected.  In the No Antibody control there was 
no ADP2 Antibody-IRDye® QC-1 to quench the fluorescence of the ADP Alexa Fluor® 
594 Tracer, therefore a FI around the Max FI was expected and that was observed.  There 
was no evolution of signal in the absence of ATP (No ATP control).  This was the 
expected result and shows that the signal generated in the assays is from the hydrolysis of 
ATP to ADP.  The enzyme titration in light of the No ATP control shows that the signal 
generated was from the hydrolysis of ATP to ADP by the enzyme as the signal evolution 
is dependent on the concentration of the PKA.     
 
 
Figure 39: The Background, the No Antibody, and the No Tracer controls for the 
time-resolved PKA assay.  None of these controls contained PKA.  Background: Assay 
conditions but no antibody and no tracer.  No Antibody: Assay conditions but no 
antibody.  No Tracer: Assay conditions but no tracer.  Assay conditions: 10µM ATP, 
2.4mg/mL DTT, 4mM Mg2+, 4.8mg/mL casein, 9.66µg/mL ADP2 Antibody-IRDye® QC-
1, 4nM ADP Alexa Fluor® 594 Tracer, 50mM HEPES, 0.01% Brij.  
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Figure 40: The No Casein (-Casein) and No ATP (-ATP) controls for the time-
resolved PKA assay.  [PKA] is found in the figure in units/mL.  No Casein: Assay 
conditions but no casein. No ATP: Assay conditions but no ATP.  Assay conditions: 
10µM ATP, 2.4mg/mL DTT, 4mM Mg2+, 4.8mg/mL casein, 9.66µg/mL ADP2 Antibody-
IRDye® QC-1, 4nM ADP Alexa Fluor® 594 Tracer, 50mM HEPES, 0.01% Brij.   
 
This data also showed some inconsistencies and results that raise questions.  The 
No Casein control was expected to result in no evolution of signal because one of the 
enzyme substrates was not included in the assay.  However, signal did evolve, and the 
evolution was dependent on the concentration of the enzyme (Figure 40).  This indicated 
PKA was either conducting non-productive ATP hydrolysis, auto-phosphorylation, or 
phosphorylation of other molecules of PKA.  In addition, the data presented in Figure 37 
and Figure 38 were collected on two consecutive days and the signal intensity and speed 
of evolution of the signal were very different for the same concentrations of PKA on the 
two consecutive days.  These were inconsistencies that would have been important to 
address if PKA or another protein kinase was the protein of interest.  However, the 
purpose of doing a PKA assay was to learn to how to use the plate reader, to learn how to 
use the Bellbrook Transcreener® ADP2 FI Assay kit, and to adapt the kit into a time-
resolved assay.  These things were accomplished with the PKA assay.  Additionally, the 
overall goal of the project was the develop a vesicle-based time-resolved assay for the 
lipid kinase Pik1.  Therefore, these concerns were left unaddressed as it was deemed 
more advantageous for the project to progress to a PI kinase related to Pik1 to develop the 
time-resolved assay relevant for a vesicle-based for the activity assay of a lipid kinase.   
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5.4 The PIK3C3 Assay  
5.4.1 10x PIK3C3 Assay Buffer: Precipitation Problems  
Table 21: The recipe for the 10x PIK3C3 Assay Buffer  
Original Plan Final Recipe  
250mM HEPES (pH 7.5)  
500mM NaCl  
30mM MgCl2  
0.25mg/mL BSA 
50mM MnCl2  
20mM DTT 
Stored at -20°C  
250mM HEPES (pH 7.5)  
500mM NaCl  
30mM MgCl2 
0.25mg/mL BSA  
Made with autoclaved mQH2O, filter 
sterilized, and stored at room temperature  
 
The original composition of the assay buffer was derived from the ADP-Glo® 
Lipid Kinase Systems technical manual (100) with some influence from (99).  50mM 
HEPES (pH 7.5), 50mM NaCl, 3mM MgCl2, 0.025mg/mL BSA, 5mM MnCl2 is the 
PI3K reaction buffer described in the ADP-Glo® technical manual for PIK3C3.  It was 
decided to use 250mM HEPES (pH 7.5) instead of 500mM HEPES for the 10x Assay 
buffer because 25mM HEPES (pH 7.5) is contributed to the assay by the lipid dilution 
buffer.  DTT was included in the original plan because it was in the kinase reaction buffer 
in (99).  Mn2+ is instructed to be added specifically for assaying PIK3C3 because the 
enzyme is more active with Mn2+ than in Mg2+ (38).  The ADP-Glo technical manual said 
to use Mn2+ and Bellbrook Transcreener® ADP2 FI Assay technical manual said to use 
either Mg2+ or Mn2+ and that either would be okay to use with the kit.        
 
Many precipitation problems were encountered when making the 10x PIK3C3 
Assay Buffer.  The first time it was made, DTT was not used and something precipitated.  
The second attempt included DTT and something precipitated.  DTT and Mn2+ are both 
redox sensitive, and since the presence or absence of DTT did not stop the precipitation, 
and the Promega ADP-Glo manual described an assay buffer for PIK3C3 that contained 
MnCl2 but not DTT, it was decided to omit DTT until it was deemed necessary or 
beneficial to the assay.  The precipitation occurred when MnCl2 was added to the buffer; 
therefore, it was concluded that it was precipitating with another component of the assay 
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buffer.  To figure out which two components were precipitating, a solution of ~250mM 
HEPES and ~50mM MnCl2 (pH 7.5) was made and each buffer component was 
sequentially added and observed for precipitation.  A white precipitate was observed 
upon the addition of 1mg/mL BSA.  It was discovered that the BSA was in a solution of 
PBS and that Mn3(PO4)2 is very insoluble and precipitates (pKsp = 23.83 (105)) .  A white 
precipitate was observed when PBS was added to another solution of ~250mM HEPES 
and ~50mM MnCl2 (pH 7.5) but no precipitate was observed when a solution of BSA in 
RO H2O was used to make 10x PIK3C3 Assay Buffer.  This confirmed the precipitate 
was Mn3(PO4)2 and it eliminated the first precipitation problem. 
 
The second precipitation problem was encountered when the pH of the 10x 
PIK3C3 Assay Buffer was adjusted after all the components of the buffer were in 
solution.  A white precipitate was observed when NaOH was added to adjust the pH to 
7.5.  From previous research about Mn2+ precipitation, it was known that Mn(OH)2 
precipitates (Ksp = 4.6 x 10-14 (106), pKsp = 13.34) .  The solution of MnCl2 was added 
after the pH was adjusted to 7.5 and no precipitate was observed.  This eliminated the 
second precipitation problem.   
 
Once the 10x PIK3C3 Assay Buffer was successfully made without precipitation, 
it was filter sterilized and stored at -20°C overnight.  This was how the PKA buffer was 
stored and there were no issues with storing the PKA buffer at this temperature.  
However, when the 10x PIK3C3 Assay Buffer was thawed the next day a cream-coloured 
solid had formed and collected at the bottom of the tube.  The FI Window Experiment 
was done with this precipitated 10x PIK3C3 Assay Buffer and the 10x PKA Assay Buffer 
to compare them.  In addition, 10x PIK3C3 Assay Buffer -MnCl2 (no MnCl2) and fresh, 
never frozen 10x PIK3C3 Assay Buffer were made.  The FI Window Experiment was 
done with these buffers before and after they were stored overnight at either room 
temperature, 4°C, or -20°C.  The buffers were judged by the size of the FI assay window 
and by the presence of precipitate based on crude visual observations.   
 
The best results (determined by the widest FI window and no turbidity) were 
achieved using the 10x PIK3C3 Assay Buffer -MnCl2 that was stored at room 
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temperature.  The FI window for this buffer was 7.40 RFUs.  The fresh 10x PIK3C3 
Assay Buffer stored at room temperature resulted in an FI window of 4.04 RFUs, which 
is a narrower FI window than the one without MnCl2.  However, no turbidity was 
observed, and the Max FI:Min FI ratio was 8.5, which is sufficient for the assay. In 
addition, PIK3C3 is more active with Mn2+ than Mg2+, therefore the 10x PIK3C3 Assay 
Buffer (containing Mn2+) was chosen to proceed with in assays.  Storing the 10x PIK3C3 
Assay Buffer at room temperature eliminated the third precipitation problem.  It was 
noticed that the FI assay window was not always consistent.  In the future the FI window 
should be measured each time the assay is run, and the data normalized to be presented as 
a percentage of the maximum signal.     
 
By eliminating the first 3 precipitation problems, the 10x PIK3C3 Assay Buffer 
could be prepared, adjusted to a pH of 7.5, filter sterilized, and stored without 
precipitation occurring.  However, a fourth precipitation problem was observed when the 
ADP2 Antibody-IRDye® QC-1 was added to the Assay Mix.  The components of the 
Assay Mix were added in a different order each time and it was noticed that the solution 
became turbid when the ADP2 Antibody-IRDye® QC-1 and the 10x PIK3C3 Assay 
Buffer were both present.  However, the cause of the turbidity was still unclear.  
Therefore, each component of the assay and each step of assay component preparation 
was scrutinized to determine possible sources of problems.  Two key things were 
identified, the first being the use of water with varying degrees of purity.  Nucleases can 
degrade nucleotide substrates and products, therefore, using water that is contaminated 
with nucleases reduces assay performance.  Just in case the water purity was 
compromising the assay performance, all of the stock solutions and buffers involved in 
the assay and in the preparation of assay components were re-made using autoclaved 
mQH2O (eg., 2.5x Lipid Dilution Buffer, the 1N HCl and 1N NaOH for adjusting the pH, 
500µM ATP, 10x PIK3C3 Assay Buffer, 5µg/mL PIK3C3, the Enzyme Mix and the 
Assay Mix).  The second key thing that was identified was the fact that the ADP2 
Antibody-IRDye® QC-1 comes in a 100mM KH2PO4 buffer.  Mn2+ is known to 
precipitate with phosphate, therefore, this was suspected to be the source of the fourth 
precipitation problem.  This was investigated by making 5 simplified buffers of the 
following compositions:  
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1. 250mM HEPES (pH 7.5)  
2. 250mM HEPES (pH 7.5), 500mM NaCl  
3. 250mM HEPES (pH 7.5), 30mM MgCl2 
4. 250mM HEPES (pH 7.5), 0.25mg/mL BSA 
5. 250mM HEPES (pH 7.5), 50mM MnCl2  
ADP2 Antibody-IRDye® QC-1 (2µL) was added to 10µL of each of the simplified 
buffers.  All of the resulting solutions were clear and colourless except for #5, which 
contained MnCl2, where a white precipitate formed.  To investigate the hypothesis that 
the precipitation was caused by the KH2PO4 buffer and not the antibody itself, a solution 
of 100mM KH2PO4 (pH 8.5) was made and 2µL of this buffer was added to 10µL of each 
of the following solutions:  
1. 250mM HEPES (pH 7.5)  
2. 250mM HEPES (pH 7.5), 30mM MgCl2 
3. 250mM HEPES (pH 7.5), 50mM MnCl2  
4. 250mM HEPES (pH 7.5), 30mM MgCl2, 50mM MnCl2 
No turbidity was observed with solutions 1 and 2, but a white precipitate was observed 
with solutions 3 and 4.  This confirmed that Mn2+ was precipitating with the phosphate 
from the KH2PO4 buffer of the ADP2 Antibody-IRDye® QC-1.  This also confirmed that 
the other metal cation, Mg2+, does not cause this effect.  The removal of MnCl2 from the 
10x PIK3C3 Assay Buffer eliminated the fourth precipitation problem.   
 The effect of the precipitation on the assay signal is reported and discussed in the 
following section.  The requirement that PIK3C3 has for Mn2+ and the necessity of Mn2+ 
to the assay is explored and discussed in Assay Results.   
 
5.4.2 “False Signal” Troubleshoot: Precipitate or Lipids?  
The assay was attempted for the first time before all of the precipitation problems 
had been solved.  The data that was gathered was “meaningless” because all of the trials 
overlapped each other despite differences in the concentration of enzyme, and all are 
elevated off the baseline and do not change substantially overtime (Figure 41).  
Especially odd was that the no enzyme control in which no ADP was being produced 
overlapped with the other trials.  It was suspected that the false signal was caused by light 
scattering from the precipitate.  However, this was also the first time that lipid vesicles 
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were used as the substrate.  Therefore, the lipids could not be ignored as a potential 
source of false signal and this was also investigated.   
 
Figure 41: PIK3C3 time-resolved assay when precipitate was present.  Variable 
[PIK3C3]. Assay conditions: 30µM ATP, 0.2mg/mL PI:3PS, 1x Lipid Dilution Buffer 
(25mM HEPES, 0.5mM EGTA), 28.25µg/mL ADP2 Antibody-IRDye® QC-1, 4nM ADP 
Alexa Fluor® 594 Tracer, 1x PIK3C3 Assay Buffer (25mM HEPES, 50mM NaCl, 3mM 
MgCl2, 0.025mg/mL BSA, 5mM MnCl2).  
 
There were two hypotheses regarding the lipids as a source of a false signal.  The 
first was that the lipid vesicles were aggregating (caused by the negatively charged lipids 
and the positively charged metal cations in the buffer) and getting large enough to scatter 
the light.  The second hypothesis was that the lipids provide a different environment for 
the fluorophore and change the fluorescence, leading to the false signal.  A series of lipid 
controls were completed, and the results can be seen in Figure 42.  
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Figure 42: Lipid Controls in Mn2+ containing buffer.  PI:3PS, No PIK3C3: Assay 
conditions with no PIK3C3.  No Lipid, No PIK3C3: 30µM ATP, 28.25µg/mL ADP2 
Antibody-IRDye® QC-1, 4nM ADP Alexa Fluor® 594 Tracer, 1x PIK3C3 Assay Buffer 
(25mM HEPES, 50mM NaCl, 3mM MgCl2, 0.025mg/mL BSA, 5mM MnCl2).  PI:3PS + 
mQH2O: 0.2mg/mL PI:3PS, 1x Lipid Dilution Buffer (25mM HEPES, 0.5mM EGTA). 
PI:3PS + Buffer: 0.2mg/mL PI:3PS, 1x Lipid Dilution Buffer (25mM HEPES, 0.5mM 
EGTA), 1x PIK3C3 Assay Buffer (25mM HEPES, 50mM NaCl, 3mM MgCl2, 
0.025mg/mL BSA, 5mM MnCl2).  
 
The PI:3PS + mQH2O and the PI:3PS + Buffer controls showed that the 
phospholipid vesicles on their own did not aggregate over time or even in the presence of 
the metal cations from the assay buffer.  The FI is approximately “baseline” (i.e., the Min 
FI), but there was no fluorophore or antibody in these controls, therefore, the vesicles 
may have contributed in a small way to the signal via light scattering.  Precipitation was 
observed in two of the controls (PI:3PS, No PIK3C3 and No Lipid, No PIK3C3, Figure 
42).  These controls had elevated FI and seemed to increase slightly over time even 
though there was no enzyme.  This may be because of increased precipitation as particles 
became larger over the time of the assay.  The only difference between the PI:3PS, No 
PIK3C3 control (everything but enzyme) and the No Lipid, No PIK3C3 control was the 
presence of lipid, but the PI:3PS, No PIK3C3 control was much higher in signal.  This 
could mean that the lipid was making the precipitation problem worse by co-
precipitating, by scattering some light without aggregating or precipitating, or the lipid 
environment may be influencing the fluorophore.  However, it was not very likely that 
the ADP Alexa Fluor® 594 Tracer was entering into the lipid environment of the vesicles 
because the headgroups of the phospholipids (PS) are negatively charged and the ADP 
Alexa Fluor® 594 Tracer is also negatively charged.  It was, therefore, concluded that the 
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inorganic precipitate was likely the problem instead of the lipid.    The solution was to 
remove MnCl2 from the 10x PIK3C3 Assay Buffer.  The assay was attempted with this 
new buffer recipe and the results of the PIK3C3 assays are reported in the following 
Section.   
 
5.4.3 The Maximum FI Window for the PIK3C3 Assay Conditions   
Before the assay could be carried out, it was essential to determine the FI window 
for the PIK3C3 assay conditions (Figure 43).  The mean FI for the minimum FI sample 
(Min FI) was 0.73 RFUs and that of the maximum FI sample (Max FI) was 7.56 RFUs.  
Max FI was over 10-fold greater than Min FI, which was excellent because the ratio of 
Max FI:Min FI must be greater than 5 for the window to be wide enough for the assay.  
The FI window for the PIK3C3 assay conditions was 6.83 RFUs.  This FI window is 1.41 
RFUs greater than that measured with Mn2+ containing buffer (Figure 41).  The FI of the 
mean of the Max FI sample increases from 5.88 RFUs when Mn2+ is present to 7.56 
RFUs when Mn2+ is not present.  An absorption spectrum of 5mM MnCl2 was measured 
(GENESYS 10S UV-Vis) from 190nm-800nm.  A peak with an absorbance of 2.5 was 
observed at 200nm, but no absorbance was observed between 250-800nm.  Therefore 
Mn2+ was not decreasing the fluorescence by absorbing some of the excitation or 
emission light.  It is possible that Mn2+ was quenching some of the fluorescence; Mn2+ is 
known to quench the fluorescence of a different fluorophore called Fura-2 (107, 108).      
 
Figure 43: The FI window for the PIK3C3 assay conditions. Min FI: 28.25µg/mL 
ADP2 Antibody-IRDye® QC-1, 1x PIK3C3 Assay Buffer (25mM HEPES, 50mM NaCl, 
3mM MgCl2, 0.025mg/mL BSA), 4nM ADP Alexa Fluor® 594 Tracer.  Max FI: 1x 
PIK3C3 Assay Buffer (25mM HEPES, 50mM NaCl, 3mM MgCl2, 0.025mg/mL BSA), 
4nM ADP Alexa Fluor® 594 Tracer.   
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5.4.4 The ATP/ADP Standard Curve for the PIK3C3 Assay Conditions  
An ATP/ADP standard curve was conducted for the PIK3C3 assay conditions 
(Figure 44).  This standard curve mimicked an enzyme reaction over 12 points in which 
ATP was decreasing and ADP was increasing proportionally.  The FI was plotted against 
the log[ADP] and a linear regression of the ATP/ADP standard curve was conducted to 
give the equation: 𝑦 = 2.499𝑥 + 5.360.  This curve correlates FI and the concentration 
of ADP produced, therefore, the equation could be used to calculate %ATP conversion 
based on FI and vice versa.  The [ATP] used in this assay was 30µM, therefore 10% ATP 
conversion corresponds to 3µM ADP.  Based on the equation, a FI equal to or lower than 
6.55 RFUs corresponds with a % ATP conversion that is 10% or lower.  It is important to 
have this estimate for the assays because the aim is typically to choose enzyme and 
substrate concentrations and run the assay for the time corresponding to less than 10% 
ATP conversion to ensure initial rates of conversion (99, 100).   
 
 
Figure 44: ATP/ADP standard curve for the PIK3C3 assay conditions. Variable 
[ATP] and [ADP], 0.2mg/mL PI:3PS substrate, 1x Lipid Dilution Buffer (25mM HEPES, 
0.5mM EGTA), 28.25µg/mL ADP2 Antibody-IRDye® QC-1, 4nM ADP Alexa Fluor® 
594 Tracer, 1x PIK3C3 Assay Buffer (25mM HEPES, 50mM NaCl, 3mM MgCl2, 
0.025mg/mL BSA). 
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5.4.5 Assay Results  
The time-resolved assay of PIK3C3 was conducted at 4 different concentrations 
of PIK3C3 between 0.5µg/mL and 10µg/mL (Figure 45).  The evolution of the signal was 
dependent on the concentration of enzyme.  An increase in signal past the baseline was 
observed for 10µg/mL and 5µg/mL PIK3C3 over the 120min that the assay was 
conducted.  The baseline was judged by the no enzyme control (purple trace in Figure 45, 
black trace in Figure 46).  PIK3C3 at concentrations of 0.5µg/mL and 2µg/mL did not 
result in a signal that increased significantly from the baseline (Figure 45). Based on the 
ATP/ADP standard curve in Figure 44, the a FI equal to or lower than 6.55 RFUs 
corresponds with a % ATP conversion that is 10% or lower.  Over the 120min of the 
assay, none of the traces exceeded a FI of 6 RFUs, therefore, the % conversion of ATP 
was less than 10% and hence initial rate conditions were maintained for all concentrations 
of PIK3C3 for the entire length of the assay.   
 
 
Figure 45: PIK3C3 titration for the time-Resolved assay of PIK3C3 using the 
Bellbrook Transcreener® ADP2 FI Assay.  The evolution of FI was measured over 
120min for 4 different concentrations of PIK3C3.  Assay conditions: 30µM ATP, 
0.2mg/mL PI:3PS, 1x Lipid Dilution Buffer (25mM HEPES, 0.5mM EGTA), 
28.25µg/mL ADP2 Antibody-IRDye® QC-1, 4nM ADP Alexa Fluor® 594 Tracer, 1x 
PIK3C3 Assay Buffer (25mM HEPES, 50mM NaCl, 3mM MgCl2, 0.025mg/mL BSA).  
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5.4.6 Controls  
The lipid controls from Figure 42 were carried out when the precipitation and 
false signal issues were being investigated.  Once Mn2+ had been removed, the 
precipitation problems solved, and the assay shown to be successful, these lipid controls 
were repeated, and the results are shown in Figure 46.   Eliminating the precipitation 
issue eliminated the increase in signal over time that was observed in the PI:3PS, No 
PIK3C3 and the No Lipid, No PIK3C3 controls that were conducted with Mn2+ 
containing buffer.  These controls also showed that the baseline for these assay conditions 
is around 2 RFUs.    
 
Figure 46: Lipid Controls in buffer that does not contain Mn2+.  PI:3PS, No PIK3C3: 
Assay conditions but no PIK3C3.  No Lipid, No PIK3C3: 30µM ATP, 28.25µg/mL ADP2 
Antibody-IRDye® QC-1, 4nM ADP Alexa Fluor® 594 Tracer, 1x PIK3C3 Assay Buffer 
(25mM HEPES, 50mM NaCl, 3mM MgCl2, 0.025mg/mL BSA).  PI:3PS + mQH2O: 
0.2mg/mL PI:3PS, 1x Lipid Dilution Buffer (25mM HEPES, 0.5mM EGTA). PI:3PS + 
Buffer: 0.2mg/mL PI:3PS, 1x Lipid Dilution Buffer (25mM HEPES, 0.5mM EGTA), 1x 
PIK3C3 Assay Buffer (25mM HEPES, 50mM NaCl, 3mM MgCl2, 0.025mg/mL BSA).  
 
Two controls were conducted in which one of the substrates of PIK3C3, ATP or 
PI, were not included (Figure 47).  The No ATP control gave no evolution of signal in the 
absence of ATP.  This was the expected result and shows that the signal generated in the 
assays was from the hydrolysis of ATP to ADP.  The enzyme titration in light of the No 
ATP control shows that the signal generated is from the hydrolysis of ATP to ADP by the 
enzyme as the signal evolution is dependent on the concentration of the PIK3C3.  The 
PC:3PS control was the control in which PC was included instead of PI; this control was 
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expected to give no evolution of signal similar to the No ATP control.  However, an 
evolution of signal was observed that overlaps with the trace for the assay at the same 
concentration of enzyme when PI:3PS was the substrate (Figure 45, 47, and 48).  This 
indicates that PIK3C3 was producing ADP at approximately the same rate whether the 
substrate phospholipid was present or not; thus, the assay may be measuring non-
productive ATP hydrolysis of the enzyme.  Autophosphorylation is also possible.  
Autophosphorylation was observed for the yeast homolog Vps34 (40), though no 
autophosphorylation of PIK3C3 was observed with Mg2+ or Mn2+ by Volinia et al. (38).  
Further investigations will be required in the future to distinguish between productive 
phosphorylation and non-productive ATP hydrolysis.   
 
 
Figure 47: The PC:3PS Control (no PI) and the No ATP Controls for the time-
resolved PIK3C3 assay.  Both controls contained 5µg/mL PIK3C3.  PC:3PS: Assay 
conditions but PC:3PS vesicles instead of PI:3PS vesicles. No ATP: Assay conditions but 
no ATP.  Assay conditions: 30µM ATP, 0.2mg/mL PI:3PS, 1x Lipid Dilution Buffer 
(25mM HEPES, 0.5mM EGTA), 28.25µg/mL ADP2 Antibody-IRDye® QC-1, 4nM ADP 
Alexa Fluor® 594 Tracer, 1x PIK3C3 Assay Buffer (25mM HEPES, 50mM NaCl, 3mM 
MgCl2, 0.025mg/mL BSA).  
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Figure 48: A comparison of the PC:3PS Control (blue trace, Figure 47) and the 
5µg/mL PIK3C3 assay trace (orange trace, Figure 45) that used PI:3PS as the 
substrate.  Both were performed at 5µg/mL PIK3C3.  PC:3PS control: Assay conditions 
but PC:3PS vesicles instead of PI:3PS vesicles. PI:3PS 5µg/mL assay: Assay conditions.    
Assay conditions: 30µM ATP, 0.2mg/mL PI:3PS, 1x Lipid Dilution Buffer (25mM 
HEPES, 0.5mM EGTA), 28.25µg/mL ADP2 Antibody-IRDye® QC-1, 4nM ADP Alexa 
Fluor® 594 Tracer, 1x PIK3C3 Assay Buffer (25mM HEPES, 50mM NaCl, 3mM MgCl2, 
0.025mg/mL BSA).  
 
 
 
5.4.7 Mn2+ vs Mg2+   
In the protein kinase catalytic domain there is evidence supporting that Mg2+ 
positions the 𝛾-phosphate for nucleophilic attack, masks charge to limit repulsion with 
the incoming nucleophile and stabilizes the transition state and reduces the transition state 
barrier by applying strong electrostatic interactions to the ADP leaving group.  The 
presence or absence of Mg2+ in the active site can change the KM of the enzyme for ATP 
(109).  PIK3C3 is a lipid kinase and not a protein kinase, but the metal cation is still 
likely involved in the coordination of ATP and the catalysis of phosphate transfer.  
PIK3C3 is active with Mn2+ and only weakly active with Mg2+ (38).  It is unclear how or 
why PIK3C3 is more active with Mn2+ than Mg2+ but the different metal cations may 
change the KM of the enzyme for ATP.     
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PIK3C3 was assayed in buffer containing 50mM HEPES (pH7.5), 50mM NaCl, 
3mM MgCl2, 0.025mg/mL BSA, and 5mM MnCl2 using the ADP-Glo® Lipid Kinase 
System and the apparent KM of PIK3C3 for ATP was 40µM ATP (100).  This apparent 
KM was determined with both Mg2+ and Mn2+ in the buffer and thus either could be in the 
active site.  PIK3C3 is significantly more active with Mn2+ than Mg2+ and it is only 
weakly active with Mg2+ (38).  This is why a great deal of effort was spent on solving the 
precipitation problems and getting the assay to work in the presence of Mn2+.  PIK3C3 
did not have an opportunity to bind Mn2+ in its active site as Mn2+ precipitated with the 
antibody phosphate buffer in the Assay Mix before the Enzyme Mix had a chance to 
come in contact with it.  Thus, in a final effort to “sneak” Mn2+ into the assay Mn2+ was 
added to the Enzyme Mix and Mg2+ and Mn2+ were not included in the PIK3C3 Assay 
Buffer.  Two concentrations of Mn2+ were attempted, 3mM and 3µM.  3µM Mn2+ was 
used in an attempt to provide PIK3C3 an opportunity to bind Mn2+ in its active site while 
reducing the amount of Mn2+ left in solution to precipitate when mixed with the Assay 
Mix.  Precipitation was observed at the beginning of both assays and the data gathered 
from these assays is shown in Figure 49.  Both concentrations of Mn2+ gave large signals 
with intensities around or above 6 RFUs for the majority of the duration of the assay.  
This signal was much higher than the FI that was seen for the other Mn2+ containing 
assays that had precipitated (Figure 41).  This high signal could a combination of light 
scattering from the precipitate and signal generated from the ADP production by the 
enzyme.  If at least some or most of this signal was from genuine ADP production by 
PIK3C3 it indicates that PIK3C3 was much more active with Mn2+ than Mg2+ and that the 
assay may have surpassed initial rate conditions by the first few minutes, as a FI of 6.55 
RFUs corresponds to 10% conversion. If this is true, a lower concentration of PIK3C3 
could be used in the assay.  However, even if this is the case (“sneaking” Mn2+ into the 
assay this way works to increase PIK3C3 activity), the precipitate would obscure the 
signal and so this “sneak” method was not useful for the assay unless there was a way to 
remove excess Mn2+ from the enzyme solution after PIK3C3 has a chance to bind Mn2+.        
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Figure 49: “Sneak” Mn2+ assays.  PIK3C3 time-resolved assays in which Mn2+ was 
added to the Enzyme Mix such that the final assay [Mn2+] was either 3µM or 3mM and 
Mg2+ and Mn2+ were omitted from the PIK3C3 Assay Buffer.  Both were performed at 
5µg/mL PIK3C3.  Assay conditions: 30µM ATP, 0.2mg/mL PI:3PS, 1x Lipid Dilution 
Buffer (25mM HEPES, 0.5mM EGTA), 28.25µg/mL ADP2 Antibody-IRDye® QC-1, 
4nM ADP Alexa Fluor® 594 Tracer, 1x PIK3C3 Assay Buffer (25mM HEPES, 50mM 
NaCl, 3mM MgCl2, 0.025mg/mL BSA).  
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6 Conclusions and Future Directions  
The eventual application of this work will be to investigate the PI presentation model 
by which Sec14 is proposed to stimulate the activity of Pik1.  Two key things were 
required to make a kinetic investigation into this model possible, a time-resolved assay 
for the activity of Pik1 and a method to express and purify the Pik1-Frq1 complex.  These 
were the two main goals of this thesis project.    
 
The expression of the Pik1-Frq1 complex by the BJ2168 transformants B8NA 
(transformed BJ2168 with clone 8 (pYEXC3H+PIK1) and clone N (pESC-
Trp+FRQ1+CDC37) at the same time, colony A) and 10NE (transformed BJ2168 with 
clone 10 (pYEXC3H+PIK1) and clone N (pESC-Trp+FRQ1+CDC37) sequentially, 
colony E) was confirmed by Western blot but the purification has yet to be successful.  It 
is possible that the transformants were expressing very little of the protein complex and 
so it just was not seen in the purification on a preparative scale.  Next steps should thus 
include the optimization of the expression and purification of the complex.  Next time 
this process is attempted, it would be logical to use YEPG to induce protein expression.  
The results in this thesis do not give an indication of protein expression levels, but they 
do show that YEPG does cause a large increase in growth, leading to a greater number of 
cells to extract protein from.  Optimization of the purification yield was set aside for 
future work because it was deemed more critical for the project to move on to developing 
the time-resolved assay.    
 
The Bellbrook Labs Transcreener ADP2 FI Assay kit was successfully adapted into a 
time-resolved assay using the catalytic subunit of Protein Kinase A (PKA).  Then it was 
developed further for use with PI kinases with vesicles as substrates using the human PI 
kinase, PIK3C3.  In both the PKA and PIK3C3 assays, the signals evolved in a manner 
that was dependent on enzyme concentration, and as seen in PKA, there is an enzyme 
concentration above which the assay does not respond with a more rapid evolution of 
signal.  This is likely a measurement of the displacement of the tracer rather than the rate 
of phosphorylation.  Conditions that supported enzyme activity and that were also 
compatible with the assay kit were established for each enzyme.  Mn2+ was found to be 
incompatible with the kit.  Conditions were found that satisfy initial rates assumptions 
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(minimal decrease in substrate concentration during the time of observation), and that 
result in signals that increase sufficiently from the base-line, making it possible to gather 
reliable kinetic information from the observed data.   
   
The goal of this work was to develop a robust, easy-to-use, time-resolved, vesicle-
based assay for a PI-kinase.  The assay in its current form is easy to use, time-resolved, 
and vesicle based, but the question of how robust the assay is still needing to be 
addressed.  This is the next step that must be completed before the assay can be routinely 
applied.  As more data is gathered with this assay, linear regressions of replicate 
measurements will have to be done and the slopes compared with a simple t-test to 
determine if similar traces from different conditions are statistically different.  This will 
help establish how robust this assay is, in effect, how well it can discern two conditions 
that differ by only a small magnitude from each other.  In addition, investigations will be 
required to distinguish between productive phosphorylation and non-productive ATP 
hydrolysis, and ATPase activity should be subtracted from all assay data.  Once it is 
established as a reliable and robust assay it can be used to probe the model it was 
designed to investigate – the Pik1 and Sec14 PI presentation model.   
 
When purified fractions of the Pik1-Frq1 complex are obtained, the first task will be 
to measure its activity under the normal conditions of the assay.  It will be essential to 
ensure the activity of Pik1 can be measured with this in vitro assay and critical to obtain a 
baseline activity to which the other experiments will be compared.  The assay conditions 
and the optimal assay concentration of Pik1 will need to be determined.  PIK3C3 was 
chosen for the development of the assay on purpose as it is a PI kinase that is related to 
Pik1.  The first attempt to assay the activity of Pik1 will likely be conducted at the same 
conditions as PIK3C3 as a starting point, then adjusted if and where necessary.  An 
enzyme titration will be needed to determine the optimal assay concentration for Pik1.  
As stated previously, the goal is to find an enzyme concentration at which the signal 
sufficiently increases off the baseline but does not exceed 10% conversion (as determined 
by an ATP/ADP standard curve) during the time of the assay.  The concentration of Pik1 
and the time of observation are to be adjusted such that the normal assay conditions give 
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a trace that significantly occupies the assay window (essentially fluorescence intensity), 
such that any variations can be seen when the assay conditions are modified in any way.  
 
   Once the assay conditions for Pik1 have been established, there are many 
experiments to explore its activity and the proposed PI presentation model.  The 
sensitivity of the Pik1-Frq1 complex to phospholipid membrane composition will be 
tested by conducting the assay with different phospholipid compositions.  The first test of 
the PI presentation model will be to run the assay in the presence and absence of wild 
type (wt) Sec14.  Further experiments will be done with mutant versions of Sec14 that are 
either PI or PC binding mutants.  Assay experiments with Sec14 pre-incubated with PI or 
PC will be conducted to see how the identity of the starting lipid bound to Sec14 effects 
the stimulation of Pik1 activity.  Members of the Atkinson research group are also 
synthesizing versions of PI called bola-PIs.  A bola-PI has two inositol head groups and a 
lipid tail that spans the membrane connecting the two (blue phospholipid in Figure 50).  
Thus, the opposite headgroup will resist being pulled into the hydrophobic core of the 
membrane and will therefore prevent the bola-PI from being out of the membrane (Figure 
50).  Since the proposed model posits that Sec14 partially pulls PI out of the membrane to 
present it as a more suitable substrate to Pik1, controlling the ability of Sec14 to pull the 
PI out of the membrane provides a test of this hypothesis.  Bola-PI analogues of different 
chain length will also be explored.   
 
 
Figure 50: The proposed PI presentation model for the function of Sec14 in PIP 
homeostasis with natural and bola-PI.  Image received with permission from Shannon 
Jewel.   
ADP
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This thesis outlines the development of a time-resolved, vesicle-based, FI assay for 
the activity of a lipid kinase.  This assay is easy to use and can be used to measure initial 
rates of lipid kinases.  Once it has been established as a reliable and robust assay it will be 
used frequently in the future work of the Atkinson research group to conduct the research 
outlined here.  Moreover, it is not only useful in investigating Pik1 and Sec14, it can be 
used to investigate the activity of any lipid kinase and any lipid transfer protein, including 
the mammalian homologues of Sec14, principally PITP𝛼 and PITP𝛽 (110–112).  Lipid 
kinase assays are not only critical to gain a greater understanding of lipid transfer protein 
and lipid kinase function, they are also key in disease research (84) and in drug 
development and safety (85).  This research provides an easy, time-resolved assay to 
investigate lipid kinase activity that can eventually be used in academic, medical, and 
pharmaceutical research labs.    
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